Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26 May2019
1  
Radiation Therapy Oncology Group (RTOG) FOUNDATION COLLABORATION 
WITH ABBVIE INC.
RTOG 3508/AbbVie M13 -813
(EudraCT 2015 -001166 -26)
AMENDMENT 9
  
[STUDY_ID_REMOVED]
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
2A Randomized, Placebo Controlled Phase 3 Study of ABT -414 with Concurrent 
Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed 
Glioblastoma (GBM) with Epidermal Growth Factor Receptor ( EGFR ) Amplification 
(Intellance1)
Investigator:

Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
3

Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
4

Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
5Sponsor: AbbVie Inc. (AbbVie)
AbbVie IND AbbVie Investigational Product: ABT -414
Date: 26May 2019
Development Phase: 3
Study  Design: This is a randomized Phase 3 of ABT -414 in 
combination with radiation therap y and 
Temozolomide (TMZ) in subjects with newly  
diagnosed Glioblastoma with EGFR amplification.
Medical Monitors/Emergency Contact:
Should in cas e of subject safet y concerns or medical emergencies the Medical Monitors are both 
unavailable, please call the following central back -up number:
Phone:

Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
6* The specific contact details of the AbbVie legal/regulatory entity (person) within the relevant country are provided 
within the clinical trial agreement with the Investigator/Institution and in the Clinical Trial Application with the 
Com petent Authority.
This study will be conducted in compliance with the protocol, Good Clinical P ractice and all other applicable 
regulatory requirements, including the archiving of essential documents.
Confidential Information
No use or disclosure outside AbbVie/RTOG Foundation is permitted without prior written 
authorization from  AbbVie.
Protocol Agent
Agent Supply IND # EudraCT # IND Sponsor
ABT -414 AbbVie 115,080 2015-001166-26 AbbVie
Temozolomide Commercial N/A N/A
Protocol Amendment:  Summary of Changes
Previous Protocol Versions
Protocol Date
Original 30 April 2015
Amendment 1 01 July 2015
Amendment 2 (VHP Amendment) 10 September 2015
Amendment 3 08 March 2016
Amendment 4 07 December 2016
Amendment 5 13 January 2017
Amendment 6 06 December 2017
Amendment 7 29 May 2018
Amendment 8 29 November 2018
The purpose of this Amendment is to:
Add brief summary  of results for the protocol -specified interim efficacy  analy sis in the 
Introduction
Provide modified study procedures and instructions for study  drug dosing in Appendix X 
for those subjects currently  receiving ABT- 414 who choose to continue ABT -414.  No 
additional efficacy  data will be collected, and procedures have been minimized to include 
those necessary  for stud y drug dosing, safet y monitoring and collection of safet y data 
related to adverse events and serious adverse events. 
Rationale:   The interim efficacy analysis results overall indicated no survival benefit for 
adding ABT
-414 to standard RT/TMZ therapy in newly diagnosed GBM patients. 
However, given that no new clinically significant safety risks were identified, the RTOG 
Steering C ommittee and AbbVie believe it is appropriate to allow subjects who are 
currently receiving ABT -414 to continue ABT -414 treatment if the investigator and 
subject believe it is in the subject’s best interest.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
7TABLE OF CONTENTS
1.0 INTRODUCTION AND BACKGROUND .......................................................12
1.1 Differences Statement ............................................................................................19
1.2
Benefits and Risks..................................................................................................19
2.0 OBJECTI VES .....................................................................................................20
2.1 Primary  Objective ..................................................................................................20
2.2 Secondary  Objectives .............................................................................................20
2.3 Explorator y Objectives ..........................................................................................20
2.4 Biomarkers .............................................................................................................21
2.5
Hepatic Impairment Sub- Study  Objectives ...........................................................21
3.0 Subject SEL ECTION, ELIGIBILITY, AND INELIG IBILITY CRI TERI A
.....22
3.1 Inclusion Criteria
...................................................................................................23
3.2 Exclusion Criteria ..................................................................................................25
4.0 Study  Overview and Study  Procedures ...............................................................28
4.1 Study  Overview .....................................................................................................28
4.2 Study  Procedures ...................................................................................................38
4.3 Definition of Disease Assessments ........................................................................53
5.0 TREATMENT PL AN.........................................................................................55
5.1 Treatment Plan Overview ......................................................................................55
5.2 Radiation Therap y
..................................................................................................56
5.2.1 Treatment 
Technology ...............................................................................56
5.2.2
Immobilization and Simulation..................................................................57
5.2.3 Imaging for Structure Definition, I mage Registration/Fusion and 
Follow -Up................................ ................................ ................................ ..57
5.2.4 Definition of Target Volumes and Margins ...............................................58
5.2.5 Definition of Critical Structures and Margins ...........................................61
5.2.6 Dose Prescription .......................................................................................63
5.2.7 Compliance Criteria ...................................................................................64
5.2.8 Treatment Planning Priorities ....................................................................66
5.2.9 Dose Calculations ......................................................................................67
5.2.10 Subject -Specific QA ................................ ................................ .................. 67
5.2.11 Daily  Treatment Locations/I GRT ..............................................................67
5.2.12 Case Review ................................ ................................ ............................... 68
5.2.13 Radiation Therap y Adverse Events ................................ ........................... 69
5.3 Temozolomide (TMZ) ...........................................................................................69
5.3.1 TMZ Admini stration
..................................................................................69
5.3.2 Chemotherap y Review ................................ ................................ ............... 71
5.4 ABT -414 / Placebo Treatment ................................ ................................ ............... 72
5.5 Eye Drops for Prophy lactic Treatment of ABT -414 Ey e Toxicity ........................ 73
5.6 Duration of Therap y................................ ................................ ............................... 75
5.7 Integral Assay /Biomarker ................................ ................................ ...................... 77
5.7.1 Avai lability  of Results ................................ ................................ ............... 78
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
85.8 General Concomitant Medication and Supportive Care Guidelines ......................79
5.8.1 Permitted Supportive/Ancillary  Care and Concomitant 
Medications ................................................................................................79
5.8.2 Prohibited Therapies ..................................................................................80
5.8.3 Unblin ding Procedure ................................................................................80
5.9 Method of Assigning Subjects to Treatment Groups .............................................81
5.10 Treatment Compliance ...........................................................................................81
5.11 Drug Ac countability ...............................................................................................82
5.12 Discussion and Justification of Study  Design ........................................................82
5.12.1 Discussion of Study  Design and Choice of Control Groups .....................
.82
5.12.2 Appropriateness of Measurements .............................................................83
5.12.3 Suitability  of Subject Population ...............................................................83
5.12.4 Selection of Doses in the Study .................................................................83
6.0 Removal of Subjects From Therap y or Assessment ...........................................86
6.1 Discontinuation of I ndividual Subjects ..................................................................86
6.1.1 Discontinuation of Temozolomide ............................................................89
6.1.2 Discontinuation of ABT -414 or Placebo ...................................................89
6.1.3
Discontinuation of Radiation .....................................................................89
6.2 Discontinuation of Entire Study .............................................................................89
7.0 Adverse Events ...................................................................................................90
7.1 Complaints .............................................................................................................90
7.2
Medical Complaints...............................................................................................90
7.2.1
Definitions..................................................................................................91
7.3 Adverse Event Severit y
..........................................................................................93
7.4
Adverse Event Collection Period...........................................................................94
7.5 Adverse Event Reporting .......................................................................................95
7.6 Pregnancy ...............................................................................................................97
8.0 Toxicity  Management and Dose Modifications
..................................................99
8.1 ABT -414/Placebo Toxicity  Management ..............................................................99
8.1.1 Dose Modifications for ABT -414/Placebo ................................................99
8.1.2
Ophthalmologic Toxicities.......................................................................100
8.1.3 Severe Allergic Reactions (Grade 3 or Grade 4) .....................................103
8.1.4 Moderate Allergic Reactions (Grade 1 or Grade 2) .................................104
8.1.5
Dermatologic Toxicities................................ ................................ ........... 104
8.1.6 Hepatic Laboratory  Abnormalities (ABT -414/Placebo) ..........................104
8.1.7 Other Toxicities .......................................................................................105
8.2 Ocular Steroid Toxicity  Management ................................ ................................ ..106
8.3 Temozolomide Toxicity  Management ................................ ................................ .106
8.3.1 Temozolomide During Concomitant Radiation Therap y ........................106
8.3.2 Post-Radiation (Adjuvant) Temozolomide ..............................................108
8.4 Hepatic Laboratory  Abnormalities ......................................................................111
9.0 Drug Information ..............................................................................................115
9.1
TMZ ................................ ................................ ................................ ..................... 115
9.1.1 TMZ Suppl y................................ ................................ ............................. 115
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
99.2 ABT -414 ..............................................................................................................115
9.2.1 Identification of Investigational Product(s)
.............................................115
9.2.2 Packaging and Labeling of Blinded ABT -414/Placebo ..........................
.115
9.2.3 Storage and Disposition of ABT -414/Placebo .........................................116
9.2.4 Preparation/Reconstitution of Dosage Form ............................................116
9.2.5 Product Complaint ...................................................................................116
10.0 Pathology /BIOSPECIMENS ............................................................................118
11.0 DATA AND RECORDS ..................................................................................119
11.1 Source Documents ...............................................................................................119
11.2 Case Report Forms ...............................................................................................119
12.0 Quality  Assurance Reviews for Drug and Radiation Therapy .........................
.121
13.0 Protocol Deviation ............................................................................................122
14.0 Statistical Considerations ..................................................................................123
14.1
Study Design ........................................................................................................123
14.2 Statistical Methods ...............................................................................................123
14.3 Primary  Endpoints Study Design .........................................................................124
14.4 Study  Monitoring of Primary  Objectives ................................ ............................. 125
14.5 Accrual/Study  Duration Considerations ..............................................................126
14.6 Secondary  or Exploratory  Endpoints (Including Correlative Science Aims) .....
.127
14.7 Exploratory  Hypothesis and Endpoints ...............................................................129
15.0 Ethics
.................................................................................................................131
15.1 Independent Ethics Committee (IEC) or Institutional Review Board (I RB).......131
15.2 Ethical Conduct of the Study ...............................................................................131
15.3 Subject I nformation and Consent .........................................................................131
16.0 DATA QUALITY ASSURANCE ....................................................................133
17.0 USE OF INFORMATION ................................................................................134
18.0 COMPL ETIO N OF STUDY ................................ ................................ ............ 135
19.0 Investigator's Agreement ................................ ................................ .................. 136
20.0 REFERENCES ................................ ................................ ................................ .137
APPENDIX I Summary  of RANO Response Criteria ................................ ............................. 140
APPENDIX II RTOG 3508/AbbVie STUDY M13 -813 protocol sy nopsis .............................. 144
Appendix III Adverse Events Expected Due to GBM or Progression of GBM .....................154
Appendix I V
New York Heart Association Functional Classification................................ ...157
Appendix V Responsibilities of the Clinical I nvestigator ................................ ..................... 158
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
10Appendix VI RPA Classification Criteria ...............................................................................160
Appendix VII Child -Pugh score ...............................................................................................161
Appendix VIII
List of Abbreviations and Definition of Terms .................................................162
APPENDIX IX. SUBJE CTS WI TH MILD TO MODERATE HEPATI C IMPAIRMENT
.......165
Appendix X SUBJECTS CONTI NUING PARTI CIPATION AFTER MAIN STUDY .....
.178
Appendix XI Protocol Amendment:  list of changes ..............................................................181
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
11RTOG 3508/AbbVie:  M13 -813
SCHEMA
SCREENING REQUIREMENTS
Central Pathology Revie w for confirmation of histology and adequacy of tissue for MGMT and EGFR analysis. 
Testing for EGFR amplification, MGMT prom oter methylation, and EGFRvIII must be complete before 
Randomization.  Only subjects with EGFR amplified tumo rs and available results for MGMT and EGFRvIII testing 
will be eligible. See protocol for details.
↓
RANDOMIZ ATION REQUIREMENTS
STRATIFY
MGMT methylation status:  methylated vs. Unmethylated*
RPA class:  III vs. IV vs. V
Region of the w orld:  US/Canada v s. Other
EGFRvIII mutation status: mutated vs. Other
RANDOMIZE
↓ ↓
Arm  A
RT:  ~60 Gy in ~30 fractions over 42 days (d) (up to 
49d)**
+
Temozolom ide:  Daily for 42 d (up to 49 d)**
+
Blinded ABT -414:  D1 of Weeks 1, 3 and 5
Approximately 28 d after completion of 
chemoradiation
Temozolom ide:  D1 -5 of 28 -d cycle x 6 cycles**
+
Blinded ABT -414:  D1 and D15 of q 28 -d cycle x 
12cyclesArm  B
RT:  ~ 60 Gy in ~30 fractions over 42 d (up to 49 d)**
+
Temozolom ide:  Daily for 42 d (up to 49 d)**
+
Blinded Placebo:  D1 of Weeks 1, 3 and 5
Approximately 28 d after completion of 
chemoradiation
Temozolom ide:  D1 -5 of 28 -d cycle x 6 cycles**
+
Blinded Placebo:  D1 and D15 of q 28 -d cycle x 
12cycles
* A test result of "insufficient tissue" indeterminate or invalid for MGMT is exclusionary (unless a valid MGMT
result is available from another approved local or central testing lab, as described in the protocol), and the 
subject w ill not be able to be cont inue to randomization.
** Per local prescribing information or local institutional guidelines.  See Section 5.2 for alternative radiation 
therapy options.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
121.0 INTRODUCTION AND BACKGROUND
Study  RTOG 3508/M13- 813 is a clinical study  of ABT -414 for subjects with newly  diagnosed 
glioblastoma (GBM).  ABT -414 is an antibody  drug conjugate (ADC) designed for the treatment 
of tumors harboring amplified genomic EGFR.  This is a Phase 3 randomized double -blind, 
placebo
-controlled trial comparing the efficacy  and saf ety of ABT -414 versus placebo, each as 
concurrent treatment with standard -of-care therapy  of radiation/temozolomide (TMZ) plus 
adjuvant TMZ and followed b y ABT -414/placebo monotherapy .
In addition there is an ABT -414 sub- study  in subjects with hepatic impairment outlined in 
Appendix I X.  The revised schedule of procedures is provided in Appendix IX, Table 3H.  The 
objective of the sub -study  is to assess the pharmacokinetics, safet y and tolerability of ABT -414 
in subjects with mild and moderate hepatic impairment.
Glioblastoma (GBM)
GBM is the most common and most aggressive t ype of primary brain tumor in adults, affecting 
8,000 to 10,000 people per year in North America alone.1  The median survival time from 
diagnosis is 3 months without any  treatment.  With treatment, patients can expect an average 
survival of 1 to 2 y ears.  The survival depends greatly  on man y patient and tumor specific 
factors, including tumor stage, age, resectability , and geneti
c characteristics as well as 
performance status.  Treatments may  include surgical resection of the tumor, chemotherap y, 
radiation therapy, and immunotherap y.  Despite advances in treatments, the prognosis of patients 
with GBM remains poor.
The current stan dard-of-care therap y for newl y diagnosed glioblastoma following surgical 
debulking is radiation therapy (RT) in combination with temozolomide (TMZ), followed b y 
6months of further TMZ monotherap y.2  The standard of care  is based on the results from a 
definitive Phase 3 trial conducted by  the European Organization for Research and Treatment of 
Cancer (EORTC) and National Cancer Institute of Canada (NCIC) that demonstrated a survival 
benefit for patients treated with TMZ in addition to surgery
 and radiation.3  In this study , patients 
in the radiation therap y plus concomitant and adjuvant TMZ arm had a longer median survival 
time (14.6 versus 12.1 months) and a greater 2 -year survival rate (27% versus 10%) than patients 
in the radiation therap y alone arm.
Despite these improvements afforded b y the addition of TMZ, the vast majority  of patients will 
have their tumor recur after aggressive primary  therapy .  At the time of recurrence, the prognosis 
is quite dismal, with median survival times measured in months an d response rates commonl y 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
13reported to be in the single digits.  Treatment to prevent tumor re -growth is direly  needed in 
order to make the most significant impact on the prognosis of those with this devastating disease.
One of the unique molecular characte ristics of GBM tumors is the aberrant signaling, expression, 
mutation, and gene amplification of the epidermal growth factor receptor, or EGFR.  The EGFR
has been h ypothesized to play
 a critical role in the development of GBM and thus has an 
extremely  high rate of overexpression (nearing 60% or more), amplification (approximating 
40 – 50%), and mutations (approximately  25% overall have been reported to harbor the 
constitutively  active EGFR variant III ( EGFRvIII ) mutation).  This makes the EGFR an attractiv e 
target for drug therap y.  Unfortunatel y, EGFR signaling inhibitors have not been successful to 
date, likely  due to the multiple signaling b ypass pathway s as well as the underly ing and reactive 
mutational resistance mechanisms, and limited brain penetrati on of t yrosine kinase inhibitors at 
routine dosing used in other solid tumors.  Other methods to exploit the EGFR, such as using the 
receptor as a target for selective chemotherap y or immunotherapy delivery, remain attractive.  
ABT -414 binds specifically  to activated wild -type EGFR and EGFRvIII mutant GBM and, as an 
antibody  drug conjugate, is constructed to deliver a potent toxin that circumvents most signaling 
resistance mechanisms and does not depend on inhibition of EGFR signaling.
ABT -414:  An Antibody Drug Conjugate that Targets Amplified EGFR
ABT -414 is an antibody  drug conjugate (ADC) designed for the treatment of tumors harboring 
amplified genomic EGFR .  Antibody  drug conjugates are a rapidly  growing class of cancer drugs 
that combine the targeting properties of monoclonal antibodies (mAbs) with the anti -tumor 
effects of potent cytotoxic drugs.  Significant advancements in linker stability  and toxin potency  
are primarily  responsible for the resurgence in ADC development.  A recent example of a 
clinic ally relevant, advanced ADC is brentuximab vedotin (Adcetris®), an anti-CD30 ADC 
which received US Food and Drug Administration approval in 2011 for Hodgkin's l ymphoma 
and anaplastic large cell lymphoma due to a high percentage of tumor responses in these largel y 
chemotherap y refractory  populations.  The distinct clinical advantage to ADCs is their ability  to 
deliver toxic pay loads directly  to a tumor, by passing man y downstream resistance mechanisms 
related to intracellular signaling.
ABT -414 is a newer gen eration antibod y-drug conjugate, consisting of:  1) a veneered 
"humanized" recombinant IgG1κ antibod y that has binding properties specific to a unique 
epitope of human EGFR with 2) non- cleavable maleimido -capro yl linkers each attached to 3) a 
potent antimi crotubule agent, monometh ylauristatin F (MMAF).  The antibody  binds to the 
EGFR epitope (even in the absence of EGFRvIII mutation), is internalized, and then intracellular 
enzy mes release the toxin leading to inhibition of microtubule function, the disrupt ion of critical 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
14cellular processes and cell death.  I mportantl y, ABT -414 binds to an epitope that is available 
predominantly  on tumor cells with the EGFRde2 -7 (EGFRvIII ) deletion mutant or on tumor cells 
with activated wild-type EGF receptors.  The epitope is largel y inaccessible when EGFR is 
expressed at normal ph ysiological levels; thus, ABT-414 has limited binding to non- activated, 
wild-type EGFR expressed on normal tissues.  These properties, therefore, favor limited effects 
of the toxin on normal tissues while maintaining a high degree of activit y on EGFR- amplified 
tumor cells.  Nonclinical studies to date have confirmed that ABT -414 has potency  greater than 
what is observed with clinically  available agents in a variet y of human xenograft animal models,
with at least an equivalent toxicity  profile.
Clinical Data of ABT -414 in GBM
Study  M12 -356 is a Phase 1, open- label study  designed to assess the safet y and 
pharmacokinetics of ABT -414 as monotherap y, in combination with TMZ, or in combination 
with RT and TMZ in subjects with newly  diagnosed or recurrent GBM.  In this study , ABT -414 
is given every  2 weeks by  intravenous (IV) infusion, with treatment arms as follows:
Arm A (ABT -414/RT/TMZ):  Subjects with newly diagnosed GBM who start ABT -414 
along with con comitant radiotherap y and TMZ and later continue ABT -414 along with 
adjuvant TMZ.
Arm B (ABT -414/TMZ):  Subjects who start ABT- 414 with TMZ alone (without 
radiotherap y).  Arm B subjects can be either newly diagnosed subjects, who are starting 
concomitant A BT-414/TMZ treatment after completion of initial concomitant radiotherapy  
and TMZ, or GBM subjects with recurrent disease, arising during or after adjuvant TMZ 
treatment.
Arm C (ABT -414 monotherap y):  Subjects with recurrent GBM only , who receive 
ABT -414 monotherapy .
As of January , 2016, 47 newly diagnosed GBM subjects in Arm A have received ABT -414 at 
dose levels ranging from 0.5 to 3.2 mg/kg in combination with radiation and TMZ.  An objective 
response rate attributable to ABT -
414 treatment alone cannot be accuratel y assessed in the newl y 
diagnosed setting because of concomitant RT/TMZ, pseudoprogression, and/or minimal residual 
disease post -operativel y.  Although recurrence -free survival data are immature given the 
relativel y brief follow -up to date on these subjects, the maximum tolerated dose (MTD) 
(2.4mg/kg), as well as the recommended Phase 2 dose (2.0 mg/kg) in Arm A have been 
identified.  As of the same cutoff date, 28 subjects with recurrent, measurable disease were 
enrolled either in Arm B (conc omitant ABT -414 and TMZ) or Arm C (ABT -414 monotherap y).  
Of these, 18 subjects had EGFR-amplified tumors, and 6 (33%) subjects thus far have 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
15demonstrated confirmed, objective responses as measured using Response Assessment in 
Neuro -oncology  (RANO) criteri a.  Objective responses in the subjects with EGFR- amplified 
disease were seen at doses ranging from 1.0 –1.5 mg/kg, with onset as early  as 2 months after 
treatment initiation but with maximum response thus far seen as late 6 months into treatment.  
Import antly , these responses were observed in both Arms B and C, including one of the 
2complete responses (CR)s observed after ABT -414 monotherap y treatment.  None of the 
subjects with tumors negative for EGFR amplification has experienced a confirmed objective
response.  The MTD and recommended phase 2 dose in Arms B and C was 1.25 mg/kg.
The dose -
limiting toxicities (DLTs) observed after ABT- 414 exposure have been limited to 
manifestations from the formation of corneal deposits related to cy s-mcMMAF, a s yndrom e 
hereafter referred to as microcy stic keratopathy .  This is thought to be a result of damage directly  
to the transient amplify ing cells of the limbus, cells that differentiate and give rise to the corneal 
epithelium.  However, with the exception of these ocular adverse events, as described in detail 
below, adverse events reported were usuall y Grade 1 or 2, infrequent, and more likely related to 
the underl ying cancer, concomitant chemotherapy  or chemoradiotherap y.  DL Ts for all groups in 
both studies were c omprised of a variet y of different preferred terms for eye -related signs 
(including keratitis, corneal cy sts, corneal deposits, ocular hy peremia) and sy mptoms (most 
commonly  vision blurred, photophobia, dry  eye, eye pain, foreign body  sensation in ey es, an d 
lacrimation increased).  Similar findings have been reported for other ADCs utilizing the 
cys-mcMMAF toxin.4  Given that the cornea regenerates every  3 –4 weeks, to date, all cases of 
microcy stic keratopathy  have resolved without long -term sequelae afte r drug discontinuation.  
Both the incidence and severit y of e ye toxicity  appear to be dose -related.  While ABT -414 dose 
reduction for subjects with high -grade toxicities generall y reduces s ymptom severit y and allows 
for continued dosing, the overall incide nce rate remains very  high at the recommended Phase 2 
doses proposed for further clinical studies.
The microcy stic keratopathy  noted in Study  M12- 356 is similarly  described with other 
chemotherap y agents, including high -dose cy tarabine.  Prophy lactic steroid ey e drops are 
routinely  used to control these sy mptoms.  Thus, prophy lactic steroid ophthalmologic solution 
was administered to subjects in Study  M12- 356 once ocular toxicities were observed.  
One subject in Study  M12 -356 who had stopped ABT -414 treatment due to a Grade 3 ey e 
toxicity  at the 1.0 mg/kg level without steroid ocular proph ylaxis was able to tolerate the same 
1.0mg/kg dose level when ABT -414 was restarted along with steroid prophy laxis.  Based on this 
and other experiences, ocular stero id proph ylaxis is indicated for all subjects receiving ABT-414 
treatment at dose levels of 1.0 mg/kg and above.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
16The dose of ABT -414 in combination with adjuvant TMZ is 1.25 mg/kg, based on the 
tolerability  of ABT -414 in Arm B of Study  M12- 356.  At this dose (and with steroid 
prophy laxis) during maintenance TMZ cy cles, 2/10 subjects had ocular DLTs, but only  1 was 
attributable to ABT -414.  To date, approximately  6 subjects have been treated at the 
recommended Phase 2 dose as part of an expanded safet y cohort .  Of these, although ey e toxicity  
of an y grade is very  common, only  approximately 20% have reported severe ocular adverse 
events (Grade 3 or greater).
The results from Arm A of Study  M12-356, in which all subjects received ABT- 414 combined 
with concomitan t RT/TMZ, demonstrate that higher doses of ABT- 414 with this combination 
can be tolerated.  The recommended Phase 2 dose was declared at 2.0 mg/kg every  other week, 
with no observed Grade 3 or higher toxicities observed.  Higher doses were associated with at 
least 1 dose-limiting toxicity  event and were not well tolerated.
As previously  mentioned, the ocular manifestations of microcy stic keratopathy  to date have been 
reversible after withholding ABT -414, for 4 to 6 weeks.  Subjects who restart ABT -414 at lower 
doses (~1.0 mg/kg) have less severe toxicities and can generall y tolerate further therap y.
A detailed discussion of the preclinical toxicology , metabolism, and pharmacology  can be found 
in the I nvestigator’s Brochure (IB).33
INTELLANCE -2 Preliminary Re sults in Recurrent GBM
INTELLANCE -2 (Study  M14 -483) was a Phase 2, open- label, randomized study  evaluating the 
efficacy  and safet y of Depatux -M (Depatuxizumab Mafodotin) alone or in combination with 
TMZ compared to lomustine (CCNU) or TMZ in subjects at fi rst recurrence of GBM whose 
tumors were EGFR -amplified.  Each subject was randomized in a 1:1:1 ratio to one of 
three study  arms:
Arm 1 (n = 88):  Depatux -M 1.0 mg/kg IV q2 weeks in combination with TMZ 
150 – 200 mg /m2on Days 1 – 5 of each 28 -day cycle.
Arm 2 (n = 86):  Depatux -M monotherap y 1.0 mg/kg IV infusion q2 weeks .
Arm 3 (n = 86):  Control arm subjects were treated according to the timing of relapse in 
relation to their last cy cle of TMZ (the same factor was used to stratify  randomization):
oArm 3A :  Subjects relapsing < 16 weeks after the first day  of the last TMZ cy cle were 
treated with lomustine 110 mg/m2on Day  1 of every  42-day treatment period.
oArm 3B:  Subjects relapsing ≥ 16 weeks after the first day  of the last TMZ cy cle were 
treated with TMZ 150 – 200 mg/m2on Day s 1 – 5 of each 28 -day cycle.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
17The ABT -414/TMZ combination group (Arm 1) showed a 29% decrease in OS hazard rate 
compared to the control group treated with TMZ or lomustine (Arm 3), a result which nearl y 
achieved statistical signif icance (HR = 0.71 [0.50 –1.02], 2- sided p- value = 0.062) despite the 
limited sample size of the Phase 2 study . The estimated percentage of patients surviving at 
1year increased from 28% (Arm 3) to 40% (Arm 1).  Of note, in the subgroup of subjects who 
relapsed ≥ 16 weeks after the last TMZ cy cle, the estimated HR OSfor the TMZ/ABT -414 
combination vs. TMZ monotherap y was 0.52 (0.27 – 1.0; p = 0.05), suggesting that adding 
ABT -414 to TMZ treatment provides additional benefit on OS.
A post hoc anal ysis cont rolling for additional prognostic factors (including MGMT methy lation 
status and baseline tumor size) showed an estimated HR OS= 0.55 (p = 0.001), suggesting that the 
primary  anal ysis may  have underestimated the benefit of ABT- 414/TMZ combination therapy .
ABT -414 monotherapy  (Arm 2) showed activity  similar to the active chemotherapy  controls 
(Arm 3) (HR = 1.04, 2 -sided p -value = 0.835).
Importantly , safet y anal yses showed that toxicity  associated with ABT -414 was consistent with 
what was seen in Phase 1 stu dies, and no new safety  signals were identified for ABT-414.  
Ocular side effects were reported b y 77% of subjects taking ABT -414 overall, with 28% 
reporting Grade 3/4 ocular events.  2.9% of subjects discontinued ABT -414 treatment due to 
ocular side effec ts.  The incidence of adverse events known to be associated with TMZ 
(neutropenia and thrombocy topenia/decreased platelet count) in the ABT
-414/TMZ combination 
group was similar to that of TMZ monotherap y.
Of note, the estimated HR OSof 0.71 observed in re current GBM subjects in the INTELLANCE-2 
study , if replicated in a larger stud y, would be considered clinicall y meaningful and is consistent 
with the underly ing assumption in the current INTELLANCE- 1 trial of a HR OS= 0.75.
INTELLANCE -2 preliminary  results were presented at SNO 2017 and a detailed discussion of 
the preclinical toxicology, metabolism, and pharmacology  will be updated in the I nvestigator's 
Brochure (IB).33
Additional Safety Information
Preliminary  safet y data were available for 468 subjects w ho received at least 1 dose of ABT -414 
in 4 open -label studies at the most recent IB update (version 6.0).  The Phase 2 Study  M14-483 
(INTELLANCE -2) in recurrent GBM is the only  trial for which safet y data from a control arm 
(TMZ or lomustine monotherap y) is available.  Adverse events reported for more than 20% of 
subjects receiving ABT -414 were fatigue (35.5%), vision blurred (26.7%), headache and keratitis 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
18(25.0% for each), dry  eye (24.2%) and corneal epithelial microcy sts (22.1%).  In addition to 
ocular side effects related to corneal epitheliopathy , treatment-emergent adverse events reported 
by ≥ 10% of subjects in the ABT -414 treatment groups and ≥ 5% more frequently  than the 
lomustine/TMZ control group included headache, fatigue, constipation, and live r transaminase 
elevations (alanine aminotransferase and aspartate aminotransferase).  The rate of constipation 
was mainly  accounted for by
 the ABT -414/TMZ combination arm, for which the rate was similar 
to that of subjects receiving TMZ monotherap y.
In the ongoing blinded Study  M13- 813 (RTOG 3508) in newl y diagnosed GBM, one subject 
receiving ABT -414 (unblinded) with radiation and TMZ in the chemoradiation phase and with 
TMZ in the adjuvant phase experienced Grade 5 (fatal) events of acute liver injury  and cerebral 
edema after approximately  5 months of treatment.  The subject had grade 4 GGT (> 33 × ULN) 
and grade 1 fatt y liver at Screening.  The investigator considered the event of fatal acute liver 
injury  to be reasonabl y possibly  related to ABT -414.  The sponsor also assessed that there was a 
reasonable possibility  that ABT -414 caused or contributed to the liver injury  and subsequent 
death.  The above -described case is the onl y event of fatal liver injury  that has been reported in 
ABT -414 open -label or blinded studies, in which approximately  800 people have received 
ABT -414 to date.
Summary of Results from Pre -planned Interim Efficacy Analysis
An interim efficacy  analy sis based on a data cut of 30 April 2019 was performed by  the RTOG 
Independent Data Monitoring Committee (IDMC), at which time 346 OS events had been 
observed out of 639 subjects included in the main part of the study .  The primary  anal ysis of OS 
based on the Intent -to-Treat (ITT) population showed no difference in OS between groups, with
a median OS of 18.9 vs. 18.7 months for ABT -414 and placebo, respectively .  The weighted 
(ρ=0, γ = 0.2) stratified log -rank test p -value (1- sided) was 0.628, and the observed hazard ratio 
(HR) (95% CI) for OS was 1.01 (0.82, 1.25).  The median PFS was 8.0 vs. 6.3 months for 
ABT -414 and placebo, respectively , with a stratified log -rank test p -value (1 -sided) of 0.029.  
The observed hazard ratio (HR) (95% CI) for PFS was 0.84 (0.70, 1.02).  Preliminary  anal ysis of 
demographic and clinical characteristics did not reveal an y factors predictive of OS benefit for 
the addition of ABT -414 to standard RT/TMZ therapy .
Overall, 99.4% and 97.8% of subjects experienced at least 1 adverse event, and 87.3% and 
62.3% experienced a Grade 3 or higher AE in the ABT -414 and placebo arms, respectivel y.  
Overall, 94.7% and 36.1% of subjects experienced at least 1 ocular adverse event related to 
corneal epitheliopathy , 61.0% and 0.6% experienced a Grade 3 or higher AE related to corneal 
epitheliopathy , and 11.8% and 0% discontinued study  drug (ABT -414 or placebo) in the 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
19ABT -414 and placebo arms due to corneal epitheliopathy , respectivel y.  The most common (> 
10%) events related to corneal epitheliopathy included keratopathy, vision blurred, photophobia, 
dry eye, ey e pain, keratit is, and punctate keratitis.  Excluding events related to corneal 
epitheliopathy , events for which the incidence in the ABT -414 group was ≥ 5% greater than in 
the placebo group included thrombocy topenia, gamma -glutam yltransferase increased, aspartate 
aminot ransferase increased, alanine aminotransferase increased, constipation, blood alkaline 
phosphatase increased, fatigue, and platelet count decreased.  Excluding events related to corneal 
epitheliopathy , Grade 3 or higher events for which the incidence in th e ABT -414 group was at 
least 5% and was ≥ 2% greater than in the placebo group included thrombocy topenia, gamma -
glutam yltransferase increased, and alanine aminotransferase increased.
The interim efficacy  analy sis results overall indicate no survival benefi t for adding ABT -414 to 
standard RT/TMZ therapy in newl y diagnosed GBM patients.  However, given that no new 
important safet y risks were identified, the RTOG Steering Committee and AbbVie believe it is 
appropriate to allow subjects who are currentl y receiv ing ABT -414 to continue ABT-414 
treatment if the investigator and subject believe it is in the subject's best interest.  For those 
subjects who choose to continue ABT -414, study  procedures have been modified as described in 
Appendix X.  The appendix provides guidance for study drug administration and collection of 
safet y data related to AEs and SAEs.   No additional efficacy  data will be collected.
1.1 Differences Statement
This is the first placebo -controlled study  evaluating the efficacy  of ABT -414 in the treatment of 
newly  diagnosed GBM .  In Study  M12
-356, the safety  and tolerability  of ABT -414 in newly  
diagnosed GBM subjects was evaluated in an open- label dose escalation study .
1.2 Benefits and Risks
ABT -414 is an ADC that has demonstrated initial evidenc e of clinical efficacy  in 
EGFR -amplified GBM.  ABT- 414 also demonstrates a favorable EGFR binding ratio of tumor to 
normal tissue.  These data together reflect an acceptable rationale and risk for treating 
EGFR -amplified GBM subjects with ABT- 414 in the co ntext of a clinical trial.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
202.0 OBJECTIVES
2.1 Primary Objective
To determine whether the addition of ABT -414 to concomitant radiotherapy  and TMZ plus 
adjuvant TMZ prolongs Overall Survival (OS) among subjects with newly diagnosed GBM 
harboring EGFR amplifi cation.
2.2 Secondary Objectives
To determine whether the addition of ABT -414 to concomitant radiotherapy  and TMZ plus 
adjuvant TMZ improves outcomes among subjects with newly  diagnosed GBM harboring EGFR
amplification for the following endpoints:
PFS (assessed b y IRC)
OS for the MGMT unmethy lated group
OS for the MGMT methy lated subgroup
Time to deterioration in symptom severit y score M.D. Anderson S ymptom I nventory  
Brain Tumor Module (MDASI -BT)
Time to deterioration in symptom interference score (MDAS I-BT)
Time to deterioration in neurocognitive functioning on the Hopkins Verbal L earning 
Test Revised (HVLT -R)
OS for the EGFRvIII -mutated tumor subgroup
PFS for EGFRvIII -mutated tumor subgroup
Safety :
Assessment of comparative safet y
2.3 Exploratory Objectives
To determine whether the addition of ABT -414 to concomitant radiotherapy  and TMZ plus 
adjuvant TMZ improves outcomes among subjects with newly  diagnosed GBM harboring EGFR
amplification for the following endpoints:
OS at 1 y ear
OS at 2 y ears
PFS at 1 y ear
PFS at 2 y ears
PFS for the MGMT unmethy lated and methy lated sub -groups
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
21OS for non- EGFRvIII subjects (comparison between arms)
PFS for non -EGFRvIII subjects (comparison between arms)
OS and PFS for Total EGFR expressions levels
EGFRvIII status (a s a prognostic factor independent of treatment assignment) overall 
and among molecular subgroups
Change from baseline in HRQoL  (EORTC QLQ -C30/BN20 scale scores)
Change from baseline in sy mptom severit y factor groupings (MDASI -BT neurologic, 
cognitive, trea tment and sy mptom interference (activity -related, mood -related)
Change from baseline in performance status (KPS)
Median time KPS score was maintained at 70 or higher
Time to deterioration in neurocognitive functioning on Controlled Oral Word 
Association (C OWA -FAS)
Change from baseline in neurocognitive functioning (HVLT -R and COWA -FAS)
Change from baseline in Vision item on the MDASI -BT and EORTC BN20
Change from baseline in health status (EQ -5D- 5L and EQ -5D- VAS)
Changes in EGFR molecular profile during therapy  among subjects who undergo 
additional surgery  as part of routine care
Pharmacokinetics of ABT- 414, total ABT -806, and unconjugated cy s-mcMMAF
Change from baseline in average daily (dexamethasone equivalent) corticosteroid 
dosing during treatment.
2.4 Biomarkers
Biospecimens (plasma, serum, tumor tissue) will be collected at designated time points 
throughout the stud y to conduct research with the intent of identifying biomarkers associated 
with subject outcome or to better characterize the disease.  A portion of t he tumor tissue will be 
used to confirm GBM diagnosis (central review of tumor histopathology ), determination of 
EGFR amplification (required for study  entry ), EGFRvIII variant, and 
O6-methy lguaninemethly transferese ( MGMT ) methy lation status (required for subject 
randomization).
2.5 Hepatic Impairment Sub- Study Objectives
This open -label, single arm sub -study , described in Appendix I X, will assess the 
pharmacokinetics, safet y and tolerability  of ABT -414 in subjects with newly diagnosed 
EGFR- amplified GBM wh o have mild or moderate hepatic impairment.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
223.0 SUBJECT SELECTIO N, ELIGIBILITY, AND INELIGIBILITY 
CRITERIA
Note:  Exceptions to inclusion and exclusion criteria are not permitted.  For questions 
concerning eligibility , please contact y our local monitor/Cli nical Research Associate.
See Appendix IX for subject selection and eligibility criteria for subjects with mild to moderate 
hepatic impairment.
Submission of tumor tissue is required for all subjects (see Section 4.2:  Collection of Tumor 
Tissues).  Invest igators should check with their site Pathology  department regarding release of 
biospecimens before approaching subjects about participation in the trial.  (See details of tissue 
submissions in Study -Specific Laboratory  Manual.)  I t is expected that approximately  40 – 50% 
of subjects tested will have EGFR amplification.
Screening Requirements
Tumor tissue from surgery submitted for histological confirmation of GBM diagnosis b y 
a central pathologist and for central biomarker testing for EGFR amplification, EGFRvIII
mutation, and MGMT promoter methy lation status.  Results for each of these tests are 
required for stud y eligibility .
If the subject has a valid result on an approved MGMT assay  from screening for a 
different stud y, those results will be accepted for eligibility  and stratification in this study  
(see Section
 5.7 for details).  L ocal MGMT testing also may  be used for stratification 
purposes if approved b y AbbVie or RTOG.  If a valid central test result also is or 
becomes available prior to randomization , the central result will be entered for 
stratification.
Randomization Requirements 
A brain MRI scan with and without contrast, performed at an y time after diagnostic 
surgery  or biops y but prior to randomization, is required to serve as a baseline scan for 
RANO tumor response assessments.  The baseline MRI  must include the image 
sequences (T1 with and without contrast, T2 FLAIR, etc.) required for making RANO 
assessments.  The most recent scan done prior to randomization will be used as the 
baseline scan.
oIf a subject starts chemoradiation more than 28 days after surgery , the baseline MRI  
will be performed no more than 21 (and preferably fewer) days before the start of 
chemoradiation.
oAlthough not required for eligibility , an MRI scan collected within ~72 hours after 
resection is strongly  encouraged as the best way  to accuratel y assess the extent of 
surgical resection; if other post-operative scans are obtained, submit and record 
results of scan(s).
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
23oAn intraoperative brain MRI  scan may  be used as the post -operative baseline scan if it 
includes the required imaging sequences.
Randomization (requiring stratification based on EGFRvIII , MGMT , RPA results, and 
region of world) must be performed in Interactive Response Technology  (IRT) before 
ABT -414/placebo is a dministered.
Prophy lactic steroid drops (open label) begin 48 hours prior to first dose of 
ABT -414/placebo.
Chemoradiation (RT/TMZ + ABT -414/placebo) begins within 49 day s (7 weeks) after 
biopsy /resection.
oIf a subject undergoes additional tumor resection( s) before randomization, the subject 
can be randomized if Chemoradiation starts within 49 day s (7 weeks) of the latest 
resection and the subject meets all eligibility  criteria.  The latest resection must have 
been performed within 30 day s after the initial biopsy /resection.
3.1
Inclusion Criteria
A subject cannot be considered eligible for this study unless ALL of the following 
conditions are met.  Eligibility criteria for sub- study subjects with hepatic impairment are 
described in Appendix IX.
Subjects may  only be randomized if additional criteria below are met:
1. Histologicall y confirmed de novo Grade IV glioma (GBM, gliosarcoma or other 
subvariants) confirmed by  central pathology  tissue screening.
2. EGFR amplification in tumor tissue confirmed b y central assessment.
3. Inclusion criterion removed in Amendment 5.
4. The subject must have recovered from the effects of surgery , post -operative infection, and 
other complications before enrollment including, suture/staple removal from brain surgery  
and suff icient wound healing before randomization.
5. ≥ 18 y ears of age.
6. Karnofsk y performance status ≥ 70 at assessment ≤ 14 day s prior to randomization.
7. Results for required stratification factors ( EGFRvIII status, MGMT methy lation status, 
Recursive Partit ioning Analy sis (RPA) class, and region of world) available prior to 
randomization.
8. Subject has adequate bone marrow, renal, and hepatic function ≤ 21 day s prior to 
randomization as follows:
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
24a)Absolute neutrophil count (ANC) ≥1,500/mm3;
b)Platelets ≥ 100,000/mm3;
c)Hemoglobin (Hgb) ≥ 9.0 g/dL (Note:  The use of transfusion or other intervention to 
achieve Hgb ≥ 9.0 g/dL is acceptable.);
d)Renal function:  calculated creatinine clearance ≥ 30 mL /min by  the Cockcroft -Gault 
formula;
e)Hepatic function:  Total b ilirubin ≤ 1.5 times upper limit of normal (ULN) , Aspartate 
Aminotransferase (AST), and Alanine Aminotransferase (ALT) ≤ 3 times ULN.  
Subjects with Gilbert's s yndrome documented in medical history may  be enrolled if 
total bilirubin is < 3 times UL N.
9. Electrocardiogram (ECG) without evidence of acute cardiac ischemia ≤ 21 day s prior to 
randomization.
10. Female subjects of childbearing potential (i.e., those who are not postmenopausal for at 
least 1 y ear or surgicall y sterile by  bilateral salpingectomy , bilateral oophorectom y or 
hysterectom y) should practice at least one accepted method of birth control listed below 
during stud y entr y, for the entire duration of the study  and for at least 6 months after 
treatment with ABT -414 and TMZ treatment has ended.  Male subjects should practice at 
least one of the accepted methods of birth control during stud y and for at least 6 months 
after ABT
-414 and TMZ.  If using a condom, practice at least one other method of birth 
control listed below during the stud y and for at least 6 months after ABT- 414 and TMZ:
Combined (estrogen and progestogen containing) hormonal contraception (oral, 
intravaginal, transdermal) associated with the inhibition of ovulation, initiated at least 
1 month prior to Study  Day  1;
Progestogen -only hormonal contraception (oral, injectable, implantable) associated 
with inhibition of ovulation, initiated at least 1 month prior to Study  Day  1;
Bilateral tubal occlusion/ligation;
True abstinence:  Refraining from heterosexual intercourse when this is in line with 
the preferred and usual lifesty le of the subject [periodic abstinence (e.g., calendar, 
ovulation, sy mptothermal, post -ovulation methods) and withdrawal are not 
acceptable];
A vasectomized male subject or a vasectomized partner of a female subject ;
Intrauterine device, IUD (females);
Intrauterine hormone -releasing s ystem, IUS (females);
Double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring 
with spermicidal jellies or cream) unless not deemed acceptable as highl y effective 
contraception by  local regulations.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
2511. Women of child- bearing potential must have a negative pregnancy  test (urine or serum) 
within 7 days prior to randomization.
12. Must voluntarily  sign and date informed consent form, for tumor tissue biomarker testing
and for stud y participation, approved b y an Independent Ethics Committee (IEC)/ 
Institutional Review Board (IRB), prior to the initiation of any screening or study -specific 
procedures.
3.2 Exclusion Criteria
Subjects with one or more of the following conditions are NOT eligible for this study.
Eligibility criteria for sub -study subjects with hepatic impairment are described in 
Appendix IX.
1. Subject has multifocal GBM, defined as discrete sites of disease without contiguous 
T2/FLAIR abnormality  that req uire distinct radiotherap y ports.  Satellite lesions that are 
associated with a contiguous area of T2/FLAIR abnormality  as the main lesion(s) and that 
are encompassed within the same radiotherap y port as the main lesion(s) are permitted.
2.Exclusion criterio n removed in Amendment 5.
3. Subject has recurrent GBM.
4.Exclusion criterion removed in Amendment 5.
5.Subject has metastatic GBM.
6.Prior chemotherap y or radiosensitizers for cancers of the head and neck region; note that 
prior chemotherap y for a different cancer is allowable, except prior temozolomide.
7.Prior radiotherap y to the head or neck (except for T1 glottic cancer), resulting in overlap 
of radiation fields.
8.Any prior therapy  for glioblastoma, except surgery  (intra -operative techniques to guide 
resection are allowed as are experimental imaging techniques).
9.Prior invasive malignancy  (except for non -melanomatous skin cancer; carcinoma in situ of 
the breast, oral cavit y, or cervix) unless disease free for ≥ 2 y ears.
10.Prior, concomitant, or planned concomitant tre atment with anti -neoplastic intent including 
but not limited to NovoTumor Treatment Fields (Novo TTF), EGFR -targeted therapy  
(including EGFRvIII -directed therapy ), bevacizumab, Gliadel wafers or other intratumoral 
or intracavitary  anti-neoplastic therap y, or other experimental therapeutics intended to 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
26treat the tumor.  Diagnostic or imaging studies; quality  of life; biomarker or 
epidemiological studies; and operative guides to improve extent of resection are allowed.
11.Subject has had major immunologic reacti on to an IgG -containing agent.
12.Subject has had LASIK (laser -assisted in situ keratomileusis) procedure within the last 
1year or cataract surgery within the last 3 months.
13.Subject has a history  of hy persensitivity  to TMZ or excipients, ABT -414 components or 
excipients, and dacarbazine (contraindication for TMZ).
14.Subject is unsuitable for receiving ocular steroids:
Subject has an y active viral disease of the cornea or conjunctiva, including epithelial 
herpes simplex keratitis (dendritic keratitis), vaccinia , and varicella; my cobacterial 
infection of the ey e; fungal diseases of ocular structures; or any  other contraindication 
for ocular steroid use.
Subject has a known or suspected h ypersensitivity to any ocular steroid.
Subject has primary  open angle glaucom a or a history  of steroid -induced intraocular 
pressure elevation.
15.Subject is a lactating or pregnant female.
16.Severe, active co -morbidity , defined as follows:
Severe hepatic impairment (Child -Pugh category  C or higher [score of 10 or higher 
(Appendix VII)]) ; Subjects with mild or moderate hepatic impairment (Child- Pugh 
score of 5 – 9) may be eligible for treatment, as described in Appendix IX.
Unstable angina and/or congestive heart failure within the last 6 months;
Transmural m yocardial infarction within th e last 6 months;
Evidence of recent my ocardial infarction or ischemia by  the findings of 
S-Televations of ≥ 2 mm using the anal ysis of an EKG performed within 21 days 
prior to enrollment;
New York Heart Association grade II or greater congestive heart fai lure requiring 
hospitalization within 12 months prior to enrollment (Appendix I V);
History  of stroke, cerebral vascular accident (CVA) or transient ischemic attack 
within 6 months;
Serious and inadequately controlled cardiac arrh ythmia;
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of 
enrollment;
Chronic obstructive pulmonary  disease exacerbation or other respiratory  illness 
requiring hospitalization or precluding stud y therapy  at the time of enrollment;
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
27Subjects with cli nically  defined Acquired Immune- Deficiency  Syndrome 
(AIDS) -defining illness.  This is necessary  to ensure subjects are likel y to be able to 
receive the full TMZ regimen;
Active connective tissue disorders, such as lupus or scleroderma, that in the opinion 
of the Investigator may  put the subject at high risk for radiation toxicity ;
Any other major medical illnesses or psychiatric impairments that in the I nvestigator's 
opinion will prevent administration or completion of protocol therap y;
17.Subjects treated on any other therapeutic clinical protocols within 30 days prior to study 
entry  or during participation in the study except intra -operative therapy  to guide resection 
or experimental imaging without therapeutic intent.
18.Inability  to undergo contrast -enhanced M RI scans.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
284.0 STUDY OVERVIEW A ND STUDY PROCEDURES
4.1 Study Overview
This is a Phase 3 randomized double -blind, placebo controlled trial comparing the efficacy  and 
safet y of ABT -414 versus placebo, each as concurrent treatment with standard-of- care therap y of 
radiation therap y/TMZ plus adjuvant TMZ and followed by  ABT -414/placebo monotherap y, in 
subjects with newly  diagnosed GBM.
Thestudy  comprises a Screening Period of up to 7 weeks from surgery /biopsy ; a 6- week 
concomitant Chemoradiation Phase; an Adjuvant Phase beginning approximately  4 weeks after 
completion of chemoradiation, and a Follow -Up Phase.  The Adjuvant Phase is compris ed of 28-
day cycles, with subjects receiving concomitant TMZ and stud y drug (ABT -414/placebo) for the 
first6cycles, and study  drug (ABT -414/placebo) monotherapy  for the following 6 cy cles.  
Subsequent cy cles will start approximately 28 days from the star t of the previous cy cle, and the 
cycle schedule will not be affected by  delay s or interruptions in TMZ or ABT- 414/placebo 
dosing.  Adjuvant treatment will be discontinued once disease progression has been determined.  
A Final Study  Drug Visit will be perfo rmed upon discontinuation of study  drug 
(ABT -414/placebo) for any  reason, followed by  35-Day and 49 Day  Follow -Up Visit (± 3 day s).  
If subjects are unable to attend the 49 Day  Follow -Up Visit, a phone call should be performed to 
obtain adverse event and c oncomitant medication information.  In the Follow- Up Phase, subjects 
who complete adjuvant treatment or discontinue study  drug prior to disease progression will 
continue to undergo MR imaging and assessment of neurocognitive functioning and PRO 
approximate ly every  8 weeks up to and including at the time of disease progression, starting 
8weeks after the last scheduled PRO assessments in the Adjuvant Phase.  After disease 
progression, overall survival will continue to be assessed quarterl y.
A sample of pre-treatment tumor tissues will be collected and sent to central laboratories to 
confirm the diagnosis of GBM (required to enroll in the trial) and test for EGFR amplification 
(required to enroll in the trial), MGMT promoter methy lation (a stratification facto r), EGFRvIII 
mutation (a stratification factor) and other biomarkers prior to starting chemoradiation.  If a 
subject has a repeat surgery  before initiating treatment then the tissue from either 
biopsy /resection may  be used for histologic and EGFR amplifica tion, EGFRvIII mutation and 
MGMT promoter meth ylation testing.  If molecular results are discordant between multiple 
specimens from the same patient, then the results that permit eligibility  will be used, unless 
EGFR amplification results differ at 2 disti nct sites of sampling.  An
y question should be 
directed to the Medical Monitor(s).  Remaining sample tissue will be retained for other 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
29exploratory  molecular analy sis where allowed by  local regulations.  If local regulations do not 
allow tissue shipment or storage, the tissue will be immediately  returned or destroy ed after 
eligibility  testing.
Screening procedures must be completed prior to Day  1 of the Chemoradiation Phase, which 
must start within 7 weeks after surgery .  Screening procedures will include si gning of a main 
study  consent form, medical history , Karnofsky  Performance Scale (KPS) assessment and 
recursive partitioning analy sis (RPA) classification (referenced in 
Appendix VI), baseline ECG, 
physical, ophthalmologic and neurological examinations, la boratory  test (chemistry , hematology , 
urinaly sis and coagulation) ( ≤ 21 day s from treatment start), and serum or urine pregnancy  test if 
applicable ( ≤ 7 day s from treatment start).  Subjects will also complete neurocognitive testing 
and PRO measures.  Subj ects must have a baseline brain MRI  prior to the start of 
chemoradiation.  If a subject starts chemoradiation more than 28 day s after surgery , the baseline 
brain MRI  will be obtained no more than 21 (but preferabl y fewer) days prior to Day 1 Week 1 
of the Chemoradiation Phase.  The timing of the MRI  should allow sufficient time to revise the 
radiation therap y plan if needed due to a significant change in tumor since surgery .  Safety -
related evaluations will be conducted 14 or fewer day s prior to Day  1 of th e Chemoradiation 
Phase.  Subjects who screen positive for EGFR amplification in the tumor tissue may  enter the 
study  if all inclusion/exclusion criteria are met.
Upon study  entry , subjects will be stratified according to the following 4 factors:
Region of the world (United States/Canada or other country );
RPA classes (III, IV or V);
MGMT methy lation (methy lated or unmethy lated);
EGFRvIII status (mutated or other).
If a subject has a repeat surgery  prior to randomization, the extent of surgical resection afterthe 
repeat surgery  (biops y-only vs. partial/total resection) will be used for determining RPA class 
(see Appendix VI ).
A test result of "insufficient tissue", invalid or indeterminate for MGMT is exclusionary  (unless a 
valid MGMT result is available from  another approved local or central testing lab using 
approved methodology , as described in the protocol), and the subject will not be able to  continue 
to randomization.  EGFRvIII status of other is defined as wild ty pe, indeterminate due to test 
failur e, or insufficient tissue.
Subjects will be randomized within each stratum on a 1:1 ratio to receive:
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
30Arm A:  ABT -414 during the Chemoradiation and Adjuvant Phases.
Arm B:  Placebo during the Chemoradiation and Adjuvant Phases.
During the Chemoradiation P hase, all subjects will undergo fractionated focal RT, with 
onetreatment of approximately  2 gray  (Gy) given daily  5 day s per week for a total of 
approximately  60 Gy  over approximately  6 weeks (and no more than 7 weeks).  TMZ will be 
administered continuou sly from Day  1 of radiotherapy  to the last day  of radiation (including 
weekends and holiday s) at a dail y oral dose of 75 mg/m2for a maximum of 49 day s.  Subjects in 
Arm A will receive blinded ABT -414 at 2.0 mg/kg IV infusion over 30 –40 minutes once ever y 
2 weeks (Day  1 of Weeks 1, 3, and 5 of the 6-week regimen).  Subjects in Arm B will receive 
blinded placebo IV infusion over 30 –40 minutes once every  2 weeks (Day 1 of Weeks 1, 3, and 
5 of the 6- week regimen).  Treatment in the Chemoradiation Phase mus t begin ≤ 7 weeks after 
surgery /biopsy .
The start of the first cy cle during the Adjuvant Therap
y Phase will be scheduled approximately 
28 day s after the last day  of radiotherapy .  During the Adjuvant Therapy  Phase, all subjects will 
receive oral TMZ 150 –200 mg/m2once daily  on Day s 1 – 5 of each 28- day cycle for 6 cycles 
unless there is disease progression, unacceptable toxicity , or other reasons to discontinue.  
Subjects in Arm A will receive blinded ABT -414 1.25 mg/kg by  intravenous infusion on Day  1 
and Day  15 of each 28- day cycle for 12 cy cles.  Subjects in Arm B will receive blinded placebo 
IV infusion on Day  1 and Day  15 of each 28- day cycle for 12 cy cles.
If after completing 12 cycles of adjuvant treatment, the subject is tolerating study  drug 
(ABT -414 or placebo) and the I nvestigator believes the subject is continuing to benefit from 
ongoing study drug treatment, the I nvestigator may  extend the Adjuvant Phase after consultation 
with the Neuro- Medical Oncology  Chair or AbbVie Medical Monitor, as long as disease 
progression has not been determined.
Occurrence of disease progression to calculate PFS will be determined by  the Investigator, based 
on local evaluation of images and other clinical information using the Response Assessment in 
Neuro -oncology  (RANO) criteria (Appendix I).  Post -baseline scans will be obtained ≤ 14 day s 
before Day  1 of each odd -numbered cy cle (C ycles1, 3, 5, etc.) of the Adjuvant Phase and 
≤ 14 days before each visit (approximately  every  8 weeks) of the Follow- Up Phase.  MR imag es 
will also be reviewed centrally  by an independent blinded reviewer for radiographic evidence of 
disease progression.  When study  drug (ABT -414/placebo) is discontinued for any  reason, a 
Final Study  Drug Visit will be conducted.  All subjects will have a 35- Day and 49 -Day 
Follow -
Up Visit (± 3 days) after the last dose of ABT- 414/placebo.  The 49 -Day Follow -Up 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
31Visit will focus on evaluation of ongoing adverse events.  Overall survival will be assessed 
quarterl y after stud y discontinuation.
Neurocognitive t esting and patient -reported outcomes will be assessed approximately  every  
8weeks during the Adjuvant and Follow -Up Phases, and then at disease progression.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
32Table 1.  Study Activities –
Chemoradiation Phase ScreeningaChemoradiation Phaseb
Activity Screening 1 Screening 2Day 1 Wk 1 
(Fraction 1 
of RT)Day 1 of 
Wk 2Day 1 of 
Wk 3Day 1 of 
Wk 4Day 1 of 
Wk 5Day 1 of 
Wk 6Day 1 of 
Wk 7
Informed Consent X
Medical and Oncologic History X
Physical Exam (Including Weight and 
Karnofsky Performance Status)cX X X X
Vital Signs X X X X
Ophthalmology Exam X XdXd
ECGeX
Serum Pregnancy Test X Xf
Chemistry X X X X X X X X
Hematology X X X X X X X X
Urinalysis X
Coagulation X
MRI With and Without Contrast Xk
Submit Tissue Sample for Confirmation of 
GBM, testing of EGFR amplification, 
EGFRvIII and MGMTX
Adverse Event Assessment/Concomitant 
Medications/Supportive CareX X X
Radiation TherapygX
Temozolomide Administration Xh
ABT-414 or Placebo Administration X X X
Prophylactic Eye Drop Administration XiXiXi
Randomization X
EORTC -QLQ -C30/BN20 Xj
MDASI -BT Xj
NEI VFQ -25 Xj
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
33Table 1.  Study Activities –
Chemoradiation Phase ScreeningaChemoradiation Phaseb
Activity Screening 1 Screening 2Day 1 Wk 1 
(Fraction 1 
of RT)Day 1 of 
Wk 2Day 1 of 
Wk 3Day 1 of 
Wk 4Day 1 of 
Wk 5Day 1 of 
Wk 6Day 1 of 
Wk 7
Neurocognitive Function
(HVLT -R, COWA -FAS)Xj
EQ-5D-5L and EQ -5D-VAS Xj
Wk = Week; F/U = Follow -up; RT= Radiation Therapy; KPS = Karnofsky Performance Status; EORTC -QLQ -C30/BN20 = EORTC Quality of Life Questionnaire, Cancer and Brain 
modules; MDASI -BT = MD Anderson Symptom Index for Brain Tumors;  NEI VFQ-25 = National Eye Institute Visual Functioning Questionnaire – 25; 
HVLT -R = Hopkins Ve rbal Learning Test-Revised; COWA = Controlled Oral Word Association (FAS form); EQ -5D-5L = EuroQoL 5 Dimensions; VAS = Visual analog scale
a. Screening procedures may be conducted before or after results of EGFR amplification are received.
b. Chemoradiation Phase will be approximately 6 weeks (up to 7 weeks) of treatment with RT, TMZ, and ABT -414.
c. Height will be assessed at Screening only.  Weight will be collected at all visits.  Complete physical examination will be pe rformed at Screening only.  Symptom directed physical 
examination will be performed at all other designated visits as clinically indicated.
d. Ophthalmology exams are to be performed 7 to 14 days after the 2ndand 3rdinfusions of ABT -414/placebo and must be completed prior to the next infusion of ABT -414/placebo.
e. ECG will be performed at screening, final visit and when clinically indicated.
f. For female subjects of childbearing potential, a serum pregnancy test will be performed within 21 days before Day 1 of chemor adiatio n.  A urine or serum pregnancy test will be 
done on Day 1 Week 1 if a serum pregnancy test was performed more than 7 days before Day 1.
g. During Chemoradiation Phase, radiation therapy will begin on Day 1, Week 1 (Fraction 1).  60 Gy will be administered in ~30 fractions over 6 weeks (up to 49 days) per the local 
prescribing information or local institutional guidelines.
h. During Chemoradiation Phase, temozolomide (75 mg/m2) will be given once per day, continuously (including weekends), from Day 1, Week 1 until completion of radiotherapy 
(up to 49 days).
i. Prophylactic eye drops will be administered for 7 days, from 2 days before until 4 days after, each dose of study drug (ABT -414 or placebo), as described in Section 5.5.
j. Baseline measure can be done at any time during Screening, up to and including Day 1 of Chemoradiation Phase, but preferably after EGFR amplification has been confirmed.  
The assessments will be translated into the local languages.
k. A brain MRI scan with and without contrast, performed at any time after diagnostic biopsy/resection but prior to randomization, is required to serve as a baseline scan for RANO 
tumor response assessments.  If a subject starts chemoradiation more than 28 da ys after surgery, the baseline MRI is to be performed no more than 21 (but preferably fewer) days 
prior to Day 1 Week 1 of Chemoradiation Phase and should allow sufficient time to revise the radiation therapy plan if needed due to a significant change in t umor since surgery.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
34Table 2.  Study Activities –
Adjuvant Phase Adjuvant Phase –28-Day Cyclesa
ActivityDay 1 of 
Every 
Cycle 
(1, 2, 3 
etc.)Day 1 of 
Odd -
Numbered 
Cycles 
(1, 3, 5, 
etc.)Day 1 
of 
Cycle 2Day 15 
of 
Every 
CyclebDay 22 
of 
Every 
CyclecFinal 
Study 
Drug 
Visitd35-Day 
F/Ue49-Day 
F/UFollow -
Up 
Phase (Every 
8Weeks 
Until Disease 
Progression)fAt 
Progression Survival
Physical Exam (Including Weight and 
Karnofsky Performance Status)gX X XdX X
Vital Signs X X X X
Ophthalmology ExamhX X Xi
ECG X
Chemistry X X X
Hematology X X X X
MRI and Clinical Disease Progression 
AssessmentXjXd,kXj
Adverse Event 
Assessment/Concomitant 
Medications/Supportive CareX X X X Xr
Temozolomide Administration Xl
ABT-414 or Placebo Administration XmXm
Prophylactic Eye Drop Administration XnXn
NEI VFQ -25oX X
EORTC -QLQ -C30/BN20oX X Xp
MDASI -BToX X Xp
Neurocognitive Function (HVLT- R, 
COWA)oX X Xp
EQ-5D-5L and EQ -5D-VASoX X Xp
Treatment Satisfaction Question X X Xp
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
35Table 2.  Study Activities –
Adjuvant Phase Adjuvant Phase –28-Day Cyclesa
ActivityDay 1 of 
Every 
Cycle 
(1, 2, 3 
etc.)Day 1 of 
Odd -
Numbered 
Cycles 
(1, 3, 5, 
etc.)Day 1 
of 
Cycle 2Day 15 
of 
Every 
CyclebDay 22 
of 
Every 
CyclecFinal 
Study 
Drug 
Visitd35-Day 
F/Ue49-Day 
F/UFollow -
Up 
Phase (Every 
8Weeks 
Until Disease 
Progression)fAt 
Progression Survival
Survival AssessmentqX
Wk = Week; F/U = Follow -up; RT = Radiation Therapy; KPS = Karnofsky Performance Status; EORTC -QLQ -C30/BN20 = EORTC Quality of Life Questionnaire, Cancer and Brain 
modules; MDASI -BT = MD Anderson Symptom Index for Brain Tumors; NEI VFQ -25 = National Eye Institute Visual Functioning Questionnaire – 25; 
HVLT -R = Hopkins Verbal Learning Test -Revised; COWA = Controlled Oral Word Association (FAS form); EQ -5D-5L = EuroQoL 5 Dimensions; VAS = Visual Analog Scale
a. Assessments in the Adjuvant Phase will be based on 28 -day treatment cycles, with the first cycle starting approxima tely 4 weeks after completion of radiation therapy.  Subjects 
will receive concomitant TMZ and study drug (placebo or ABT-414) for the first 6 cycles,and study drug monotherapy for an additional 6 cycles or until disease progression or 
study drug discontin uation.  Subjects demonstrating continued benefit and no unacceptable toxicity from adjuvant TMZ can continue adjuvant TMZ to a maximum of 12 cycles at 
the discretion of the Investigator if this is considered an acceptable standard of care per local regula tions.  For subjects demonstrating continued benefit and no unacceptable 
toxicity with ABT -414/placebo after 12 cycles, the Adjuvant Phase may be extended at the discretion of the Investigator in discussion with the Neuro -Medical Oncology Chair or 
AbbVie M edical Monitor, with continued ABT -414/placebo treatment until disease progression is confirmed.
b. Day 15 visit will not be performed after discontinuation of study drug (ABT -414/placebo) treatment.
c. As per TMZ prescribing information, during the 28-day cycle of TMZ, a blood count for ANC and platelets should be performed 21 days (± 2 days) after the start of each TMZ 
cycle.  If the ANC falls below 1,500/µL or if the platelet count falls below 100,000/mm3, then blood counts should be performed weekly unt il recovery to these levels before 
TMZ dosing. A certified local lab may be used instead of central lab; if so, ANC and platelet results should be reported in t he eCRF.  Day 22 testing may be omitted for cycles in 
which TMZ is not administered or if local prescribing information allows for a different testing schedule for ANC and platelets.
d. Final Study Drug Visit to be performed approximately 14 days after last dose of ABT -414/placebo.  The physical examination and MR imaging from the first visit of the 
Follow -Up Phase will be used for the Final Study Drug Visit if these visits coincide (e.g., if the subject completes 12 cycles of Ad juvant Phase).
e. To be performed 35 days (± 3 days) after the last dose of study drug (placebo or ABT -414).  If the Final S tudy Drug Visit is more than 35 days after the last dose of study drug, 
then 35 -day safety follow -up procedures will not be performed.
f. Visits in Follow -Up Phase to occur every 8 weeks, beginning 8 weeks after Day 1 of the last odd -numbered cycle in the Adjuvant Phase.
g. Height will be assessed at Screening only.  Weight will be collected at all visits.  Complete physical examination will be pe rformed at Screening only.  Symptom directed physical 
examination will be performed at all other designated visi ts as clinically indicated.
h. Ophthalmology exam to be performed prior to ABT -414/placebo dosing on Day 1 (or up to 7 days prior to Day 1) of Cycle 1, Cycle 2, and every odd -numbered cycle thereafter 
(Cycles 3, 5, 7, etc.).  Ophthalmology exam for Cycle 1 Day 1 may be omitted if the subject had no corneal microcysts or ocular adverse events during or after the 
Chemoradiation Phase.  Ophthalmology exams may be discontinued if the subject has been on Level 1 eye drops with no ocular to xicity for 2 consecutiv e eye exams.
i. Ophthalmology exam at Day 35 Follow -Up Visit to be done only if subject had corneal microcysts or other ocular findings related to ABT -414 or ocular steroids on previous 
exam and repeated at least every 8 weeks until satisfactory resolution of eye toxicities. 
j. MRI to be performed ≤ 14 days before the start of each odd -numbered cycle or follow -up visit, starting at Cycle 1.  If the subject discontinues study drug prior to disease 
progression, MRIs should continue to be obtained approximate ly every 8 weeks until disease progression is confirmed.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
36k. MRI to be performed, if not performed within last 3 weeks, if subject withdraws from study prior to disease progression.
l. TMZ will be administered once daily on Days 1 through 5 of each 28 -day c ycle for 6 cycles per the local prescribing information.
m. ABT-414 or placebo infusion will be administered on Day 1 and Day 15 of each 28 -day cycle for 12 cycles.  For subjects demonstrating continued benefit and no unacceptable 
toxicity with ABT -414/pla cebo after 12 cycles, the Adjuvant Phase may be extended at the discretion of the Investigator in discussion with the Neuro -Medical Oncology Chair or 
AbbVie Medical Monitor, with continued ABT -414/placebo treatment until disease progression is confirmed.
n. Prophylactic eye drops will be administered daily for 7 days with each dose of ABT -414/placebo, from 2 days before until 4 days after each dose of study drug (ABT -414 or 
placebo), as described in Section 5.5.
o. These assessments should be completed prio r to study drug administration and any other study procedures being performed at these visits, and prior to discussing with t he subject 
whether disease progression has occurred.
p. To be assessed at the time of disease progression (as soon as possible), re gardless of the study phase in which disease progression occurred, or upon study withdrawal for any 
other reason.
q. Survival will be assessed quarterly after treatment discontinuation until death.
r. If the subject is unable to return to the site for the Day 49 Follow Up Visit, a phone call may be conducted to obtain AE and concomitant medication information.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
37Table 3.  Blood Samples for Biom arker and Pharmacokinetic Schedule of Assessments*
Chemoradiation Phase
ActivityDay 1 Wk 1 
(Fraction 1 of RT) Day 1 of Wk 2 Day 1 of Wk 3 Day 1 of Wk 4 Day 1 of Wk 5
Plasma Markers 0 hour (pre -dose)
Serum Markers 0 hour (pre -dose)
PK –ABT -414 and Total 
ABT-806 Assays0 hour (pre -dose) & within 
30 min post -doseAnytime from 4 days 
before (preferred) to 
1day after the scheduled 
visits 0 hour (pre -dose) & 
within 30 min post -doseAnytime from 4 days 
before (preferred) to 
1day after the scheduled 
visits0 hour (pre -dose) & within 
30 min post -dose
PK –CysmcMMAF assay 0 hour (pre -dose) & within 
30 min post -doseAnytime from 4 days 
before (preferred) to 
1day after the scheduled 
visitswithin 30 min post -dose Anytime from 4 days 
before (preferred) to 
1day after the scheduled 
visitswithin 30 min post -dose
PK – Antidrug Antibody 0 hour (pre -dose) 0 hour (pre -dose) 0 hour (pre -dose)
Pharmacogenomic sample 0 hour (pre -dose)
Adjuvant Phase (28 -Day Cycles) and Post -Progression
Activity Day 1 of Cycle 1Day 1 of Cycles 2 –12 
(Every Cycle)Day 1 of Cycle 14 and 
Every Other Cycle (14, 
16, 18, etc.) while 
ABT -414/Placebo 
Treat ment is Ongoing Final Study Drug Visit Post-Progression**
Plasma Markers 0 hour (pre -dose) 0 hour (pre -dose)
Serum Markers 0 hour (pre -dose)
Relapse Biopsy collection yes
PK –ABT -414 and Total 
ABT-806 Assays0 hour (pre -dose) & within 
30 min post -dose on Day 1 
of Cycle 1 0 hour (pre -dose) 0 hour (pre -dose)
PK –Antidrug Antibody 0 hour (pre -dose) 0 hour (pre -dose) 0 hour (pre -dose)
* For subjects in the hepatic sub-study the Biomarker and Pharmacokinetic Schedule of Assessments can be found in Appendix IX.  Additional blood for PK can be collected at the 
discretion of the investigator in discussion with the Sponsor.
** For subjects who undergo tumor surgery (biop sy or resection) for medically directed reasons at any time during treatment or post -progression, a portion of the tumor tissue can be 
submitted for biomarker -related research.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
384.2 Study Procedures
The study  procedures outlined in Table 1 and Table 2 are discussed in detail in this section with 
the exception of the monitoring of treatment compliance (Section 5.10) and the collection of 
adverse event information (Section 7.0).  All study data will be recorded on electronic case 
report forms (eCRFs), with the exception of pregnancy  reporting forms and the neurocognitive 
function tests.
Procedures performed at Screening will serve as baseline, unless repeated prior to dosing; in 
which case the latter will serve as baseline.  Unless otherwise noted, subsequent study  
procedures should be performed within 3 day s prior to the scheduled study visit date when 
possible.  Subjects who are not randomized will be considered a screen failure and will not be 
included in an y intent -to-treat anal yses.
Informed Consent
The informed consent for tissue and other pre -screening and for activities in the main study  may  
be used separatel y or combined as a single informed consent document where allowed b y local 
regulation and t he IEC/IRB.
The IEC/I RB-approved informed consent must be signed and dated b y each subject or the 
subject's legally  acceptable representative prior to the submission of tumor tissue for screening, 
undergoing an y stud y procedures or before an y prohibited me dications are withheld from the 
subject in order to participate in this study .  Separate informed consent documents will also be 
required for the optional substudies in this protocol:  for the collection of pharmacogenetic 
samples and the collection of tumor tissue post- treatment after disease progression, Section 15.3.
Tumor tissue testing will be conducted to confirm GBM diagnosis (central review of tumor 
histopathology ), determination of EGFR amplification, EGFRvIII mutation and MGMT
methy lation status a re all required for subject randomization.  All clinical screening procedures 
should proceed simultaneously  while tissue testing results are pending and should not be delay ed 
until after EGFR amplification status is obtained.
For details on obtaining and d
ocumenting informed consents, Section 15.3.
Medical and Oncologic History
The following will be collected during the Screening Visit:
Demographic information, including age, sex, and ethnicity .  Ethnicit y will include whether 
a subject is first generation Han Chinese.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
39Complete medical history, including documentation of an y clinicall y significant medical 
condition.
History  of tobacco and alcohol use.
Detailed oncologic history  including:
Date of primary  cancer diagnosis;
Histology  at the time of study  entry ;
Date and extent of surgical resection ;
Neurologic deficits, if any , at the time of enrollment;
At each visit, the subject's medical history  will be reviewed, and an y changes from baseline will 
be recorded in the source documents and on the adverse event eCRF.  On Day  1, any  changes 
observed from the Screening Visit will be recorded in the subject's medical history .
Physical Examination
A complete ph ysical examination (PE), including body  weight and height, will be performed at 
Screening.  A s ymptom direc ted ph ysical examination will be performed at all other designated 
visits as clinically  indicated.  Weight will be collected at all visits and a PE will be performed as 
clinically  indicated as outlined in Table 1.  Clinically  significant changes from baseline will be 
documented in the source documentation and electronic case report forms (eCRFs) as adverse 
events.
ABT -414-Targeted Ophthalmologic Examinations (ABT - 414-TOE)
The ABT -414 Targeted Ophthalmologic Examination (ABT -
414 TOE) was designed for this 
study  to sy stematicall y identify and grade objective findings of ABT -414-related ey e toxicity  and 
to assess for adverse effects potentially  related to ocular steroid use.  The ABT -414 TOE will be 
provided as stud y specific start up materials.  Changes in the steroid potency  of prophy lactic ey e 
drops to be used with ABT -414/placebo dosing will be based on corneal findings from the 
ABT -414- TOE assessments performed throughout the study , as described below in Table 4.
Subjects will undergo ophthalmologic examinations as follows:
Screening:   prior to starting chemoradiation
Any clinically  significant abnormal findings at Screening ophthalmologic examination 
are to be documented a s part of the subject's medical history .
Chemoradiation Phase:   within 7 day s to 14 day s after the 2ndand 3rdinfusions of 
ABT -414/placebo
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
40Adjuvant Phase:   within 7 day s prior to ABT -414/placebo dosing on Day  1 of Cy cle 1, 
Cycle2, and all odd -numbered cy cles thereafter (Cy cles 3, 5, 7, etc.) and at the 
35-DayFollow -Up Visit.
Additional ey e exams may  be performed as needed throughout the study , including 
additional exams if evidence of microcy stic keratopathy  persists after the 35 -Day Follow -Up 
Visit to mo nitor reversibility .  A subset of sites will be asked to provide ophthalmic 
photograph y (e.g., slit lamp, confocal microscop y, Heidelberg Retina Tomographer [HRT3], 
etc.) of corneal abnormalities.
Ophthalmologic exams may be discontinued for subjects who h ave no evidence of eye toxicity on 
2 consecutive examinations after being decreased to Level 1 eye drops.
Qualified medical personnel will perform the ophthalmologic examination, which will include 
assessments of visual acuity , intra -ocular pressure, fundu
scopic examination (at Screening,  35 
DayFollow -Up Visit only ), and slit lamp examination according to standard procedures of the 
ophthalmologist.  The corneas will be evaluated via slit lamp at every  exam to identify  potential 
pathological changes.  Grading on the ABT -414-TOE findings for "microcysts/edema" and 
"superficial punctate keratopathy " will be used to inform potential changes in the level of 
prophy lactic steroid ey e drops to be used with ABT
-414/placebo dosing, as described in 
Section 5.5.  Gradi ng for these two items is as follows:
Microcy sts/Edema
0 = None
+0.5 (Trace) = Trace, localized epithelial haze
+1 (Mild) = Dull glass appearance that may  include fine individual microcy stic 
changes
+2 (Moderate) = Dull glass appearance of epithelium with large number of vacuoles 
with or without stromal edema
+3 (Severe) = Epithelial bullae and/or whorl keratopathy , localized or diffuse, 
with or without stromal striae
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
41Superficial Punctate Keratopathy
0 = None
+0.5 (Trace) = Trace (1 – 5 puncta)
+1 (Mild) = Mild (6 – 20 puncta)
+2 (Moderate) = Moderate (> 20 puncta, but countable)
+3 (Severe) = Severe (too man y puncta to count)
Table 4:  Ophthalmology Examination Schedule
STUDY VISIT/PERIOD* EXAM REQUIRED? COMMENTS
Screening Yes Establishes baseline assessment for 
corneal exam and visual acuity
Chemoradiation Phase
Day 1, Week 5 ( ≤ 7 days before 
Week 5 ABT -414/placebo dose)Yes Do not decrease Level of eye drops until 
after the subject has received at least 
2eye exams
Day 1, Week 7 (7 –14 days after 
Week 5 ABT -414/placebo dose)Yes --
Recovery Period
No ophthalmology exam required No As-needed basis only
Adjuvant Phase
Day 1, Cycle 1** No Exam not required if the subject had no 
corneal microcysts or ocular adverse 
events during or after the 
Chemoradiation Phase
Day 1, Cycle 2* Yes --
Day 1 of Cycles 3, 5, 7, etc.* Yes*** Continue while subject is taking study 
drug (ABT -414/placebo)
35-Day Follow -Up Visit Yes
Ophthalmology exams required as scheduled for subjects on Level 2 –4 eye drops.
* Additional eye exams may be performed as needed.  For eye toxicity considered by the investigator to be related to 
ABT-414, ophthalmology exams will be repeated until symptoms related to eye toxicity have resolved.
** Scheduled ophthalmology exams may be done at any time, up to 7 days before the scheduled date, prior to the scheduled 
infusion of ABT-414/placebo.
*** Eye exams may be discontinued for subjects who have no findings of ocular toxicity on 2 consecutive scheduled exams
while on Level 1 (non -steroid) drops.
Adverse Event Reporting of ABT -414- TOE Findings
ABT -414- TOE reports will be reviewed b y the Investigator (or medically  qualified delegate).  
Examination records should be retained in the subject's source file.  With the exception of the 
corneal findings described below, decisions on which findings, if an y, from the ophthalmologic 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
42examination or ABT -414-TOE report to be reported as adverse events will be made according to 
the Investigator's judgment.  Adverse events wi ll be graded according to National Cancer 
Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.4.0 criteria , as 
discussed in Section 7.2 and not according to the ABT -TOE grading system .
To ensure consistent reporting of microcy stic kerato pathy , which is characteristic of ABT -414 
but for which there is no Medical Dictionary  for Regulatory  Activities (MedDRA) preferred term 
or CTCAE adverse event term, an y abnormal finding on the "corneal epithelium" and/or 
"superficial punctate keratopathy "fields of the ABT -414-TOE will be recorded as an adverse 
event, using the term "microcy stic keratopathy ."  These events will be graded as shown in 
Table 5
, which is based on CTCAE criteria for "keratitis."
Table 5.  Adverse Event Reporting in eCRF for Cor neal Findings from the ABT -414- TOE
Corneal finding from  
ABT -414-TOEAdverse Event Report for eCRF
Adverse Event 
Verbatim  Term CTCAE Grade
Microcysts/Edema
OR
Superficial punctate 
keratopathyMicrocystic 
keratopathy1 –Asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated
2 –Symptomatic; medical intervention indicated (e.g., topical 
agents); limiting instrumental ADL
3 –Decline in vision (worse than 20/40 but better than 20/200); 
limiting self care ADL
4 –Perforation or blindness (20/200 or w orse) in the affected eye
Vital Signs
Vital sign determinations of sitting blood pressure, heart rate and bod y temperature will be 
measured at all visits, as outlined in Table 1.  If possible, blood pressu re and heart rate 
measurements should not immediately  follow scheduled blood collections.
Blood pressure and pulse rate should be measured after the subject has been sitting for at least 
3minutes.
12-Lead Electrocardiogram (ECG)
A resting 12 -lead ECG will be performed for all subjects as outlined in Table 1 and Table 2.
Each ECG will be printed and evaluated b y an appropriatel y qualified ph ysician (in consultation 
with a cardiologist if necessary ) at the study  site.  A qualified phy sician will determine if any 
findings outside normal phy siological variation are clinically  significant, document the presence 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
43or lack of findings and the clinical significance (if any ) on the ECG report and then sign and date 
the ECG report.
The ECG tracings will be retained as source documentation in the subject's records at the study  
site.  The baseline (Screening) ECG will be used to document baseline status of the subject so 
that safet y comparisons can be made if necessary.  Repeat ECGs will be performed whenever 
clinically  necessary .
Karnofsky Performance Status
Karnofsk y Performance Status (KPS)5will be evaluated at the same time as the physical 
examinations.  The status will be determined as:
100 –normal, no complaints, no signs of disease
90 – capable of normal activity ,few s ymptoms or signs of disease
80 – normal activity  with some difficulty , some s ymptoms or signs
70 – caring for self, not capable of normal activity or work
60 – requiring some help, can take care of most personal requirements
50 – requires help often, requires frequent medical care
40 – disabled, requires special care and help
30 – severel y disabled, hospital admission indicated but no risk of death
20 – very ill, urgently  requiring admission, requires supportive measures or treatment
10 – moribund, ra pidly  progressive fatal disease processes
0 –death
Pregnancy Test
For female subjects of childbearing potential, a serum pregnancy  test will be performed 
≤ 21 days before Day  1 of chemoradiation.  A urine or serum pregnancy  test will be done on 
Day 1 Wee k1 if a serum pregnancy  test was performed most recentl y more than 7 days before 
Day 1.
The test may  be repeated at the discretion of the investigator at any  time during the study .  A 
lactating or pregnant female will not be eligible for participation in this study .
Clinical Laboratory Tests
All subjects will have the laboratory  anal yses performed as outlined in Table 6.  Laboratory  
samples will be assessed using a certified central laboratory , and these data will be used for all 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
44data anal ysis.  The centra l laboratory  for this study will provide instructions regarding the 
collection, processing, and shipping of samples.
Clinical chemistry , hematology , and urinal ysis labs will be collected according to the schedule 
shown in Table 1 and Table 2 (± 3 day s).  Screening labs will be performed within 21 day s prior 
to Day  1 of the Chemoradiation Phase, and results must be reviewed by  the I nvestigator or 
designee prior to dosing on Day  1.  Screening labs may  be repeated if clinically  indicated to 
confirm eligibilit y.
The Principal Investigator or designee as noted on the delegation of authority log will review, 
initial and date all laboratory  results.  Any  laboratory  value outside the reference range that is 
considered clinically  significant by  the Investigator will be followed as appropriate.  Clinically 
significant laboratory values will be recorded as adverse events if they  meet the criteria as 
specified in Section 7.
A certified local reference laboratory  may  perform laboratory  testing as needed for immediate 
subject management.  For laboratory  results that are required per protocol to make study  
treatment decisions (e.g., to determine eligibility  to continue TMZ), results from a certified local 
lab may  be used if central results may  not be available prior to dosi ng.  However, the sample for 
central laboratory  anal ysis should be drawn and sent as per the protocol schedule to be used in 
the data analy sis.  In the case of contradictory  results, in which the local lab result supports 
eligibility  or treatment decision that would be prohibited based on the central lab result, the local 
laboratory  result must be recorded in the eCRF to be included in the data analy sis.  Other local 
laboratory  values should not be captured in the eCRF.  The appropriate documents will be 
collected for both the central and local laboratories, as needed.
For Day  22 hematology  assessments during the Adjuvant Phase (performed when adjuvant TMZ 
treatment is ongoing) a certified local laboratory  may  be used alone without central testing.  If a 
central laboratory  result is not available for the Day  22 lab, the local lab results for platelet count 
and absolute neutrophil count (ANC) will be recorded in the eCRF.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
45Table 6. Clinical Laboratory Tests
Hem atology Clinical Che mistry Urinalysis
Hem atocri t
Hem oglobin
Red blood cell (RBC) count
White blood cell (WBC) count
Neutrophils
Bands (if detected)
Lymphocytes
Monocytes
Basophils (if detected)
Eosinophils (if detected)
Absolute platelet count
Mean corpuscular volume (MCV)
Coagulation (screening Only)
Prothrombin time (PT)
Activated PartialThromboplastin 
Time(aPTT)
International normalized ratio 
(INR)Blood urea nitrogen (BUN)
Creatinine
Total bilirubin
Serum glutamic -pyruvic
transaminase (SGPT/ALT)
Serum glutamic -oxaloacetic
transaminase (SGOT/AST)
Alkaline phosphatase (ALP)
Gamma -glutamyl transferase (GGT)
Sodium
Potassium
Calcium
Inorganic phosphorus
Glucose
Cholesterol
Triglycerides
Total protein
Uric Acid
Albumin
Lactate dehydrogenase (LDH)
Magnesium
Chloride
BicarbonateSpecific gravi ty
Ketones
pH
Protein
Blood
Glucose
Microscopic examination if 
dipstick results are positive
For an y laboratory  test value outside the reference range that the Investigator considers to be 
clinically  significant:
The Investigator will follow the out-of- range value to a satisfactory clinical 
resolution.
A laboratory  test value that requires a subject to be discontinued or interrupted from 
any study  treatment agent (ABT -414, TMZ or RT) or from the study , or requires a 
subject to receive treatment (medical intervention) will be recorded as an adverse 
event.
MRI and Clinical Assessment for Disease Progression
A brain MRI scan with and without contrast, performed at an y time after diagnostic surgery  or 
biopsy  but prior to randomization, is required to serve as a baseline scan for RANO tumor 
response assessments.  The most recent scan done prior to randomization will be used as the 
baseline scan.  A baseline MRI  must include the image sequences (T1 with and without contrast 
and T2 FLAIR) required for making RA NO assessments.  I f a subject starts chemoradiation 
≤ 28 days after surgery , the post -operative MRI scan (including an intraoperative or 
post-operative MRI scan) performed as part of standard care prior to Screening may  be used as 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
46the baseline scan for RAN O assessments; if so, this scan must be included with the submission 
of scans for central imaging reviews.  If the subject starts chemoradiation more than 28 day s 
after surgery , then the baseline MRI  must be performed within 21 (preferably  fewer) day s prior 
to Day  1 Week 1 of Chemoradiation and must allow sufficient time to revise the radiation 
therap y plan if needed due to a significant change in tumor since surgery.
Post-baseline MRI s with contrast will be obtained ≤ 14 day s before Day  1 of each odd -numbe red 
cycle (C ycles 1, 3, 5, etc.) of the Adjuvant Therapy Phase; approximately  every  8 weeks of the 
Follow -Up Phase ( ≤ 14 day s before each Follow -Up Visit), and at the Final Study  Drug Visit (if 
the subject withdraws from the study  prior to disease progress ion and has not had an MRI with 
contrast within the previous 3 weeks).  At the discretion of the Investigator, MRI  with contrast 
may be performed at additional times as clinically indicated or as needed to assess whether there 
has been progression of disea se.  If the subject discontinues study  drug prior to disease 
progression, every  effort should be made to acquire MRI s according to the same schedule while 
the subject is willing.
Scheduled tumor assessments are not affected b y delay s in therapy  or drug hol idays.  Subjects 
will continue to be monitored b y the same techniques as at baseline.  Ideally, subjects should be 
imaged on the same MRI scanner, or at least with the same magnet strength, for the duration of 
the study  to reduce difficulties in interpreti ng changes.  The Standardized Brain Tumor Imaging 
Protocol should be used wherever technicall y feasible at the site
.6
Changes in measurable lesions over the course of therap y and changes in systemic corticosteroid 
dose and clinical status will be assessed, and the assessment of disease progression will be 
determined b y the Investigator using the updated Response Assessment in Neuro -Oncology  
(RANO) criteria7(Appendix I ).  MRI images will also be reviewed centrally  by an independent 
blinded reviewer for radi ographic evidence of disease progression.
Scan Submission Quality Assurance and Quality Control in Imaging
The designated central imaging vendor will track all scans of all subjects received from the sites 
and will request/query  missing/incomplete scans.  Scan submissions should include pre -study  
(pre-surgical and post- surgery ) scans and all on -study  scans.  Furthermore, if the scans arrive in 
unacceptable qualit y or in a non-acceptable format, the site will be informed to provide substitute 
scans.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
47Scans ma y be uploaded by the participating centers via a central imaging platform.  Please refer 
to the imaging guidelines/manual for more details regarding submission of images, qualification 
of sites, and imaging QA/QC level description.
Assignment of Subject Nu mbers
All screening activities must be completed and reviewed prior to randomization.  Subjects who 
meet the eligibility  criteria will proceed to randomization via the I RT s ystem.  Randomization 
may be registered in IRT up to 3 day s prior to Day  1 Week 1 o f chemoradiation.
Screening numbers will be unique 5 -digit numbers and will begin with 10101 with the 
first3digits representing the investigative site, and the last 2 digits representing the subjects at 
that site.  Randomized subjects will keep their scr eening number as their subject number.  
Subjects will be randomized on Day  1 as described in Section 5.9 and will receive a separate 
unique 6 digit randomization number that will be recorded automaticall y in the eCRF through the 
IRT s ystem.  This randomiza tion number will be used only b y the Sponsor for loading the 
treatment schedule into the database.
Systemic Corticosteroid Use
Systemic corticosteroid dates of use, dosing, and frequency  will be recorded as concomitant 
medications beginning from 7 day s prior to the start of chemoradiation and throughout the study .
Neurocognitive Function –Verbal Memory and Executive Function
Two brief, sensitive, repeatable, highly  standardized, and objective tests will be used to assess 
neurocognitive changes across time; the Hopkins Verbal Learning Test -Revised (HVLT- R) and 
COWA -FAS verbal fluency  test.  The COWA test form used in this trial (which includes the 
letters F, A, and S in English and frequency -matched letters in other languages) is different than 
the two forms used as part of the Multilingual Aphasia Exam (MAE) which use C, F, and L or P, 
R, and W.  Several previous studies of neurocognitive function in subjects with GBM or 
metastatic brain tumors have used the MAE COWA test as part of a multi- domain assessment
called the Clinical Trial Battery  (CTB).8,9  The FAS and CFL forms of the COWA test may  vary  
in difficulty , which could in turn influence subject performance
.10  The Trail Making Test 
(TMT), which is also included as part of the CTB will not be used in th is study  because 
treatment -related changes in visual acuity  may  confound the interpretation of neurocognitive 
outcomes measured b y this assessment.  Administration of the HVLT -R and COWA -FAS verbal 
fluency  test is practical in terms of burden on the subjec t.11,12 
 Neurocognitive function has been 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
48demonstrated to predict tumor progression13and to independentl y predict survival for subjects 
with central nervous sy stem tumors.14-17
The neurocognitive tests are administered b y certified test administrators at each site, and the 
total time for the cognitive testing is approximately 30 minutes, as follows:
Cognitive Dom ain TestAdministration Time 
(minutes)
Mem ory Hopkins Verbal Learning Test -Revised185 
Executive Function FAS verbal fluency105
The healthcare professional (e.g., nurse, psy chologist) at each study  site who is responsible for 
test administration in this study  must be trained and pre -certified.  Training materials and testing 
forms are produced, distributed and collected b y VeraSci (formerl y NeuroCog Trials) 
(http://www.verascience.com).  See the VeraScitesting materials for additional details regarding 
administration and scoring of these assessments.
Subjects will complete the neurocognitive testing as outlined in Table 1 and Table 2.  
Neurocognitive testing should be completed prior to study  drug administration and any  other 
study  procedures being performed at these visits, and prior to discussing with the subject that 
their disease has progressed.
Health -Related Quality of Life (HR QoL)
Health-related qualit y of life will be assessed with the European Organization for Research and 
Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ -C30) version 320
and with the EORTC Brain Cancer module (QLQ- BN20) module.21  The QL Q - C30 is 30- item 
patient self -report questionnaire composed of both multi -item and single scales, including 
fivefunctional scales (phy sical, role, emotional, social, and cognitive), three s ymptom scales 
(fatigue, nausea and vomiting, and pain), a global h ealth status/HRQoL scale, and six single 
items (dy spnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).  
Subjects rate items on a four- point scale, with 1 as "not at all" and 4 as "very  much."  The 
QLQ -C30 was developed and validated for use in a cancer patient population, and its reliability  
and validity  is highl y consistent across different language -cultural groups.20
The QLQ -BN20 is a 20 -item patient self- report questionnaire that was developed specifically  as 
a module for subjects with brain cancer.  It consists of four domain scores, including future 
uncertaint y, visual disorder, motor d ysfunction, and communication deficit, as well as 
seven individual sy mptom items (headache, seizures, drowsiness, hair loss, itching, diff iculty 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
49with bladder control, and weakness of both legs).  Subjects rate items on a four -point scale, with 
1 as "not at all" and 4 as "very  much."  A retrospective validation study  has been conducted 
confirming its ps ychometric validity.22
Subjects will com plete the EORTC QLQ -C30/BN20 as outlined in Table 1 and Table 2.  These 
assessments should be completed prior to study  drug administration and any  other study  
procedures being performed at these visits, and prior to discussing with the subject that their 
disease has progressed.
MD Anderson Symptom Inventory –Brain Tumor
The MD Anderson Sy mptom I nventory  brain tumor module (MDASI -BT) is a patient self -report 
or interviewer -administered measure used to assess the severit y of multiple brain tumor -related 
symptoms and the impact of these s ymptoms on daily  functioning in the last 24 hours.23  It was 
developed and validated specificall y for use in patients with primary brain tumors.  The 
MDASI -BT consists of the core 13 s ymptom items (pain, fatigue, nausea, d isturbed sleep, 
distress, shortness of breath, lack of appetite, drowsiness, dry  mouth, sadness, vomiting, 
difficulty  remembering, and numbness or tingling), and 6 interference items (general activity , 
mood, walking abilit y, normal work, relations with oth er people, and enjo yment of life and 
9
brain tumor-specific s ymptom items: weakness on one side of the bod y, difficulty 
understanding, difficult y speaking, seizures, difficulty  concentrating, vision, change in 
appearance, change in bowel pattern (diarrhea or constipation), and irritability .  MDASI -BT 
items are rated from 0 to 10, with 0 indicating that the sy mptom is either not present or does not 
interfere with the patient’s activities and 10 indicating that the s ymptom is "as bad as you can 
imagine" or "i nterfered completely " with the patient's life.  S ymptoms can be grouped into 
measured domains including neurologic, cognitive, affective, constitutional, general, and 
gastrointestinal.  The interference items can be grouped into activity -and mood -related 
interference domains.
Subjects will complete the MDASI -BT as outlined in Table 1 and Table 2.  These assessments 
should be completed prior to study  drug administration and any  other stud y procedures being 
performed at these visits, and prior to discussing with the subject that their disease has 
progressed.
EuroQol 5 Dimensions (EQ-5D- 5L) and EuroQol 5 Dimension Value Sets ( EQ -5D- VAS)
The EuroQol 5 Dimensions (EQ-5D- 5L) is a generic preference instrument that has been 
validated in numerous populations. The EQ - 5D- 5L has five dimensions:  mobility , self -care, 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
50usual activities, pain/discomfort and anxiety /depression. These dimensions are measured on a 
five level scale: no problems, slight problems, moderate problems, severe problems, and extreme 
problems.  The EQ-5D-5L also contains a visual analog scale (VAS) to assess the subject's 
overall health.24
Subjects will complete the EQ-5D- 5L and EQ -5D- VAS as outlined in Table 1 and Table 2.  
These assessments should be completed prior to study drug administration and any other stud y 
procedures being performed at these visits, and prior to discussing with the subject that their 
disease has progressed.
NEI VFQ -25
Visual functioning will be assessed with the National Ey e Institute Visual Functioning 
Questionnaire – 25- item version questionnaire (NEI -VFQ -25), a reliable and valid 25 -item 
version of the 51 -item National Ey e Institute Visual Function Questionnaire (NEI- VFQ).  The 
NEI-VFQ -25 evaluates visual function and limitations in daily  activities related to impaired 
visual function as well as the impact of ocular disease on patients' lives.  The NEI VFQ -25 is a 
patient self -report questionnaire consisting of 25 questions, with a total score and subscale scores 
ranging from 0 – 100.  In this questionnaire, the score of 0 corresponds to the lowest and of 100 
to the highest vision -related quality  of life.  There are 12 subscales, each consisting of one or 
more questions, including general health, general vision, ocular pain, near activities, distance 
activities, vision speci fic social functioning, vision specific mental health, vision specific role 
difficulties, vision specific dependency , driving, color vision and peripheral vision.
The NEI VFQ -25 will be assessed as outlined in Table 1 and Table 2.
Treatment Satisfaction Qu estion
A single treatment satisfaction question will be used to assess the subject's treatment experience.
The following question asks about y our treatment experience.  Please choose the response that 
best describes how you feel about the stud y treatment.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
511.Based on your experience in this study , would y ou choose to receive the study  treatment 
again?
(Circle One)
Definitely  would 1
Probably  would 2
Unsure 3
Probably  would not 4
Definitely  would not 5
Survival Assessment
Overall survival will be assessed quarterly  after treatment discontinuation until death.  This can 
be conducted remotel y such as b y phone or other means.
Blood Biomarker Sample Collection
The collection, processing and storage should be performed as described in the study -specific
laboratory  manual.
Collection for Plasma Markers
Approximately  12 mL of blood will be collected pre -dose at time points outlined in Table 3.  
The collection, processing and storage should be performed as described in the study -specific 
laboratory  manual.
Blood Collection for Serum Markers
Approximately  5 mL of blood will be collected pre -dose as outlined in Table 3.  The 
collection should be performed as described in the study -specific laboratory manual.
Collection of Tumor Tissue
Subjects must consent to provide a tissue sample.  Tissue blocks should be submitted as 
described in the stud y-specific laboratory  manual.  Tissue blocks can be returned upon request.  
Collection and submission of the samples should be performed as described in the study -specific
laboratory  manual.  If permission is granted to submit slides, instructions will be provided to the 
sites at that time.
Subjects should have at least 1 block of tumor tissue; submission of 2 blocks is strongly 
encouraged to maximize the chances of eligibi lity.  The size of tumor on the submitted block(s) 
should be sufficient to represent at least 1 square centimeter of viable glioblastoma tumor when a 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
52section is cut onto a slide.  I n rare circumstances, alternative forms of tissue submission may  be 
considered on a case b y case basis in discussion with the Neuro -Medical Oncology  Chair and 
Study  Neuro -Pathologist.
Relapse Tissue Collection
For all subjects in the study  who undergo tumor surgery  for medicall y directed reasons upon 
suspected disease progression or for other medical reasons during treatment , biopsy /resection 
material can be made available for biomarker analysis.
Blood Samples for ABT -414 and Total ABT -806 Drug Concentration Measurements
A single blood draw at the specified time points will allow for ABT -414 and Total ABT -806 
pharmacokinetic anal ysis.  Samples will be collected into appropriatel y labeled evacuated serum 
collection tubes without a gel separator at the time points specified in Table 3.
Pharmacokinetic (PK) samples should not be drawn from the same arm in which study  drug 
(ABT -414 or placebo) is infused.  Samples collected immediately  after infusion should be 
collected after the full infusion procedure is complete.
Approximately  3.0 mL of blood will be collected to provide approximatel y 1.5 mL  serum at each 
time point for both ABT -414 and Total ABT -806 determination (approximately  0.75 mL 
required for each assay ).
The time that each serum sample is collected will be recorded to the nearest minute in the source 
documents and in the appropriate eCRFs.  The date and start/end time of each ABT -414/placebo 
infusion shall also be recorded, in the appropriate eCRFs, to the nearest minute on day s when 
pharmacokinetics sampling is performed.
ADA and Neutralizing ADA (nADA) Assays
Approximately  3.0 mL of blood for ADA/nADA anal ysis will be collected into appropriatel y 
labeled serum collection tubes at the time points specified in Table 3.  It is important that serum, 
and not plasma, be harvested.
ADA/nADA samples should not be drawn from the same a rm in which study drug is infused.
Approximately  3.0 mL of blood will be collected to provide approximately 1.5 mL  serum at each 
time point for both ADA and nADA determination (approximately 0.75 mL required for each 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
53assay ).  Samples for the nADA assay  will be analyzed upon request.  Pharmacokinetics and 
ADA samples collected may  also be used for future assay  development and validation activities.
The time that each serum sample is collected will be recorded to the nearest minute in the source 
documents and in the appropriate eCRFs.
Blood Samples for Unconjugated Cys -mcMMAF Assay
Blood samples for unconjugated C ys-mcMMAF for pharmacokinetic analysis will be collected 
in evacuated potassium edetic acid (ethy lenediaminetetraacetic acid) K 2EDTA -containing 
colle ction tubes at the time points specified in Table 3.  The time that each sample is collected 
will be recorded to the nearest minute in the source documents and in the appropriate eCRFs.
The collection, processing and storage should be performed as describe d in the study -specific 
laboratory  manual.
Plasma concentration of unconjugated Cys-mcMMAF will be determined using validated 
methods under the supervision of Drug Anal ysis Department at AbbVie.
Blood Samples for Pharmacogenetic Analysis
One 4 mL whole blo od sample for DNA isolation will be collected on Day  1 from each subject 
who consents to provide a sample for pharmacogenetic anal ysis.  If the sample is not collected 
on Day  1, it may  be collected at any  time throughout the study .
Samples will be processe d and shipped to AbbVie or a designated laboratory  for 
deox yribonucleic acid (DNA )extraction and long -term storage. Instructions for the preparation 
and shipment of pharmacogenetic samples will be provided in the study  specific lab manual.
Abbvie will st ore the DNA samples in a secure storage space with adequate measures to protect 
confidentiality .  The samples will be retained while research on ABT- 414 (or drugs of this class) 
continues but no longer than 20 y ears.
4.3 Definition of Disease Assessments
Progression Free Survival
Time to progression -free survival (PFS) will be defined as the number of day s from the date of 
randomization to the date of earliest disease progression based on RANO criteria or to the date of 
death, if disease progression does not occur.  All disease progression will be included regardless 
of whether the event occurred while subject was taking the stud y drug or had previousl y 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
54discontinued the study  drug.  All events of death will be included for subjects who had not 
experienced di sease progression.  Subjects for whom neither death nor progression have been 
documented will be right -censored on the date of the last adequate assessment of disease.  PFS 
will be anal yzed by the Kaplan- Meier method.
The phenomenon of pseudoprogression should be considered when determining if there is 
disease progression, particularl y during the first 3 months after radiotherapy.  Pseudoprogression 
refers to the occurrence of "earl y delay ed radiation reactions" that occur usually  within the 
first3months post radiation treatment.  These transient adverse signs and sy mptoms may  
spontaneously  improve without therapy  or with supportive care such as corticosteroids.  Thus, 
care should be taken in making the diagnosis of tumor progression or recurrence (Appendi x I).
Overall Survival
Overall survival (OS) will be defined as the number of days from the date of randomization to 
the date of death due to any  cause.  Subjects for whom death has not been documented will be 
right -censored at the last date the subject is documented to be alive.  OS will be anal yzed by the 
Kaplan -Meier method.
Karnofsky Performance Status
Changes from baseline will be summarized for each scheduled post -baseline visit and for the 
Final Study  Drug Visit for Ka rnofsky  performance status.  The baseline will be defined as the 
last measurement collected before randomization.  The post-baseline visit will include those 
occurring within 49 day s of the last dose of study  drug.  The Final Study  Drug Visit will be 
defin ed as the last post -baseline measurement collected within 49 day s of the last dose of study  
drug (ABT -414, or placebo).
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
555.0 TREATMENT PLAN
Treatment must begin ≤ 7 weeks after brain tumor biopsy/resection.
5.1 Treatment Plan Overview
During the Chemoradiation Phase, all subjects will undergo focal RT, with one treatment given 
daily  5 day s per week over approximately  6 weeks (and no more than 7 weeks).  TMZ will be 
administered 75 mg/m2orally  once dail y continuously  from Day  1 of radiotherap y to the last da y 
of radiation for a maximum of 49 day s.  Subjects in Arm A will receive ABT- 414 at 2.0 mg/kg 
IV infusion once every  2 weeks (on Day  1 of Weeks 1, 3, and 5) during this period.  Subjects in 
Arm B will receive placebo IV infusion once every 2 weeks (on Day  1 of Weeks 1, 3, and 5) 
during this period.  Treatment in the Chemoradiation Period must begin ≤ 49 day s after surgery  
diagnosing GBM.  Occasionally , a subject might require a staged or two
-surgery  approach; for 
such cases, subjects will still be considere d eligible for this study  if the latest surgery  was 
performed within 30 days after the initial surgery /biopsy  diagnosing GBM and if all screening 
procedures are completed and chemoradiation treatment begins ≤ 49 day s after the latest surgery .
The start of the first cy cle during the Adjuvant Phase will be scheduled approximately  28 day s 
after the last day  of chemoradiation.  The AbbVie Medical Monitor or RTOG Neuro -Oncology  
should be notified if Adjuvant Phase treatment is to be started more than 42 days aft er the last 
day of chemoradiation.  During the Adjuvant Phase, all subjects will receive oral TMZ 
150 – 200 mg/m2once daily  on Day s 1 –5 of each 28- day cy cle for 6 cy cles.  Subjects in Arm A 
will receive ABT -414 at 1.25 mg/kg on Day  1 and Day  15 of each 28-day cycle for a total of 
12cycles.  Subjects in Arm B will receive placebo IV infusion on Day  1 and Day  15 of each 
28-day  cy cle for a total of 12 cy cles.  Adjuvant treatment will be discontinued upon 
determination of tumor progression as defined b y RANO criteria, unacceptable toxicity , or 
refusal to continue stud y treatment.
Duration of Adjuvant TMZ
Subjects demonstrating continued benefit and no unacceptable toxicity  from adjuvant TMZ can 
continue TMZ to a maximum of 12 cy cles at the discretion of the Investigator if this is 
considered an acceptable standard of care per local regulations.
Subjects in Arm A will receive ABT -414 on Day  1 and Day  15 of each 28- day cycle.  Subjects in 
Arm B will receive placebo IV infusion on Day  1 and Day  15 of each 28- day cycle.  Subjects 
who discontinue TMZ for TMZ- related toxicity  will continue ABT -414/placebo treatment.  
Subjects who discontinue ABT -414 or placebo due to ABT -414- related or placebo -related 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
56toxicity  prior to completion of the Adjuvant Therapy  Phase will continue TMZ treatment as 
scheduled.
Duration of Adjuvant ABT -414 or Placebo
If after completing 12 cycles of adjuvant ABT -414/placebo, the subject is tolerating treatment 
and the Investigator believes the subject is continuing to benefit from ongoing study  drug 
treatment, the Investigator may  extend the Adjuvant Phase with ABT-414/placebo after 
consultation with the Neuro -Medical Oncology  Chair or AbbVie Medical Monitor.  The 
ABT -414/placebo will continue at the same dosing schedule, as long as disease progression has 
not been determined.
5.2 Radiation Therapy
Chemoradiation treatment must begin within 7 WEEKS after biopsy/resection.
The schema at the beginning of the protocol should be followed.
Within 3 months after site initiation, assessment of spec ific technology  requirements is required 
for this study ; please refer to the study -specific radiation manual for detailed instructions.  
Pneumocystis ( jirovecii ) pneumonia (PCP) prophylaxis should be per local regulation guidelines 
during the radiation pha se (Section 5.8).
5.2.1 Treatment Technology
This protocol requires photon treatment. 3D -CRT and IMRT are allowed.  Any  of the methods of 
IMRT, including fixed gantry  IMRT, helical tomotherapy , or volumetric arc therapy  (VMAT) 
may be used, subject to protocol localization and dosimetry  constraints.  Computerized 
tomograph y (CT) -based treatment planning is necessary  to assure accuracy in the selection of 
field arrangements.  MRI -fusion for accurate target delineation is strongl y recommended.
Treatment shall be delivered with megavoltage (MV) machines of a minimum energy  of 6 MV 
photons.  Selection of the appropriate photon energy (ies) should be based on optimizing the 
radiation dose distribution within the target volume and minimizing dose to non -target norma l 
tissue.  Source skin distance for SSD techniques or source axis distance for SAD techniques must 
be at least 80 cm.  Electron, particle, or implant boost is not permissible.  IMRT delivery  will 
require megavoltage radiation therap y machines of energy ≥ 6 MV.
Treatment may  be performed using a sequential boost to the contrast -enhanced region of the 
target; otherwise treatment may  be delivered straight through without sequential boost detailed 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
57in Section 5.2.4.  Any  institution can choose any  one technique, but once selected, should remain 
consistent through the completion of this protocol.  Subject specific QA (Section 5.2.10) is 
highl y recommended prior to start of treatment and is described in the study specific radiation 
manual.
5.2.2 Immobilization and Simulation
Immobilization
Proper immobilization is critical for this protocol.  Subject setup reproducibility  must be 
achieved using appropriate clinical devices.
Subjects shall be treated in a supine position and immobilized with a thermoplastic mask and 
headrest.  Additional immobilization devices such as a bite block and/or knee -wedge are 
permitted.  In rare instances, based on tumor location and patient anatom y, prone set -up is 
permissible.
Simulation Imaging
A planning CT scan of the cranial contents with 3.0 mm slice thickness or less will be required 
which will be fused with the pre- and post -operative MRI  scans.  Rigid registration is permitted, 
but deformable fusion is not permitted.
5.2.3 Imaging for Structure Definition, Image Registration/Fusion and Follow -Up
Rigid image registration must be used for the protocol.  Deformable fusion is not allowed.  
Post-operative MRI with T2/fluid attenuated Inversion recovery (FLAIR) and contrast enhanced 
T1 sequences is required and must be obtained after surg ical resection.  Additionally , if a subject 
starts chemoradiation more than 28 day s after surgery , the subject will have a brain MRI with 
T2/FLAIR and contrast enhanced T1 sequences included no more than 21 (but preferabl y fewer) 
days prior to Day  1 Week 1 of Chemoradiation Phase to be used as the baseline MRI  scan for 
efficacy  anal yses; the timing of the MRI must allow sufficient time to revise the radiation 
therap y plan if needed due to a significant change in tumor since surgery .  Radiotherapy  planning 
is recommended to be completed as soon as reasonably feasible, but in all cases, chemo-
radiotherap y MUST begin NO LATER than 7 weeks after initial biops y or latest tumor resection.
The scans used for planning MUST be submitted as a complete series along wit h the treatment 
plan as well.  If a pre -operative MRI scan is not available for fusion, fusion with only  the 
post-operative MRI scan is permitted.  I t is recommended, not required, to obtain the 
pre-operative MRI scan to assist in treatment planning.  Targ et volume delineation will be based 
on a contrast enhanced MRI  scan obtained after surgery , ideall y obtained within 72 hours after 
surgery  although that timing is not mandatory .  Pre -operative imaging should be used to guide 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
58identification of target deline ation, but critical structures are best contoured on the post- operative 
MRI  and/or CT, as there is expected structural shift between the pre -and post -operative scans.
5.2.4 Definition of Target Volumes and Margins
Differences exist in methods utilized for GTV/CTV/PTV definitions; this protocol 
accommodates and permits two key  philosophical concepts, labeled the "RTOG" and the 
"EORTC" approaches; each institution will be required to declare upfront which approach they 
will pursue, and will be required to ad here to that single approach during the conduct of this 
protocol.
The main "RTOG" approach describes a sequential boost or cone- down radiotherap y technique 
which is described below.  However, this approach is less widely  used in Europe. As such, the 
radiot herap y technique for sites wishing to follow the "EORTC" approach is also defined below 
as an alternative straight through or single phase technique, designed to reflect the broad 
overall tenets of radiotherap y practices for glioblastoma treatments in EORT C institutions.  
Although man y individual variations on the themes exist, in this multi- institutional international 
study , these two concepts, as specifically  defined within the protocol are permitted, and other 
variations, unless approved by  one of the Ra diation Oncology  co-chairs, will be considered a 
major protocol violation.  As mentioned in Section 5.2.1, any institution can choose either of 
the two techniques, but once selected, must remain consistent through the completion of 
this protocol for all patients enrolled under this amendment or later by that institution (a 
site that used the RTOG approach prior to Amendment may switch to the EORTC 
approach, as long as that approach is maintained until the end of the study).  An institution 
may not choose both techniques, and may not use different techniques for different 
patients, or different techniques for different physicians within the same institution.  
Additionally, if an institution starts a patient's treatment with a sequential boost approach 
using a certain fraction size (e.g., 1.8 GY per fraction), they are expected to complete the 
cone down with the same fraction size.  Institutions must also send a composite plan 
showing the final accumulated dose distribution.  The composite dose distribution wil l be 
used to score the plans for critical structure dose.  Exceedingly rare exceptions on a case -
by-case basis will only be permissible if approved in writing by a Radiation Oncology study 
chair.
Note:  All structures must be named for digital RT data subm ission as listed as in the table 
below.  The structures marked as "Required" in the table must be contoured and submitted when 
applicable.  Resubmission of data may  be required if labeling of structures does not conform to 
the standard DI COM name listed.  Capital letters, spacing and use of underscores must be 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
59applied exactly  as indicated, to ensure appropriate, timely , accurate, and reproducible QA 
process application to all cases.
Target Structured Labeling:  Option 1:  RTOG Approach – Sequential Boost
Standard Name DescriptionValidation
Required/Required When 
Applicable/Optional
GTV1 GTV to receive 45 or 46 Gy Required
CTV1 CTV to receive 45 or 46 Gy Required
PTV1 PTV to receive 45 or 46 Gy Required
GTV2 GTV to receive 59.4 or 60 Gy Required
CTV2 CTV to receive 59.4 or 60 Gy Required
PTV2 PTV to receive 59.4 or 60 Gy Required
Details Specifications
Target volumes will be based upon post- operative -enhanced MRI.  Pre -operative imaging should 
be used for correlation and improved identification.
GTV1 –Either the T2 or the FLAIR abnormality  on the post -operative MRI scan, inclusive of all 
contrast -enhancing T1 abnormality  on the post- operative MRI and the surgical cavit y.  Areas of 
vascular infarction or compromise of normal brain should be exclud ed if they  are deemed to not 
be part of the original pre -operative tumor volume, and a comparison of the pre- and 
post-operative scans will assist in this process.
CTV1 – Is defined as the GTV1 plus a margin of 2 cm, which may  be reduced around natural 
barriers to tumor growth such as the skull, ventricles, falx, etc. to as low as 0 mm to "fixed" 
barriers, i.e., bone, and falx and as low as 3 
–5 mm to “non- rigid” barriers such as brain stem, 
ventricles, etc.  If no surrounding edema is present (i.e., the F LAIR and/or T2 MR images do not 
demonstrate an y significant abnormality), the CTV 1 in those instances should include the 
post-operative MRI enhancement and the surgical resection cavity  plus a 2 cm margin, with 
reduction permitted as described above.
GTV2 –Contrast enhancing T1 abnormality  and the surgical cavity  on the post -operative MRI 
scan.  Areas of vascular infarction or compromise of normal brain should be excluded if they  are 
deemed to not be part of the original pre- operative tumor volume, and a comparison of the 
pre-and post -operative scans will assist in this process.  The exception to this is the polar tumor, 
e.g., temporal lobe, frontal lobe, or occipital lobe tip, where a gross total resection is achieved, 
and no post -operative "cavity " rema ins, consequential to the partial or total lobectomy .  For these 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
60uncommon patients, GTV2 will be defined as either the T2 or the FLAI R abnormality  on the 
post-operative MRI scan, i.e., in these cases, GTV1 = GTV2.
CTV2 – Is defined as the GTV2 plus a margi n of 2 cm.  The CTV2 margin may  be reduced 
around natural barriers to tumor growth such as the skull, ventricles, falx, etc. to as low as 0 mm 
to "fixed" barriers, i.e., bone, and falx and as low as 3 
–5 mm to "non -rigid" barriers such as 
brain stem, vent ricles, etc.
PTV1 and PTV2 – In general the PTV is the CTV plus a geometric 5 –7 mm expansion in all 
dimensions.  This can be reduced to 4 mm if daily volumetric (3D) or non-volumetric (2D) 
IGRT is utilized.  PTV may  extend bey ond bony margins and the skin surface.
Target Structure Labeling:  Option 2:  EORTC Approach – Single Phase
Standard Name DescriptionValidation
Required/Required When 
Applicable/Optional
GTV GTV to receive 59.4 or 60 Gy Required
CTV CTV to receive 59.4 or 60 Gy Required
PTV PTV to receive 59.4 or 60 Gy Required
Detailed Specifications
Target volumes will be based upon the post -operative -enhanced MRI.  Pre -operative imaging 
should be used for correlation and improved identification.
GTV –Contrast enhancing T1 abnormality  and the surgical cavity  on the post -operative MRI 
scan.  Areas of vascular infarction or compromise of normal brain should be excluded if they  are 
deemed to not be part of the original pre- operative t umor volume, and a comparison of the 
pre-and post -operative scans will assist in the process.  The exception to this is the polar tumor, 
e.g., temporal lobe, frontal lobe, or occipital lobe tip, where a gross total resection is achieved, 
and no post -opera tive "cavity " remains, consequential to the partial or total lobectomy .  For these 
uncommon patients, GTV will be defined as either the T2 or the FLAI R abnormality  on the 
post-operative MRI scan.
CTV – Is defined as the GTV plus a margin of 2 cm, which may be modified in two respects:  
1)The CTV margin may  be reduced around natural barriers to tumor growth such as the skull, 
ventricles, falx, etc., to as low as 0 mm to "fixed" barriers, i.e., bone, and falx and as low as 
3 – 5 mm to "non -rigid" barriers s uch as brain stem, ventricles, etc., and 2) in all areas of 
persisting edema on FLAIR (preferred) or T2 -weighted MRI images, the CTV will be expanded 
beyond 2 cm to include these regions.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
61PTV – In general the PTV is the CTV plus a geometric 5 mm expansion in all dimensions.  This 
can be reduced to 4 mm if daily volumetric (3D) or non-volumetric (2D) IGRT is utilized.  
PTV may  extend bey ond bony  margins and up to the skin surface.
5.2.5 Definition of Critical Structures and Margins
Note:   For either "RTOG" o r "EORTC" approaches, all structures must be named for digital RT 
data submission as listed in the table below.  The structures marked as "Required" in the table 
must be contoured and submitted with the treatment plan.  Structures marked as "Required when 
applicable" must be contoured and submitted when applicable.
Resubmission of data may be required if labeling of structure does not conform to the standard
Digital Imaging and Communications in Medicine (DICOM) name listed.  Capital letters, 
spacing and use of underscored must be applied exactly  as indicated.
All structures should be contoured on the planning CT, using the post -operative MRI  for 
guidance.  Due to variance in ey e position between the CT and MRI , if possible, the lenses, 
retina, and optic ner ves should be contoured using the CT dataset only .
Special consideration should be given to avoid doses greater than the prescription dose within the 
scalp as well as limiting exit dose through the oral cavity and mucosa.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
62Organs-at- Risk Structure Labeling:   Option 1 and 2:  RTOG and EORTC Approaches
Standard Name DescriptionValidation
Required/Required When 
Applicable/Optional
Lens_L Left lens Required
Lens_R Right Lens Required
Retina_L Left retina Required
Retina_R Right retina Required
OpticNrv_L Left optic nerve Required
OpticNrv_R Right optic nerve Required
OptNrv_PRV_L Left optic nerve planning risk volume Required
OptNrv_PRV_R Right optic nerve planning risk volume Required
OpticChiasm Optic chiasm Required
OptChiasm_PRV Optic chiasm planning risk volume Required
BrainStem Brainstem Required
SpinalCord Spinal cord Required
Brain Whole brain parenchyma Required
Glnd_Lacrimal_L Left lacrimal gland Required
Glnd_Lacrimal_R Right lacrimal gland Required
Cochlea_L Left cochlea Optional
Cochlea_R Right cochlea Optional
Detailed Specifications
Please refer to the organs at risk contouring guidelines and supplement published in 
Radiotherap y and Oncology:  http://www.thegreenjournal.com/article/S0167 -8140(15)00080-
8/pdf.
Lens_L, Lens_R, Retina_L, Retina_R, OpticNrv_L, OpticNrv_R:  Due to variance in ey e 
position between the CT and MRI , if possible, the structures should be contoured using the CT 
dataset only .  The retina is defined as the innermost of the three lay ers that form th e wall of the 
eyeball.  Please contour 5 mm posterior wall of the ey e.  Please refer to supplemental figure 
V:Va -Vg in the organs at risk contouring guidelines.
OptNrv_PRV_L :  Left optic nerve should be expanded by  a volumetric expansion of 3 mm.
OptNrv_PRV_R:  Right optic nerve should be expanded by  a volumetric expansion of 3 mm.
OpticChiasm:  L ocated above the pituitary  fossa, the optic chiasm includes both anterior and 
posterior limbs.  I t is best visualized on post -operative T2/FLAIR MRI Seque nce, but should be 
confirmed on CT dataset due to potential variation in CT/MRI  fusion.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
63OptChiasm_PRV:  Optic chiasm should be expanded by  a volumetric expansion of 3 mm.
BrainStem:  Brainstem contour should include all three components:  midbrain, pons, a nd 
medulla.  The brainstem is bordered superiorl y by the tentorial incisures and inferiorl y by the 
foramen magnum.  It can be visualized on post-operative MRI sequence, but should be 
confirmed on CT dataset due to potential variation in CT/MRI  fusion.
SpinalCord:  Spinal cord should be contoured, wherever possibly , on the CT dataset onl y.
Brain:  Whole brain parenchyma includes all intracranial contents, inclusive of target volumes.  
Because some volumetric change could have occurred in the whole brain pare nchyma due to 
evolving post -operative changes, it is recommended, whenever possible to contour the whole 
brain parench yma using the CT dataset onl y.
Cochlea_L, Cochlea_R:  Although not mandated, it is recommended that the left and right 
cochlea be contoure d using the CT dataset on bone window.
Glnd_L acrimal_L, Glnd_Lacrimal_R:  The lacrimal gland is located supero -laterall y to the 
extraconal portion of the orbit, medial to the zy gomatic process of the frontal bone and is 
superior to the lateral rectus muscl e and lateral to the superior rectus muscle.  Please refer to 
supplementary  figure V:Vd-Vh in the organs at risk contouring guidelines paper.
5.2.6 Dose Prescription
Note:  The information provided in this section can be used for adjusting the dose constra ints for 
treatment planning purposes.  This table together with the planning priority table should be used 
during dose optimization .  It is important to remember that ideal plans might not be achievable in 
all cases.  Thus the Compliance Criteria table cou ld be different than the information given here.  
Cases will be scored using the Compliance Criteria table.
Option 1:  RTOG Approach –Sequential Boost
Target Standard 
Nam e Dose (Gy) Fraction Size (Gy) # of Fractions Dose Specification Technique
PTV1 44 –46 2 23 ≥ 95% of PTV receives 46 Gy
Optional:PTV1 45 1.8 25 ≥ 95% of PTV receives 45 Gy
PTV2 60 2 30 95% of PTV should receive 
≥60 Gy
Optional:PTV2 59.4 1.8 33 95% of PTV should receive 
≥59.4 Gy
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
64Option 2:  EORTC Approach – Single Phase
Target Standard 
Nam e Dose (Gy) Fraction Size (Gy) # of Fractions Dose Specification Technique
PTV 60 2 30 95% of PTV should receive 
≥60 Gy
Optional:PTV 59.4 1.8 33 95% of PTV should receive 
≥59.4 Gy
5.2.7 Compliance Criteria
The compliance criteria listed here will be used to score each case.  Given the limitations 
inherent in the treatment planning process, the numbers given in this section can be different than 
the prescription table.  The Per Protocol and Variation Acceptab le categories are both considered 
to be acceptable.  The Per Protocol cases can be viewed as ideal plans, and the Variation 
Acceptable category  can include more challenging plans that do not fall at or near the ideal 
results.
Normalization of Dose:  95% of the PTV (D 95%) should be covered b y 100% of the prescription 
dose.
Option 1:  RTOG Approach –Sequential Boost
Target Volume Constraints and Compliance Criteria
Nam e of Structure Dosimetric Param eter Per Protocol Variation Acceptable
PTV1 D95%(%)* 100% of prescribed dose (PD) at least 95% of PD
PTV2 D95%(%)* 100% of prescribed dose (PD) at least 95% of PD
D10%(%)* ≤ 105% of PD ≤ 110% of PD
D0 03cc(%)* ≤ 106% of PD ≤ 112% of PD
* Dose is normalized to prescription dose (PD) in Gy.
Variation Acceptable ranges exclude those from Per Protocol.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
65Option 2:  EORTC Approach – Single Phase
Target Volume Constraints and Compliance Criteria
Nam e of Structure Dosimetric Param eter Per Protocol Variation Acceptable
PTV D95%(%)* 100% of prescribed dose (PD) at least 95% of PD
D10%(%)* ≤ 105% of PD ≤ 110 of PD
D0 03cc(%)* ≤ 106% of PD ≤ 112% of PD
* Dose is normalized to prescription dose (PD) in Gy.
Variation Acceptable ranges exclude those from Per Protocol.
Normal Structure Constrains and Compliance Criteria for Both RTOG and EORTC 
Approaches
Nam e of Structure Dosimetric Param eter Per Protocol Variation Acceptable
SpinalCord D0 03cc ≤ 50 Gy
Brainstem D0 03cc ≤ 55 Gy ≤ 60 Gy
OpticChiasm_PRV D0 03cc ≤ 55 Gy ≤ 60 Gy
OptNrv_PRV_L or 
OptNrv_PRV_RD0 03cc ≤ 55 Gy ≤ 60 Gy
Retina_L or Retina_R D0 03cc ≤ 45 Gy ≤ 50 Gy
Brain D5% ≤ 65 Gy ≤ 67 Gy
Lens_L or Lens_R D0 03cc ≤ 7 Gy ≤ 10 Gy
Glnd_Lacrimal_L or 
Glnd_Lacrimal_RD0 03cc ≤ 40 Gy ≤ 45 Gy
Cochlea_L or Cochlea_R Mean dose ≤ 45 Gy ≤ 50 Gy
Note:  A final category , called Deviation Unacceptable, results when cases do not meet the 
requirements for either Per Protocol or Variation Acceptable.  Plan falling in this category  are 
considered to be suboptimal and additional treatment plann ing optimization is recommended.
Exceptions:
1. SpinalCord does not have a Variation Acceptable; Deviation Unacceptable occurs when 
SpinalCord dose limit for Per Protocol is not met.
2. Deviation Unacceptable occurs when dose limits for Variation Acceptable are not met for 
both OptNrv_PRV_L  andOptNrv_PRV_L ; or OptNrv_PRV_L   if the subject does not 
have a serviceable vision in the right ey e; or OptNrv_PRV_R  if the subject does not have 
aserviceable vision in the left ey e.
3. Deviation Unacceptable occurs when dose limits for Variation Acceptable are not met for 
both Retina_L  andRetina_R; or Retina_L  if the subject does not have serviceable vision 
in the right ey e; or Retina_R if the subjec t does not have serviceable vision in the left ey e.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
664. Exceeding the dose limits for Variation Acceptable for Lens_L or Lens_R will not be 
scored as Deviation Unacceptable.
Delivery Compliance Criteria
Per Protocol Variation Acceptable
Start date ≤ 7 w eeks after surgery None
Interruptions ≤ 4 days 5 –7 days
5.2.8 Treatment Planning Priorities
Critical Structure and Target priorities must be listed in order of decreasing importance.
1.SpinalCord
2.BrainStem
3.OptChiasm_PRV
4.OptNrv_PRV_L  and OptNrv_PRV_R
5.PTV1
6.PTV2 (If using the EORTC technique, PTV1 and PTV2 should be replaced by  PTV)
7.Brain
8.Retina_L  and Retina_R
9.Glnd_L acrimal_L and Glnd_L acrimal_R
10.Lens_L and Lens_R
In the event that an OAR with higher priority  that PTV2 or PTV (depending on which approach 
is taken e.g., "RTOG" or "EORTC") is in immediate proximity  to PTV2 or PTV such that dose 
to the OAR cannot be constrained within Unacceptable Deviation limits, then D95% for PTV2 or 
PTV should be lowered to Varian Acceptable range to ensure that the OAR with higher priorit y 
does not exceed Unacceptable Deviation limits.  I f this approach does not constrain the OAR 
with higher priority  than PTV2 or PTV within Unacceptable Deviation limits, then D95% for 
PTV2 or PTV can be further lowered to below but as close as possible to Variation Acceptable 
range to ensure that the OAR with higher priority does not exceed Unacceptable Deviation 
limits; this will be scored as an Unacceptable Deviation for PTV2 or PTV.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
675.2.9 Dose Calculations
Required algorithms
Acceptable choices of algorithm are listed at 
http://rpc.mdanderson.org/rpc/Services/Anthropomorphic_%20Phantoms/TPS%20 -
%20algorithm%20list%20updated.pdf.  An y algorithm used for this study  must be credentialed 
by IROC Houston.
Plan Review and Evaluation
Traditional DV Hs and dose distribution display s will be used for plan review and evaluation 
DVHs will also be used for retrospective outcome anal ysis.
Dose matrix resolution
Dose matrix grid size must be 3 mm × 3 mm × 3 mm or smaller
5.2.10 Subject -Specific QA
For photon IMRT plans, subject specific QA is highl y recommended.  QA is performed b y 
delivering the plan onto a phantom and measuring the dose using an ion chamber array  or other 
2D/3D device.  Measured dose distribution will be compared to planned dose distributi on using a 
Gamma criterion of 3% dose difference and 3 mm distance to agreement.  For plans with highl y 
modulated dose distributions a 5% dose difference and 3mm distance to agreement criterion may  
be used.  The pass rate should be at least 90% measured fo r the entire plan.
Subject -specific QA data should be kept on record at each institution but will not be centrall y 
collected or reviewed b y RTOG.
5.2.11 Daily Treatment Locations/IGRT
Imaging should be performed at least once per week.  Dail y image -guided radiation therap y 
(IGRT) is optional for this protocol, and image- guidance is per individual institutional standards 
and the margins stated in Section 5.2.4.  The RTOG defines IGRT as a computer assisted 
process.  That is, image handling together with calc ulation of shift and rotations (if available) 
must be determined with computer assistance.  Acceptable non -volumetric or two -dimensional 
IGRT s ystems include:  1) Orthogonal or near-orthogonal 2D imaging that is integrated with the 
functioning of the deliv ery device.  These s ystems can use the treatment beam or special kV 
x-ray head(s) positioned at a known position in the treatment room.  Acceptable volumetric or 
three -dimensional IGRT sy stems include:  1) A diagnostic quality  CT scanner positioned with a 
known geometry  in the treatment room.  2) Volumetric cone-beam devices that use either MV or 
kV x -ray beam.  3) Tomotherapy  technology  that uses a fan -beam imaging approach.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
68For this study , the cranium is used for image registration.  I t is important to in clude as much of 
the anatom y of this structure as possible to ensure correct alignment of the head.  Caution 
should be taken to avoid excess repeat imaging on a given treatment day to minimize 
subject dose outside the treatment region, and steps to control subject position to less than 
3 mm should not be taken.
5.2.12 Case Review
These reviews will be ongoing and performed remotely  by the Radiation Oncology  study  chair or 
his/her designee.
Digital RT Data Submission to RTOG Using the TRIAD Portal
RTOG will provide sites with the American College of Radiology  Imaging Network's image 
acquisition and management software, Transmission of Imaging and Data ( TRIAD), via 
electronic installation.  TRIAD-OA offers a web -based, software solution allowing institutions to 
submit DI COM data securely through electronic transmission.  I nternal to the site, TRIAD 
allows the site to "DICOM push" from the site's Treatment Planning S ystem (TPS), thus 
eliminating the need to burn phy sical media.  Once the institution has transfer red the RT data 
onto a TRIAD workstation, the software will anony mize, encrypt, and submit the DI COM RT 
data via secure internet to the RTOG image archive.  For more information please visit the 
TRIAD web site at https://triad.acr.org.
TRIAD technical assi stance may be requested by e- mailing TRIAD-Support@acr.org.  Please 
alway s include the institution name and trial number when requesting TRIAD technical 
assistance.
Summary of Dosimetry Digital Data Submission 
ItemDue
Preliminary Dosimetry Information
Digital data submission includes the following:Within 1 week of start of RT
DICOM I tems:
DICOM Post -Op MR ENTI RE Post -Op Series must be submitted along with the 
RT data
DICOM CT Data Set
DICOM Dose – Initial
DICOM Dose – Boost
DICOM Dose – Composite
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
69DICOM RT Plan – Initial
DICOM RT Plan – Boost
5.2.13 Radiation Therapy Adverse Events
Acute
Expected acute radiation -induced toxicities include hair loss, fatigue, and ery thema or soreness 
of the scalp.  Potential acute toxicities include nausea and vomi ting as well as temporary  
aggravation of brain tumor sy mptoms such as headaches, seizures, and weakness.  Reactions in 
the ear canals and on the ear should be observed and treated s ymptomatically ; these reactions 
could result in short -term hearing impairme nt.  Dry  mouth or altered taste have been 
occasionall y reported.
Early Delayed
Possible early  delay ed radiation effects include lethargy  and transient worsening of existing 
neurological deficits occurring 1 –3 months after radiotherapy  treatment.
Late Del ayed
Possible late delay ed effects of radiotherapy  include radiation necrosis, endocrine dy sfunction, 
and radiation- induced neoplasms.  I n addition, neurocognitive deficits, which could lead to 
mental slowing and behavioral change, are possible.  Permanent hearing impairment and visual 
damage are rare.  Cataracts can be encountered.
5.3 Temozolomide (TMZ)
Because TMZ as prescribed in this study  is considered the standard- of-care (SOC) treatment for 
this indication, commercial sources will be used for TMZ drug supply , unless otherwise 
mandated b y the country.  AbbVie may provide or reimburse for TMZ to participating sites as 
required based upon availability  or local regulations.
5.3.1 TMZ Administration
5.3.1.1 Chemoradiation
TMZ will be administered continuously  from Day 1 of radiotherapy  to the last day  of radiation at 
a daily  oral dose of 75 mg/m2(for a maximum of 49 day s).  The timing of each daily  dose will be 
at the discretion of the Investigator.
The dose will be determined using actual bod y surface area (BSA) as calculated in square meters 
at the beginning of the concomitant treatment.  The BSA will be calculated from the height 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
70obtained at the screening visit and the weight obtained at the visit immediately  before the 
firstday of treatment.  The do se of TMZ does not have to be adjusted unless there has been at 
least a 10% change in body  weight; recalculation of dose for < 10% weight changes is allowed at 
the discretion of the Investigator.  Recalculations for subsequent changes in height are 
permiss ible but not required.  The dose will also not be capped for those that are overweight.  
The daily  dose will be rounded to the nearest 5 mg.  The exact dose administered should be 
recorded in the eCRF.  Each dail y dose should be given with the least number of capsules.
Subjects should be instructed to swallow the capsules whole, in rapid succession, without 
chewing them.  If vomiting occurs during the course of treatment, no re -dosing of the subject is 
allowed before the next scheduled dose.  The capsules s hould be taken on an empty  stomach, 
therefore a minimum of 2 hours after eating and with no food consumption for at least 1 hour 
after TMZ administration.
Antiemetic proph ylaxis is usually  not required for the continuous daily  dosing schedule (during 
radia tion).  However, prophy laxis with a 5-hydroxy tryptamine3 (5-HT3) antagonist is 
recommended prior to administration of the first few TMZ doses and should be administered 
orally  30 to 60 minutes before TMZ treatment.  Most subjects report optimal nausea control with 
the use of a 5
-HT3 antagonist.  Routine use of antiemetics is recommended during the adjuvant 
phase of treatment.
IV temozolomide (as per local institutional standard) may  be used instead of oral TMZ if there is 
a change in the subject's socia l situation (e.g., move to a nursing home or changes in drug 
reimbursement) after treatment TMZ initiation such that oral dosing of temozolomide is no 
longer possible.
5.3.1.2 Adjuvant Treatment
TMZ will be administered orally  once per day  for 5 consecutive day s (Day s 1 –5) of a 28 -day 
(+/–3 day ) cycle.  The starting dose for the first cy cle will be 150 mg/m2/day, with a single dose 
escalation to 200 mg/m2/day in subsequent cy cles if no treatment- related adverse events > Grade 
2 are noted.  The timing of each daily  dose will be at the discretion of the Investigator.
The start of the first cy cle will be scheduled approximately  28 day s after the last day  of 
radiotherap y.  The start of all subsequent cy cles (Cy cles 2 – 12) will be scheduled every  4 weeks 
(28 days ± 3 days) after the first daily  dose of TMZ of the preceding cy cle.
The dose will be determined using the BSA calculated at the beginning of each treatment cy cle.  
The BSA will be calculated from the height obtained at the screening visit and from the weight 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
71obtained at the visit immediatel y before each cycle.  More frequent assessment and use of height 
and/or weight and calculation of BSA are permitted throughout the study .  The dose of TMZ 
does not have to be adjusted unless there has been at least a 10% change in body  weight; 
recalculation of dose for < 10% weight changes is allowed at the discretion of the Investigator.  
The dose will also not be capped for those that are overweight.  The daily  dose will be rounded 
to the nearest 5 mg (where dosage strengths are available to accommodate rounding to 5 mg).  
The exact dose administered should be recorded in the eCRF.  Each daily  dose should be given 
with the least number of capsules.
Prior to each treatment cycle with TMZ a complete blood count (CBC) w ill be obtained (within 
72 hours prior to dosing).  Subjects should be instructed to fast at least 2 hours before and 1 hour 
after TMZ administration.  Water is allowed during the fast period.  Subjects will be instructed to 
swallow the capsules whole, in rapid succession, without chewing them.
If vomiting occurs during the course of treatment, no re-dosing of the subject is allowed before 
the next scheduled dose.
Antiemetic proph ylaxis with a 5 -HT3 antagonist is strongl y recommended and should be 
administe red 30 to 60 minutes before TMZ administration (Section 5.8).
IV temozolomide (as per local institutional standard) may  be used instead of oral TMZ if there is 
a change in the subject's social situation (e.g., move to a nursing home or changes in drug 
reimbursement) after treatment TMZ initiation such that oral dosing of temozolomide is no 
longer possible.
Subjects will be treated with post -radiation TMZ for 6 cy cles unless there is evidence of tumor 
progression (RANO) or treatment- related toxicity  (Section 8.3).
Subjects demonstrating continued benefit and no unacceptable toxicity  from adjuvant TMZ may  
continue TMZ for an additional 6 cy cles (12 cy cles in total) at the discretion of the investigator if 
this is considered an acceptable standard of care per local regulations.  TMZ treatment for more 
than 12 cy cles will not be allowed.
5.3.2 Chemotherapy Review
Chemotherap y reviews will be ongoing and performed by the Neuro -Oncology /Medical 
Oncology  study  chair or his/her designee.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
725.4 ABT -414 / Placebo Treatme nt
During the Chemoradiation Phase, subjects in Arm A will receive blinded ABT -414 at 2.0 mg/kg 
IV infusion over 30 – 40 minutes once every  2 weeks (Day  1 of Weeks 1, 3, and 5 of the 6 -week 
regimen).  Subjects in Arm B blinded placebo IV infusion over 30 – 40 minutes once every  
2weeks (Day  1 of Weeks 1, 3, and 5 of the 6- week regimen).  The dosing interval must be at 
least 12 day s after the previous dose of ABT- 414/placebo, and the doses must be administered no 
later than the last day  of radiation treatmen t.
During the Adjuvant Therap y Phase, subjects in Arm A will receive blinded ABT -414 at 
1.25 mg/kg on Day  1 (± 2 day s) and Day  15 (± 2 day s) of each 28- day cycle as a 30 –40 minute 
infusion, and subjects in Arm B will receive blinded placebo IV infusion o n Day  1 and Day  15 of 
each 28 -day cycle for 12 cy cles.  If, after completing 12 cy cles of study  drug, the subject is 
tolerating the drug and the Investigator believes the subject is continuing to benefit from ongoing 
study  drug treatment, the Adjuvant Phas e may  be extended following consultation with the 
Neuro -Medical Oncology  Chair or AbbVie Medical Monitor.  ABT -414/placebo will continue 
according to the same dosing schedule at the discretion of the Investigator as long as disease 
progression has not been determined.
The mg/kg dose will be determined from the weight on Day 1 of the Chemoradiation Phase and 
need not change during the Chemoradiation Phase unless there is a weight change b y more than 
10% from Week 1 Day  1.  Recalculation of dose for < 10% wei ght changes is allowed at the 
discretion of the Investigator.  There will be no cap on the weight of the subject or on the number 
of milligrams administered for overweight subjects.  More frequent assessment and use of height 
and/or weight and calculation of BSA are permitted throughout the study .
If TMZ treatment is discontinued due to intolerance during either the Chemoradiation Phase or 
Adjuvant Phase, subjects will continue receiving study  drug (ABT -414 or placebo) infusions 
according to the same study  schedule.
The ABT -414 (active and placebo) will be provided as a l yophilized powder in vials.  Each 
100mg vial of ABT -414 and placebo will be reconstituted with 5.0 mL  of sterile water for 
injection to provide a 20 mg/mL  ABT -414 active or a placebo soluti on.  Each 20 mg vial of 
ABT -414 and placebo will be reconstituted with 1.0 mL  of sterile water for injection to provide a 
20 mg/mL  ABT -
414 active or a placebo solution.  The ABT- 414 is dosed as a fixed dose [or] 
based on bod y weight.  The contents of two o r more reconsitituted vials may  be diluted to 
accomplish the desired dose.  The total volume administered will be dependent upon the 
assigned dose for that dosing period and/or the tolerability of the ABT -414/placebo.  The 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
73ABT -414 and placebo solution(s) w ill be administered via intravenous (IV) infusion.  Specific 
dose preparation and documentation details will be provided to the site pharmacy  outside of this 
protocol.
Guidelines for ABT -414 dose preparation, volume, and rate of infusion will be supplied by 
AbbVie to study  site staff, within the study  manual.
The dosing schedule for the hepatic impairment sub -study  can be found in Appendix I X.
5.5 Eye Drops for Prophylactic Treatment of ABT -414 Eye Toxicity
Eye drops are to be used regardless of an y systemic (oral/IV) corticosteroids that the subject may  
be taking concurrentl y.
All subjects will receive prophy lactic ey e drops with each dose of ABT- 414/placebo for 
7consecutive day s, starting from 2 day s prior to infusion and continuing until 4 day s after 
infusion.  The ey e drop formulations recommended for the study , ranked by  steroid potency  from 
Level 1 (non- steroid artificial tears) to Level 4 (high -potency  steroid where available), and 
dosing schedule for each are listed in Table 7.  Alternatives may  be discussed with the sponsor in 
cases where the recommended formulation(s) for one or more levels are not available locall y.  
All subjects will begin on a Level 3 (moderate -potency ) steroid at the initiation of the 
Chemoradiation Phase.  Subjects will be mon itored with regular ophthalmologic examinations 
(with additional sy mptom -driven examinations as needed) using the ABT -414- TOE 
(Section 4.2
).  The potency  of the ey e drop formulation given with subsequent ABT- 414/placebo 
doses will be adjusted upward or dow nward, as needed, based on corneal findings from the 
ABT -414- TOE, as shown by  the decision algorithm in Table 8.  To minimize unnecessary  risks 
associated with prolonged administration of ocular steroids (including potential for infection, 
glaucoma, and ca taracts), the algorithm requires a step- down in the level of ey e drop potency  for 
subjects with Grade 1 or no ey e toxicity  who have no evidence of corneal microcysts on 
ophthalmic examination.  The rationale for this approach is described in further detail in 
Section 5.12.4.
Though not well understood, ocular steroids may  slow down the turn- over of transient 
amplify ing cells in the eye and thereby  protect them from damage caused by  the MMAF toxin 
portion of ABT -414 that targets cells in rapid division.  Although early  use has shown that 
steroid ey e drops may  reduce the severit y of s ymptoms related to microcyst formation, they  
generall y do not prevent them completely.  Because steroid ey e drops are used to protect 
transient amplify ing cells during exposure to MMAF, the best time to administer them is around 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
74the time of infusion when the levels of MMAF are at their peak.  Prolonged use of steroid ey e 
drops outside of the time when there is MMAF exposure is not recommended, as they  may  cause 
other side effects a nd prevent the healing process.
Table 7:  Eye Drop Recommended Dosing Regimen
All subjects will start on Level 3 eye drop regimen.  The choice of specific prophy lactic ey e drop 
formulation is at the Investigators discretion.
LEVEL PRIMARY CHOICE ALTERNATIV E CHOICES DOSE SCHEDULE
Level 1Artificial Tears
(non-steroid)Dexpanthenol
Visine
Thera Tears
Refresh
Systane1 –2 drops (gtts) in each eye (OU) 
TID for 7 days, starting 48 hours 
before each infusion
Level 20.12% prednisolone
acetate suspension0.1% fluorometholone
1% rimexolone suspension
0.25% desonide solution
Medrysone
0.2% Ioteprednol
Hydrocortisone sodium 
phosphate1 –2 drops (gtts) in each eye (OU) 
TID** for 7 days, starting 48 hours 
before each infusion
Level 3
(Initial
Strategy^)1% prednisolone
acetate suspension*0.1% dexamethasone 
phosphate solution
0.5% Ioteprednol etabonate
Dexamethasone sodium 
phosphate
Betam ethasone1 –2 drops (gtts) in each eye (OU) 
TID** for 7 days, starting 48 hours 
before each infusion
Level 40.05% difluprednate 
emulsion
(if locally available)1 –2 drops (gtts) in each eye (OU) 
TID** for 7 days, starting 48 hours 
before each infusion
* 1% prednisolone is the preferred steroid for Level 3.  TID = three times daily.
** Dosing more frequently than TID is allowed at investigator discretion.
^ Level 3 is the starting level for all subjects.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
76General or specific changes in the subject's condition render the subject unacceptable for 
further treatment in the judgment of the Investigator
Subject become pregnant while on study
Subjects unable to continue either TMZ or ABT -414/placebo due to excessive drug -specific 
toxicity  will be allowed to continue therap y with the other, tolerated therapy components until 
one of the other criteria above is met.
Subjects discontinuing therap y in the absence of progression should not receive an y other cancer 
treatment before their disease progresses, unless this is clearly  not in the interest of the subject.
ABT -414 treatment may  be continued at the investigator's discretion if for any  reason there is 
uncertaint y about whether true disease progression has occurred.  As anecdotal cases of drug -
related pseudoprogression have been reported, which were associated with both initial clinical 
and radiological deterioration and appeared to have a different temporal course and 
characteristics to traditional radiotherapy -related pseudoprogression, investigators may  consider 
biopsy  prior to study  drug discontinuation.  If, after treatment discontinuation, there is additional 
clinical information leading the investigator to conclude that the reason for discontinuation is no 
longer valid, the subjec t may  resume study  treatment as long as no other chemotherap y, 
radiotherap y, immunotherap y, NovoTTF, or other treatment with antineoplastic intent has been 
received, with the exception of surgical intervention that y ields histology  not demonstrative of 
tumor progression.
After progression, the treatment will be left to the discretion of the Investigator.  An y anti -cancer 
therap y other than the study drug will not be considered as part of the protocol treatment.  
However, treatments will be recorded.
The pro tocol or an y portion of the protocol may  also be discontinued or placed on hold by  
AbbVie due to unacceptable toxicity  events, inadequate drug suppl y, or other reasons after the 
study  sites have been notified in writing.
If subject withdraws consent, the t ype of withdrawal should be specifically indicated (further 
treatment with TMZ, ABT -414/placebo, an y follow up for progression, or any follow -up of 
toxicity , or an y follow up for survival).  In an y case, data collected until the date of withdrawal 
will rem ain available for study  anal ysis.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
775.7 Integral Assay/Biomarker
EGFR Amplification Testing
Subjects must consent to provide tumor tissue, a portion of which will be used to assess EGFR
amplification status, MGMT promoter methy lation, and EGFRvIII .  Onl y subjects with tumors 
that demonstrated EGFR gene amplification b y centralized testing using the study  designated 
EGFR FISH assay  as well as sufficient tissue for MGMT testing will be eligible for enrollment.  
Tissue should be prepared and shipped to central lab as described in the study  specific laboratory  
manual.  Sites will be provided with EGFR amplification results.
EGFRvIII Mutation Testing
Subjects tumors will be assessed for EGFRvIII mutation status by  centralized testing using a 
designated R T-PCR assay .  EGFRvIII testing will be performed at the same time as EGFR
amplification testing to reduce delay  and will be used to determine stratification for subject 
randomization.  Tissue should be prepared and shipped to central lab as described in th e study  
specific laboratory  manual.  Study  sites will be provided with EGFRvIII results.
MGMT Testing
Subjects tumors will be assessed for MGMT methy lation status by  centralized testing using a 
PCR assay .  MGMT methy lation status will be assessed in parallel with EGFR amplification 
testing to reduce delay  and will be used to determine stratification for subject randomization.  
Tissue should be prepared and shipped to central lab as described in the study  specific laboratory  
manual.  Study  sites will be provided with MGMT results.
If the subject has a previously  available valid result from an approved vendor such as LabCorp, 
Laboratory  Corporation of America, or Covance which use the same central assay  (or in limited 
cases local MGMT testing performed for cli
nical or research purposes if, upon review of the local 
MGMT testing methodology , approval is granted by  RTOG or AbbVie), then those MGMT
results will be accepted for eligibility  and stratification in this study .  If the MGMT results tested 
as part of this study  (central results) are or become available prior to randomization, then the 
central results will be used for stratification UNLESS the central results obtained are 
"insufficient tissue," indeterminate, or invalid, in which case the valid result from the approved 
non-central MGMT assay will be used for stratification.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
78Other
Remaining tissue, serum, plasma and whole blood will be retained to conduct exploratory
research to investigate biomarkers where allowed by  local regulations.  If local regulations do 
not allow for tissue shipment or storage, the tissue will be returned or destroy ed immediatel y 
after eligibility  testing.  Ty pes of biomarkers analy zed may  include (but are not limited to):  
nucleic acids, proteins, transcriptome profile, or metabolites .  Evaluation may  include 
biomarkers related to pathway (s) targeted b y drug, those believed to be related to the disease or 
to drug response.  The samples may  be anal yzed as part of a multi -study  assessment of factors 
involved in the response to therap y orthe disease state.  The information learned from these 
collected samples may  be used to investigate factors influencing response to treatment, scientific 
questions related to cancer, and/or in the development of new therapies and diagnostic tests.  The 
results of exploratory  biomarker testing may  not be included with the study summary .
AbbVie (or people or companies working with AbbVie) will store and analy ze the samples in a 
secure space with adequate measures to protect confidentiality .  The samples will be retained for 
analysis while research on ABT- 414, or drugs of this class, or GBM (or related oncology  
diseases), continues up to, but no longer than, 20 years from the end of the study, or per local 
requirements.
Pharmacogenetic Testing
DNA samples may  be sequenced and data anal yzed for genetic factors contributing to the disease 
or to the subject's response to ABT -414, or other study  treatment in terms of pharmacokinetics, 
efficacy , tolerability , and safet y.  Such genetic factors may include genes for d rug metabolizing 
enzy mes, drug transport proteins, genes within the target pathway , genes believed to be related to 
the disease or to drug response.  Some genes currently  insufficientl y characterized or unknown 
may be understood to be important at the time of analy sis.  The samples may  be anal yzed as part 
of a multi- study  assessment of genetic factors involved in the response to ABT- 414, drugs of this 
class, or the disease state.  The samples may  also be used for the development of diagnostic tests 
related to ABT -414, drugs of this class, or the disease state.  The results of pharmacogenetic 
analyses may  not be reported with the study  summary .
5.7.1 Availability of Results
Sites will be provided with EGFR amplification, EGFRvIII , and MGMT results, but not other 
pharmacod ynamics, pharmacogenetic, or exploratory  results.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
795.8 General Concomitant Medication and Supportive Care Guidelines
Any medication or vaccine (including over -the-counter, prescription medicines, vitamins and/or 
herbal suppl ements) that the subject is receiving at the time of enrollment, receives during the 
study , and continuing for 49 day s following the last dose of study  drug must be recorded in 
source documents and electronic case report forms (eCRFs).  The reason for use, date(s) of 
administration (e.g., start, ongoing, and end date), dosage information, including dose and 
frequency  must be entered into the database.
Non-pharmacologic supportive care measures for ocular toxicities (e.g., use of bandage contact 
lenses, punc tal plugs, sunglasses, etc.) that the subject is receiving at the time of enrollment, 
receives during the stud y, and continuing for 49 days following the last dose of study drug must 
be recorded in source documents and electronic case report forms (eCRFs), including the reason 
for use and date(s) of administration (e.g., start, ongoing, and end date), must be entered into the 
database.
Both corticosteroid therapy  and continuous TMZ therap y induce lymphocy topenia.  Subjects 
receiving either of these drugs or both concomitantly  are at an increased risk for opportunistic 
infections.  Therefore, a prophy laxis against Pneumocy stis ( jirovecii ) pneumonia (PCP) for all 
subjects receiving TMZ during radiation therap y such as trimethoprim -sulfamethoxazole 
(Bactrim for te®, Bactrim DS®), monthly  pentamidine inhalations, dapsone, or as required by  
local regulation guidelines for TMZ administration.  Prophy laxis during adjuvant TMZ is at the 
discretion of the Investigator per the local prescribing information for TMZ.
Best supportive care and treatment should be given as appropriate to each subject (antibiotics, 
transfusions, ox ygen therapy, nutritional support, palliative treatment for pain or cough, etc.).
5.8.1 Permitted Supportive/Ancillary Care and Concomitant Medicati ons
Antiemetic proph ylaxis with a 5 -HT3 antagonist is strongl y recommended and should be 
administered 30 to 60 minutes before TMZ administration for at least the first few doses during 
the Chemoradiation Phase and all doses of the Adjuvant Phase.
All supportive therap y for optimal medical care will be given during the study period at the 
discretion of the treating Investigator.  The locally approved product label, institutional 
guidelines, local practice, or applicable Summary  of Product Characteristics (Sm PC) should be 
referenced for an y concomitant therapy guidelines.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
805.8.2 Prohibited Therapies
Growth factors and transfusions are permissible for routine supportive care in treatment 
of patients with chemotherap y per local prescribing regulations and Investi gator 
discretion.  However, they are not permitted to induce elevations in neutrophil, 
hemoglobin, hematocrit or platelet count for the purposes of:  (1) protocol eligibility ; or 
(2) administration of TMZ on the scheduled dosing interval without delay  when a delay  
would otherwise be required b y cytopenias; (3) allowing treatment with TMZ at a higher 
dose; or (4) avoiding interruption of the treatment during concomitant radiotherap y that 
would otherwise be required for cy topenias.
Dacarbazine h ypersensitivit y is a contraindication for TMZ administration.  No other 
investigational anti -neoplastic drugs will be allowed during the study .  Subjects who 
come off stud y after progression of disease may be allowed to use other investigational 
drugs.  Every  effort should be made to document the use of post -progression therapies.
Use of other t ypes of surgery , chemotherap y, immunotherap y or biologic therap y during 
study  treatment (prior to disease progression) as an anticancer therapy  is prohibited.  Any  
medication or v accine (including over -the-counter, prescription medicines, vitamins 
and/or herbal supplements) used for antineoplastic intent is prohibited.  Further, 
additional stereotactic boost radiotherap y during study  treatment (prior to disease 
progression) is not allowed. If an y of these treatments are required, the subject will not 
receive further therap y with TMZ and ABT -414 or placebo according to this protocol; 
however, the subject will continue to be followed for disease progression and survival 
information.  All therap y after stud y treatment discontinuation is at the I nvestigator's 
discretion, but should be recorded in the eCRF.
5.8.3 Unblinding Procedure
AbbVie, the RTOG, the investigator, the study  site personnel and subject will remain blinded to 
each subj ect's treatment with ABT -414 or placebo throughout the course of the study , except in 
two situations:
rare cases where the sponsor has determined that unblinding is necessary  for subject 
safet y, or
after unequivocal disease progression has been documented, where knowledge of the 
study  drug treatment assignment is necessary  to determine the subject's eligibility  for a 
subsequent clinical trial or is necessary , in the judgment of the investigator, for 
appropriate management of the subject.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
81The I RT will provi de access to blinded subject therap y information for an individual subject in 
the case of a medical emergency  or if necessary , after confirmed disease progression, to 
determine eligibility  for a subsequent clinical trial or to appropriatel y manage the subj ect.  In the 
event the investigator believes that knowledge of study  treatment is required, every  effort must 
be made to contact the Neuro -Medical Oncology  Chair or the AbbVie Medical Monitor (or 
qualified designee) listed at the top of the study  protocol prior to contacting the I RT for 
unblinding (as long as subject safet y is not compromised).  In the case of unblinding for reasons 
other than safety  (e.g., to determine eligibility  for another clinical trial), eCRFs confirming the 
date and criteria for esta blishing disease progression must be completed prior to performing 
unblinding.  The date and reason that the blind was broken must be convey ed to AbbVie and 
recorded on the appropriate eCRF.  In the event the AbbVie Clinical Project Team should break 
the blind, the reason will be documented in a note to study  file and on the appropriate eCRF.
5.9 Method of Assigning Subjects to Treatment Groups
At the Screening Visit, all subjects will be assigned a unique subject number through the use of 
IRT.  For subject s who do not meet the study selection criteria, the site personnel must contact 
the IRT s ystem and identify  the subject as a screen failure.
Subjects who are enrolled will retain their subject number, assigned at the Screening Visit, 
throughout the stud y. For enrollment of eligible subjects into the study , the study  site will utilize 
the IRT s ystem in order to receive unique study  drug kit numbers and a unique randomization 
number.  Subjects will be randomized to either Arm A or Arm B in a 1:1 ratio.  The 
randomization will be stratified, as described in Section 3.1.  The randomization number will be 
used only  by AbbVie for loading the treatment assignments into the database.  The study  drug kit 
numbers and randomization numbers will be assigned according t o schedules 
computer -generated before the start of the study  by the AbbVie Statistics Department.  Upon 
receipt of stud y drug, the study  site will acknowledge receipt in the I RT system.
5.10 Treatment Compliance
The Investigator or his/her designated and qualified representatives will administer study  drug 
only to subjects enrolled in the study  in accordance with this Protocol M13 -813.  The stud y drug 
must not be used for reasons other than that described in the protocol.  Subjects will be 
supervised at the time of study  drug administration.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
825.11 Drug Accountability
The Investigator or designee will verify  that study drug supplies are received intact at the 
appropriate temperature and in the correct amounts.  This will be documented by  signing and 
dating the Proof of Receipt or similar document or via direct recording in the I RT.  An accurate 
(running) inventory  of study  drug will be kept by  the site, and will include the lot number, Proof 
of Receipt number(s), kit numbers, the number of vials dispensed, sub ject initials, initials of 
person who administered the drug and the date study  drug was administered for each subject.  An 
overall accountability  of the study  drug will be performed and verified by  AbbVie monitor 
throughout the stud y and at the study site closeout visit.
After verification of drug accountabilit y, used vials must be destroyed at the site according to 
local regulations governing hazardous waste.  Disposal of used study  supplies must be 
documented in IRT.  All study  drug must be inventoried, accounted for, and returned to AbbVie 
or destro yed per instructions from AbbVie and according to local regulations.  A cop y of the 
Return Shipment Form, in accordance with instructions provided by  the AbbVie monitor, will 
also be included in the shipment.
Labels must remain attached to the containers.  If pre -arranged between AbbVie and the site, 
destruction of the stud y drug may be performed at the site.
5.12 Discussion and Justification of Study Design
5.12.1 Discussion of Study Design and Choice of Control Groups
The background treatment regimen for the current study —6 weeks of concomitant radiation and 
TMZ treatment, followed by  6 cy cles of adjuvant TMZ therapy  (dosed on Day s 1 
–5 of each 28-
day cycle) is currently  an established standard- of-care treatment for newl y diagnosed GBM.25  
Consistent with other recent or ongoing trials of experimental therapies (bevacizumab, Opdivo, 
and NovoTTF) in this indication, ABT -414 will be prescribed as add -on treatment to the 
RT/TMZ standard of care.  The stud y will be placebo- controlled and double -blind, which is the 
gold standard for assessing efficacy .  The original design was a seamless Phase 2b/3 that allowed 
early termination of the study and reduced unnecessary subject exposures to an ineffective 
treatment if the Phase 2b r esults demonstrated futility .  However, rapid acceleration in the 
enrollment rate of INTELLANCE- 1 suggested that the Phase 3 portion of the study  would likel y 
be finished enrolling before results of the planned PFS- based futility  anal ysis would be availabl e.  
In addition, recent information gathered from the INTELLANCE- 2 trial, suggesting an OS 
benefit of the ABT -414/TMZ combination in recurrent GBM and a safet y profile consistent with 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
83previous Phase 1 results, provide increased confidence that the addition of ABT -414 to standard 
frontline therap y would demonstrate a statisticall y significant and clinicall y relevant benefit for 
OS, as well as an acceptable safet y profile, in newly diagnosed subjects in the INTELLANCE -1 
study .  For these reasons, the study  design has been modified to eliminate the PFS -based 
Phase 2b interim futility  anal ysis and to complete the study  as a Phase 3 study  based on the gold 
standard efficacy  endpoint of OS.
5.12.2 Appropriateness of Measurements
OS, the primary  efficacy  endpoint for the study , is widely  accepted as the most clinically  
relevant endpoint for oncology  trials.  PFS is a clinically  relevant endpoint but does not alway s 
correlate with OS.  PFS will be studied as a secondary  endpoint.  Standard pharmacokinetic, 
statistical, clin ical and laboratory  procedures will be utilized in this study .
5.12.3 Suitability of Subject Population
The study  population is restricted to subjects with newly  diagnosed GBM whose tumors exhibit 
EGFR amplification (including that subset of the population with EGFRvIII mutation).  Selective 
efficacy  for the EGFR -amplified population is consistent with the understood mechanism of 
ABT -414, as the antibody  selectivel y targets EGFR -amplified tumors, and is strongl y supported 
by clinical data from the ongoing Phase 1 Study  M12 -356.  As of April 2015, there have been 
6subjects with confirmed objective responses to ABT -414, all of whom have tested positive for 
EGFR amplification.  There have been no subjects who have tested negative for EGFR
amplification with a confir med objective response.
5.12.4
Selection of Doses in the Study
Radiotherapy and TMZ Treatment
Radiation and drug doses for the background treatment in this study , consisting of 6 weeks of 
concomitant radiotherapy  (~60 Gy  over 30 fractions) and TMZ (at 75 mg/m2daily), followed by  
6 cycles of adjuvant TMZ (at 150 – 200 mg/m2for 5 day s of each 28- day cycle) is the 
established standard of care for treatment of newly  diagnosed GBM.25  TMZ will be prescribed 
as per local guidelines.
ABT -414 Dose Selection
For the Chem oradiation Phase, the recommended ABT- 414 dose of 2.0 mg/kg infused once 
every  2 weeks was selected based on results from Arm A of Study  M12 -356, in which all 
subjects received ABT -414 combined with concomitant radiation and TMZ treatment.  During 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
84dose esc alation at this level, no Grade 3 or higher toxicities were observed.  Higher doses were 
associated with at least 1 dose- limiting toxicity  event and were not well tolerated.  Compared to 
dosing with TMZ alone, ABT -414 appears to be better tolerated when given with concomitant 
RT and TMZ.
For the Adjuvant Phase, the recommended ABT -414 dose of 1.25 mg/kg infused once every  
2weeks was selected based on results from Arm B of Study  M12 -356, in which all subjects 
received ABT -414 along with maintenance TMZ.  During dose escalation at this level (and with 
steroid proph ylaxis) during maintenance TMZ cycles, 2/10 subjects had ocular DLTs, but only  
1was attributable to ABT -414.  Since the 1.25 mg/kg dose was chosen for an expanded safety  
cohort added to that study ,this dose level has been generall y well tolerated, only  approximately  
20% of subjects developing ocular adverse events (Grade 3 or greater) requiring a dose 
reduction.
As previously  mentioned, the ocular manifestations of microcy stic keratopathy  to date h ave been 
reversible after withholding ABT -414, usually  after 4 to 6 weeks.  Subjects who restart ABT-414 
at lower doses (~1.0 mg/kg) have less severe toxicities and can generally  tolerate further therapy .
Prophylactic Eye Drop Dosing Strategy
The strategy  for dosing prophy lactic ey e drops to manage the ey e toxicity  associated with 
ABT -414 in this study , which starts all subjects (including those assigned to placebo instead of 
ABT -414) on moderate potency  ocular steroid drops, was designed to help preserve t he stud y 
blind needed to conduct a successful controlled study  while minimizing the risk associated with 
prolonged use of ocular steroids.  Placebo subjects unblinded to their treatment assignment in 
this study  population are expected to have unacceptably  high dropout rates, leading to s ystematic 
bias and increased risk of a failed stud
y due to a loss of statistical power.  A recent trial 
evaluating the efficacy  of rindopepimut (ACT III trial) in the same newly  diagnosed GBM 
population and a similar treatme nt paradigm —with rindopepimut added to standard - of-care 
therap y with RT/TMZ —was originally  designed as an open -label study  with a standard- of-care 
treatment arm as a control group.  However, due to high attrition rates for the subjects assigned 
to the stan dard-
of-care treatment arm, the stud y had to be redesigned as a single -arm trial without 
a control group.26
During Phase 1 studies, use of proph ylactic steroid ey e drops (for 7 day s of each 14- day dosing 
interval) was deemed necessary  for all subjects taki ng ABT -414 in order to minimize the severity  
of ocular adverse events related to microcy stic keratopathy , the adverse effect characteristic of 
ABT -414.  To avoid s ystematic unblinding in this study , placebo subjects must receive ey e drops 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
85matching those gi ven to subjects receiving ABT -414.  Using blinded placebo ey e drops in this 
study  was considered but found to be infeasible due to differences in the packaging and visual 
appearance of the ey e drops themselves between the ocular steroid suspensions/solutions to be 
used for proph ylaxis and available saline or lubricant formulations.  Therefore, all subjects in this 
study  will receive moderate potency  steroid ey e drops (e.g., prednisolone acetate 1% suspension) 
with the first two doses of ABT -414/placebo.  Ta rgeted ophthalmologic examinations, to assess 
and grade an y objective findings characteristic of ABT -414- mediated corneal toxicity , will be 
performed regularly , starting no later than after the first two infusions ABT- 414/placebo, and the 
steroid potency  of the eye drops for subsequent doses will be adjusted based on these objective 
findings.  Subjects who have no evidence of microcy stic keratopathy  on ophthalmic examination 
are required to step down to a Level 2, low -potency  steroid safer for long -term use , or in certain 
cases, to a Level 1 non -steroid solution.
Because the appearance of microcy stic keratopathy  seen with ABT -
414 is a relativel y unique and 
specific finding unlikel y to occur spontaneousl y or with other drugs used for GBM, it is highl y 
unlikel y that a placebo-assigned subject would continue on a moderate- potency  steroid for a 
prolonged period.
In addition to the step- down in steroid potency  required for subjects without objective findings of 
microcy stic keratopathy , risks related to prolonged steroid use are further reduced b y a) the fact 
that subjects are off steroid drops for 7 day s of each 14- day dosing interval, and b) the 
requirement for scheduled ophthalmologic examinations (including assessments for 
steroid- related effects such as increas ed intraocular pressure/glaucoma or cataract formation) at 
least every  4 weeks during the Chemoradiation Phase and first 2 cy cles of the Adjuvant Phase, 
followed b y ever y 8 weeks thereafter, or more frequently  if indicated by  eye sy mptoms.  Based 
on this dosing schedule and frequent safet y monitoring for potential steroid -related effects, 
long-term term use of Level 2 (low -potency  steroid) ey e drops constitutes a minimal safety  risk 
to subjects.  Maintaining subjects on low potency  steroid ey e drops is expe cted to improve study  
retention, because receiving active ey e drops will support the subjects' belief that they  may  have 
been assigned to ABT -414.  (While not recommended, subjects who have no evidence of 
microcy stic keratopathy  may  be required, on an individual site -level basis, to step down to a 
Level 1, non- steroid ey e drop if that site's IRB/EC or regulatory  authority  has determined that 
long-term use of ocular steroids at any  potency  is unacceptable in such subjects.)
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
866.0 REMOVAL OF SUBJE CTS FROM THERA PY OR ASSESSMENT
6.1 Discontinuation of Individual Subjects
Each subject has the right to withdraw from the study  treatment at an y time.  I n addition, the 
Investigator may  discontinue a subject from the study  at any  time if the Investigator considers it 
necessary  for any  reason, including the occurrence of an adverse event or noncompliance with 
the protocol.
Subjects who withdraw consent to continue study  therapy  will be encouraged to continue 
participation with other study  procedures and assessment unles s unwilling to do so.  Clinical 
assessment needed for the 49 -Day safet y assessment after ABT -414 discontinuation and to 
determine the occurrence and timing of disease progression (for PFS) and/or death (for OS) 
should be prioritized.  Subject may  withdraw from the treatment without withdrawing consent 
for follow up of PFS, OS or drug toxicities.
A subject will be withdrawn from the stud y treatment if an y of the following occur:
1) The subject or subject's legally  acceptable representative withdraws consent.
In the event a subject withdraws from the study, stored biomarker samples will be 
retained unless the subject also withdraws consent for use of unused stored biomarker 
samples.  If the subject changes his/her consent, and the samples have already  been 
tested, those results will still remain part of the overall research data.
If a subject withdraws consent or discontinues from the main study , their optional 
sub-study  samples will continue to be stored and anal yzed until sub- study  consent is 
withdrawn as wel l.
Unless the withdrawal of consent specifically  withdraws consent from follow up of OS, 
subjects will continue to be followed for OS, and OS will be recorded.  The opt out of OS 
follow -up must be clearly  documented.  Of note, OS may  still be obtainable fr om a query  
of publically  available information unless prohibited by  local regulations.
2) The subject experiences radiographic disease progression per RANO (Appendix I ).  
Progression is defined b y any of the following:
at least 25% increase in sum of the p roducts of perpendicular diameters of enhancing 
lesions (compared with baseline if no decrease) on stable or increasing doses of 
corticosteroids;
a significant increase in T2/FLAIR nonenhancing lesions on stable or increasing doses of 
corticosteroids compa red with baseline scan or best response after initiation of therap y, 
not due to comorbid events;
the appearance of an y new lesions;
clear progression of nonmeasurable lesions;
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
87definite clinical deterioration not attributable to other causes apart from the tumor, or to 
decrease in corticosteroid dose;
Failure to return for evaluation as a result of death or deteriorating condition.
The phenomenon of pseudoprogression should be considered when determining if there is 
disease progression, particularl y during the first 3 months after radiotherapy.  
Pseudoprogression refers to the occurrence of "early  delay ed radiation reactions" that occur 
usually  within the first 3 mont hs post radiation treatment.  These transient adverse signs and 
symptoms may  spontaneously  improve without therap y or with supportive care such as 
corticosteroids.  Thus, care should be taken in making the diagnosis of tumor progression or 
recurrence (Appe ndix I ).
Clinical Progression and Other Factors
Note that increase in corticosteroid dose alone, in the absence of clinical deterioration related to 
tumor, will not be used as a determinant of progression.  Subjects with stable imaging studies, 
whose cort icosteroid dose was increased for reasons other than clinical deterioration related to 
tumor, do not qualify  for stable disease or progression.  Subjects should be observed closely .  If 
their corticosteroid dose can be reduced back to baseline, they  will b e considered as having 
stable disease; if further clinical deterioration related to tumor becomes apparent, they  will be 
considered to have progression.  The date of progression should be the first time point at which 
corticosteroid increase was necessary .
The definition of clinical deterioration is left to the discretion of the Investigator, but it is 
recommended that a decline in the KPS from 100 or 90 to 70 or less, a decline in KPS of at least 
20 from 80 or less, or a decline in KPS from an y baseline to 50 or less, for at least 7 day s, be 
considered neurologic deterioration unless attributable to comorbid events or changes in 
corticosteroid dose.
Subjects with nonmeasurable enhancing disease whose lesions have significantly  increased in 
size and become measurable (minimal bidirectional diameter of at least 10 mm and visible on at 
least two axial slices that are preferabl y, at most, 5 mm apart with 0 -mm skip) will also be 
considered to have experienced progression.  The transition from a nonmeasurable lesion to a 
measurable lesion resulting in progression can theoreticall y occur with relatively small increases 
in tumor size (e.g., a 9 × 9 mm lesion [nonmeasurable] increasing to a 10 × 11 mm lesion 
[measurable]).  Ideall y, the change should be significant (at least 5 mm increase in maximal 
diameter or at least 25% increase in sum of the products of perpendicular diameters of enhancing 
lesions).
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
88In general, if there is doubt about whether the lesion has progressed, continued treatment and 
close follow -up evaluation will help clarify  whether there is true progression.  If there is 
uncertaint y regarding whether there is progression, the subject may continue on treatment and 
remain under close observation (e.g., evaluated at 4-week intervals).  If subsequent evaluations 
suggest that the subject is in fact experiencing progression, then the date of progression should 
be the time point at which the issue was first raised.
Note:   During the first 12 weeks after completing chemoradiation:  progression can only  be 
defined using diagnostic imaging if there is new enhancement outside of the radiation field 
(beyond the high-dose region or 80% isodose line) or if there is unequivocal evidence o f viable 
tumor on histopathologic sampling (e.g., solid tumor areas [i.e., more than 70% tumor cell nuclei 
in areas], high or progressive increase in MIB
-1 proliferation index compared with prior biopsy , 
or evidence for histologic progression or increased anaplasia in tumor).  Note:  Given the 
difficulty  of differentiating true progression from pseudoprogression, clinical decline alone, in 
the absence of radiographic or histologic confirmation of progression, will not be sufficient for 
definition of progres sive disease in the first 12 weeks after completion of concurrent 
chemoradiotherap y.  In addition, subjects who remain clinically stable and/or are suspected to 
have pseudoprogression based on metabolic or vascular imaging should continue with their 
curren t therapy  (Appendix I).
3)The subject experiences unacceptable toxicity  with ABT -414 in combination with TMZ.
4)The subject requires a dose modification for ABT -414 below 0.5 mg/kg.
5)The subject requires other anti -cancer treatment, such as surgery  or alternate anti -cancer 
agents, during the study  period.
6) The subject experiences a ≥ Grade 3 allergic reaction.
7)Significant noncompliance with the protocol that could impact subject safety  or data 
integrit y.
8)The Investigator believes it is in the be st interest of the subject.
9)The subject has a positive pregnancy  test result.
If, after treatment discontinuation, there is additional clinical information leading the Investigator 
to conclude that the reason for discontinuation is no longer valid, the subject may  resume study  
treatment as long as no other chemotherap y, radiotherap y, immunotherap y, NovoTTF, or other 
treatment with antineoplastic intent has been received, with the exception of surgical intervention 
that y ields histology  not demonstrative of tumor progression.  
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
896.1.1 Discontinuation of Temozolomide
Subjects should discontinue TMZ if an y of the criteria for discontinuation, as described in the 
guidelines provided in local approved regulatory  prescribing information are met.
6.1.2 Discontin uation of ABT -414 or Placebo
Study  drug (ABT -414/placebo) will be continued as discussed above in Section 5.4 unless 
toxicities prohibit further use.  Severe allergic reactions (Grade 3 or Grade 4) require the 
immediate interruption of ABT -414/placebo and discontinuation from the study .
6.1.3 Discontinuation of Radiation
Subjects should discontinue radiation if an y of the criteria for discontinuation, as described in the 
institutional guidelines or local approved regulatory prescribing information are met.
6.2 Discontinuation of Entire Study
AbbVie may  terminate this study  prematurel y, either in its entirety or at an y study  site, for 
reasonable cause provided that written notice is submitted in advance of the intended 
termination.  The Investigator may  also terminate the study  at his/her site for reasonable cause, 
after providing written notice to AbbVie in advance of the intended termination.  Advance notice 
is not required b y either party if the study is stopped due to safety concerns.  If AbbVie 
terminates the study  for safet y reasons, AbbVie will immediately  notify  the Investigator by  
telephone and subsequently  provide written instructions for study  termination.
If the stud y is prematurely discontinued to due safety or futility reasons, study drug will no 
longer be provided once the entire stud y is discontinued.  When possible, AbbVie and the 
Investigator will develop a plan to provide ABT -414/placebo as required by  local regulations.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
907.0 ADVERSE EVENTS
7.1 Complaints
A complaint is any  written, electronic, or oral communication that alleges deficiencies related to 
the phy sical characteristics, identity , quality, purity, potency, durability, reliability, safet y, 
effectiveness, or performance of a product after it is released for distribution.  The investigat ional 
product in this trial contains biologic compound(s).
7.2 Medical Complaints
The Investigator will monitor each subject for clinical and laboratory  evidence of adverse events 
(AE) on a routine basis throughout the stud y.  The Investigator will assess and record an y 
adverse event in detail including the date of onset, event diagnosis (if known) or sign/s ymptom, 
severit y, time course (end date, ongoing, intermittent), relationship of the adverse event to study 
drug, and an y action(s) taken.  For serious adverse events considered as having "no reasonable 
possibility " of being associated with study  drug, the Investigator will provide an Other cause of 
the event.  For adverse events to be considered intermittent, the events must be of similar nature 
and seve rity.  Adverse events, whether in response to a query , observed by  site personnel, or 
reported spontaneously  by the subject will be recorded.
All adverse events will be followed to a satisfactory  conclusion.
Adverse event reporting is required for all prot ocol treatment modalities:  ABT- 414/placebo, 
TMZ, and radiation therapy .
The NCI CTCAE v.4 will be used for adverse event reporting/grading of event severit y.
All ophthalmology  exam reports will be reviewed by  the Investigator (or medicall y qualified 
deleg ate).  With the exception of the corneal findings described below, decisions on which
findings from ophthalmologic examinations, if any , will be reported as adverse events, as well as 
the grading of an y such events, will be made according to the Investigat or's judgment.  These 
events will be graded according to NCI CTCAE v.427criteria, and notaccording to the grading 
system used for the ophthalmology  examinations.
To ensure consistent reporting of the corneal findings characteristic of ABT -414 that are 
not well described by the MedDRA preferred terms or CTCAE grading, any abnormal 
finding on either the "Microcysts/Edema" or "Superficial Punctate Keratopathy" field of 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
91the ABT -414- TOE must be recorded as an adverse event of "microcystic keratopathy" 
with sev erity grading as shown in
 Table 5 (see Section 4.2 for additional details).
7.2.1 Definitions
7.2.1.1 Adverse Event
An adverse event is defined as an y untoward medical occurrence in a subject or clinical 
investigation subject administered a pharmaceutical product and which does not necessaril y have 
a causal relationship with this treatment.  An adverse event can therefo re be any  unfavorable and 
unintended sign (including an abnormal laboratory finding), s ymptom, or disease temporally  
associated with the use of a medicinal (investigational) product, whether or not the event is 
considered causall y related to the use of the product.
Such an event can result from use of the drug as stipulated in the protocol or labeling, as well as 
from accidental or intentional overdose, drug abuse, or drug withdrawal.  Any  worsening of a 
pre-existing condition or illness is considered an ad verse event.  Worsening in severity  of a 
reported adverse event should be reported as a new adverse event.  Laboratory abnormalities and 
changes in vital signs are considered to be adverse events only  if they  result in discontinuation 
from the study , neces sitate therapeutic medical intervention, meet protocol specific criteria 
(regarding toxicity  management, (Section 8)) or if the I nvestigator considers them to be adverse 
events.  When Grade 3 or higher elevations in glucose, cholesterol or trigl ycerides is reported 
under non- fasting conditions, the I nvestigator may choose not to report the abnormality  as an 
adverse event until it has been confirmed b y repeated testing under fasting conditions.  Repeat 
testing for such confirmation may  be done at the next sc heduled laboratory  visit or earlier.  An 
elective surgery /procedure scheduled to occur during the stud y will not be considered an adverse 
event if the surgery /procedure is being performed for a pre
-existing condition and the 
surgery /procedure has been pre- planned prior to study  entry .  However, if the pre -existing 
condition deteriorates unexpectedly  during the study  (e.g., surgery  performed earlier than 
planned), then the deterioration of the condition for which the elective surgery /procedure is being 
done will be considered an adverse event.
7.2.1.2 Serious Adverse Events
If an adverse event meets any  of the following criteria, it is to be reported to AbbVie as a serious 
adverse event (SAE) within 24 hours of the Investigator being made aware of the serious adverse 
event:
Death of Subject An event that results in the death of a subject.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
92Life-Threatening An event that, in the opinion of the Investigator, would have 
resulted in immediate fatality  if medical intervention had not 
been taken.  This does not include an event that would have 
been fatal if it had occurred in a more severe form.
Hospitalization or 
Prolongation of 
HospitalizationAn event that results in an admission to the hospital for an y 
length of time orprolongs the subject's hospital stay . This 
does not include an emergency  room visit or admission to an 
outpatient facility , hospitalization for respite care, or 
hospitalization due solely  to progression of the underly ing 
cancer.  This does not include hospitalization for elective or 
diagnosti c procedures.
Congenital Anomaly An anomal y detected at or after birth, or an y anomaly that 
results in fetal loss.
Persistent or Significant 
Disability/IncapacityAn event that results in a condition that substantially  interferes 
with the activities of daily  living of a study  subject.  Disability  
is not intended to include experiences of relativel y minor 
medical significance such as headache, nausea, vomiting, 
diarrhea, influenza, and accidental trauma ( e.g., sprained 
ankle).
Important Medical Event 
Requiring Medical or 
Surgical Intervention to 
Prevent Serious 
OutcomeAn important medical event that may  not be immediately  life-
threatening or result in death or hospitalization, but based on 
medical judgment may  jeopardize the subject and may  require 
medical or surgical intervention to prevent an y of the 
outcomes listed above (i.e., death of subject, life- threatening, 
hospitalization, prolongation of hospitalization, congenital 
anomaly , or persistent or significant disability /incapacity).  
Additionally ,any elective or spontaneous abortion or stillbirth 
is considered an important medical event.  Examples of such 
events include allergic bronchospasm requiring intensive 
treatment in an emergency room or at home, blood dy scrasias 
or convulsions that do not result in inpatient hospitalization, or 
the development of drug dependency  or drug abuse.
For serious adverse events with the outcome of death, the date and cause of death will be 
recorded on the appropriate case report form.
7.2.1.3 Adverse Events Expec ted Due to Study Related Endpoints
7.2.1.3.1 Deaths
For this study , mortalit y is an efficacy  endpoint.  Deaths that occur during the protocol specified 
adverse event reporting period (Section 7.3) that are more likel y related to disease progression 
will therefore be an expected adverse event and will not be subject to expedited reporting.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
93Death should be considered an outcome and not a distinct event.  The event or condition that 
caused or contributed to the fatal outcome should be recorded as the single medical concept on 
the Adverse Event eCRF.  Generally , only one such event should be reported.  The term "sudden 
death" should onl y be used for the occurrence of an abrupt and unexpected death due to 
presumed cardiac causes in a subject with or without pre existing heart disease, within 1 hour of 
the onset of acute sy mptoms or, in the case of an unwitnessed death, within 24 hours after the 
subject was last seen alive and stable.   If the cause of death is unknown and cannot be 
ascertained at the time of repo rting, "unexplained death" should be recorded on the Adverse 
Event eCRF.  If the cause of death later becomes available (e.g., after autopsy ), "unexplained 
death" should be replaced by  the established cause of death.
7.2.1.3.2 Expected Adverse Events Due t o Glioblastoma
Adverse Events that may be expected due to the subject's underl ying glioblastoma or its standard 
therap y include headache, seizure, neutropenia and progression of underlying GBM, and 
progression of GBM leading to death, etc.  These events ar e considered expected AEs for this 
study  regardless of ABT -414 treatment.  As such, individual subject cases of these events, when 
considered serious, will not be reported in expedited fashion as individual cases, but will be 
evaluated during aggregate rev iews b y the IDMC.  Appendix III includes a complete list of the 
adverse events that will be considered as expected for reporting purposes, based on events 
commonly  related to underly ing glioblastoma or complications from glioblastoma standard 
therap y.
7.3 Adverse Event Severity
The Investigator will rate the severit y of each adverse event according to the National Cancer 
Institute Common Terminology  Criteria for Adverse Events (NCI CTCAE Version 4.0)27
For adverse events not captured by  the Common Terminolo gy Criteria, the following should be 
used:
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
94Grade 1 The adverse event is transient and easil y tolerated by the subject 
(mild).
Grade 2 The adverse event causes the subject discomfort and interrupts the 
subject's usual activities (moderate).
Grade 3 The adverse event causes considerable interference with the subject's 
usual activities and may  be incapacitating (severe).
Grade 4 Life threatening; urgent intervention.
Grade 5 The adverse event resulted in death of the subject (severe).
Relationship to Protocol Treatment
The Investigator will use the following definitions to assess the relationship of the adverse event 
to the use of protocol treatment, with separate assessments for each component of therap y 
(ABT -414/placebo, TMZ and radiation therap y):
Reasonable 
PossibilityAfter consideration of factors including timing of the event, biologic 
plausibility , clinical judgment, and potential alternative causes, there 
is sufficient evidence (information) to suggest a causal relationship.
No Reasonable 
Poss ibilityAfter consideration of factors including timing of the event, biologic 
plausibility , clinical judgment, and potential alternative causes, there 
is insufficient evidence (information) to suggest a causal relationship.
Reasonable possibility  is def ined such that the specific treatment (ABT -414/placebo, TMZ, or 
radiation therap y) is more likely  to be the cause of the event than any  other reason, whereas no 
reasonable possibility  is defined as the Other cause of the event is more likely .  For causalit y 
assessments, events assessed as having a reasonable possibility  of being related to protocol 
treatment will be considered "associated."  Events assessed as having no reasonable possibility  of 
being related to protocol treatment will be considered "not associated."  In addition, when the 
Investigator has not reported a causality  or deemed it not assessable, AbbVie will consider the 
event associated.
If an Investigator's opinion of no reasonable possibility  of being related to protocol treatment is 
given, a n Other cause of event must be provided by  the Investigator for the serious adverse 
event.
7.4 Adverse Event Collection Period
All protocol related serious adverse events and non- serious adverse events must be reported as 
follows:
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
95From time the study -specific informed consent is signed, but prior to the initial 
administration of component therap y, will only be collected if they are considered b y the 
Investigator to be causally  related to the study -required procedures.
From first day  of component therap y administration until 49 days after last administered 
dose of ABT -414.
Adverse event information will be collected as shown in Figure 1.
Figure 1. Adverse Event Collection
Protocol Related 
Serious and
Non-Serious AEs*Serious and Non -Serious AEs
Elicited and/or Spontaneously Reported
   
Consent 
SignedRT, TMZ, 
ABT -414
StartABT -414 
Stopped49 Days After 
ABT -414 
Stopped
* Only if considered by the Investigator to be causally related to study required procedures.
7.5 Adverse Event Reporting
In the event of a serious adverse event, whether associated with protocol treatment or not, the 
Investigator will notify   AbbVie Clinical Pharmacovigilance within 24 of the site being made 
aware of the serious adverse event b y entering the serious adverse event data into the electronic 
data capture (EDC) s ystem.  Serious adverse events that occur prior to the site hav ing access to 
the EDC or EDC is not operable should complete the SAE Non- CRF paper forms and be faxed 
to  AbbVie Clinical Pharmacovigilance within 24 hours of being made aware of the serious 
adverse event.
Email to
FAX to: 

Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
96For serious adverse event concerns, contact the AbbVie Oncology  Safety  Team at:
Oncology  Safet y Management 
AbbVie
1 North Waukegan Road
North Chicago, IL  60064
Contact I nformation:
Safety  Line:
Email:
Fax:
For an y subject safety concerns, please contact the RTOG phy sician listed below:
For questions that need to be addressed b y the study sponsor, please contact the AbbVie 
physician below:
Primary  Clinical Monitor:
AbbVie
Telephone Contact Information:
Mobile:
Email:

Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
97Primary  Medical Monitor:
AbbVie
1 North Waukegan Road
North Chicago, IL  60064
Telephone Contact Information:
Office:
Mobile:
Fax:
Email:
In emergency  situations involving study  subjects when the primary  Medical Monitor is not 
available b y phone, please contact the 24 -hour AbbVie Medical Escalation Hotline where your 
call will be re -directed to a designated backup Medical Monitor MD.
Phone:   
AbbVie will be responsible for Suspected Unexpected Serious Adverse Reactions (SUSAR) 
reporting for the Investigational Medicin al Product (I MP) in accordance with 
Directive 2001/20/EC.  The reference document used for SUSAR reporting in the European 
Union (EU) countries will be the most current version of the Investigator's Brochure for 
ABT -414 or Summary  of Product Characteristic s for TMZ.
Serious adverse events which are considered expected due to the underly ing disease of GBM28as 
described in Appendix III would not be expedited as individual safet y case reports to regulatory 
authorities.
7.6 Pregnancy
Inthe event of a positive pregnancy  test, subjects must immediately  discontinue protocol therap y 
and must be discontinued from the study .  The Investigator must report the positive pregnancy  
test to the appropriate contact listed in protocol Section 7.4 within 1 working day  of the site 
becoming aware of the pregnancy .
All subjects should be informed that contraceptive measures should be taken throughout the 
study  and for 6 months after discontinuing study  drug.  Information regarding a pregnancy  
occurrence in a study  subject and the outcome of the pregnancy  will be collected.  The 
Investigator must follow the pregnancy  to completion and provide an update to AbbVie after 
delivery .

Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
98Male subjects should be informed that contraceptive measures should be taken by  their female 
partners.  If the subject's partner should become pregnant during the stud y, this should also be 
reported and data may  be collected.  In the event of pregnancy  occurring in the partner of an 
enrolled subject, written informed consent for release of medical informatio n from the partner 
must be obtained prior to the collection of an y pregnancy -specific information and the pregnancy  
will be followed to outcome.
Pregnancy  in a study  subject is not considered an adverse event.  The medical outcome for either 
mother or infa nt, meeting any  serious criteria including elective or spontaneous abortion, is 
considered a serious adverse event and must be reported to AbbVie within 24 hours of the site 
becoming aware of the event.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
998.0 TOXICITY MANAGEM ENT AND DOSE MODIFIC ATIONS
For th e purpose of medical management, all adverse events and laboratory  abnormalities that 
occur during the stud y must be evaluated b y the Investigator.  The table of clinical toxicity  
grades modified from the NCI  CTCAE Version 4.0 (available on the CTEP home p age 
http://ctep.cancer.gov) is to be used in the grading of adverse events and laboratory  abnormalities 
that are reported as adverse events, each of which will be followed to satisfactory  clinical 
resolution.
A drug -related toxicity  is an adverse event or laboratory  value outside of the reference range that 
is judged b y the Investigator or AbbVie as having a reasonable possibility of being related to 
protocol treatment.  A toxicity  is deemed "clinically  significant" on the basis of the Investigator's 
medica l judgment.
Dose reductions or delays should be made for the likely  causative agent.  If one of the agents 
should be stopped for any reason other than disease progression, the subject can continue on the 
other single agent alone at the same dose and schedu le.
8.1 ABT -414/Placebo Toxicity Management
Subjects will be closely  monitored for treatment -related adverse events, especiall y allergic 
reactions, during all infusions.  For the initial ABT -414/placebo infusion, pre infusion vital signs 
will be taken and direct observation is required for the first 15 minutes of the infusion.  Also for 
the initial ABT -414/placebo infusion, subjects must remain at the site for monitoring for 
60 minutes post infusion.  For subsequent infusions, post-infusion monitoring is not required; 
however, pre -infusion vital signs should still be taken.  L onger observation periods and more 
frequent vital sign checks may  be required in subjects who experience infusion reactions.
Institutional standards shoul d be used to treat all allergic reactions.
Based upon results from the first clinical and preclinical safet y pharmacology evaluation of 
ABT -414, experience with other inhibitors of EGFR , and experience with MMAF ADCs, 
potential toxicities may  include fatig ue, vomiting, thrombocytopenia, allergic reactions, rash, ey e 
complaints, and liver function test abnormalities.
8.1.1 Dose Modifications for ABT- 414/Placebo
For all observed toxicities, subjects should be assessed for inter -current illness or other causes
and treated as appropriate.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
100Starting doses and suggested dose level reductions are shown in Table 9, and subsequent 
subsections discuss when dose reductions should be considered or are required.  More aggressive 
dose reductions are alway s allowed if the I nvestigator believes that it is in the best interest of the 
subject.
With the exception of ophthalmologic toxicities as described in Section 8.1.2 and hepatic 
laboratory  abnormalities as described in Section 8.1.6, all dose reductions are permanent unless a 
toxicity  initially  attributed as potentially  related to ABT -414/placebo is later re -attributed as not 
potentially  related and discussed with the Neuro -Medical Oncology  study  chair, AbbVie Medical 
Monitor or their designee.
Table 9.  ABT -414/Placebo Dose Modification Table during Chemoradiation and Adjuvant 
Phase
Dose LevelDose
Chemoradiation Phase Adjuvant Phase
Starting Dose 2.0 mg/kg 1.25 mg/kg*
1stReduction 1.5 mg/kg 1.0 mg/kg
2ndReduction 1.0 mg/kg 0.75 mg/kg
3rdReduction - 0.5 mg/kg
- Discontinue
* If CTCAE Grade 3 eye toxicity is observed during the Chemoradiation Phase, then 1.0 mg/kg is recommended, but not 
required, as the starting dose for the Adjuvant Phase.
8.1.2 Ophthalmologic Toxicities
Microcy stic keratopathy  is a very  commo n adverse effect of ABT-414, occurring in over 50% of 
subjects.  Key  elements in the overall management of microcy stic keratopathy  include subject 
education, use of proph ylactic ey e drops to reduce severit y, supportive care measures, and 
careful ophthalmol ogical monitoring to identify  microcy stic changes or steroid- related adverse 
effects and guide supportive treatment.
8.1.2.1 Ophthalmologic Monitoring and Prophylactic Eye Drop Use
As described in Section 4.2, subjects will receive ophthalmological examinations at regular 
intervals throughout the study , and additional examinations may  be done as needed.  The 
ABT -414-TOE examinations are intended to s ystematically  identify  and grade objective findings 
of ABT -414- related ey e toxicity  and to assess for adverse effects potentially  related to ocular 
steroid use.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
101Administration of prophylactic eye drops for 7 days is required with each administration of 
ABT -414/placebo, from 2 day s prior until 4 day s after drug infusion.  A description of the 
steroid- potenc y levels and dosing schedule for each, as well as considerations for adjusting 
prophy lactic ey e drop levels or frequency  based on ophthalmologic findings, is described in 
Section 5.5.
Prophy lactic and s ymptomatic use of cold compresses over the ey es and op hthalmologic 
vasoconstrictors around the time of ABT -414 infusions is allowed, as it may  reduce drug uptake 
in the cornea.
8.1.2.2 Treatment of Ophthalmologic Toxicity Once Symptoms Occur
Supportive care measures (e.g., lubricating eye drops, therapeutic b andage contact lenses, 
punctal plugs, antibiotic drops, etc.) play a pivotal role in ABT -414 treatment, as they can 
provide considerable relief for symptoms of ABT-414- related eye toxicity, including 
photophobia, blurry vision and eye discomfort.  Therefor e, supportive care measures 
should be used early and extensively to minimize the need for ABT -414 dose interruptions 
and dose reductions.
Once corneal microcy sts have formed, there are no known therapies that can remove them from 
the cornea.  Thus, only  therapies that can control symptoms and promote healing are indicated.  
Use of steroid ey e drops outside the prescribed prophy lactic period is allowed but may  not be the 
best strategy , as it may  inhibit the healing process.  Supportive care measures should b
e activel y 
considered and fully  utilized when sy mptoms of ABT -414- related ey e toxicity  occur, as they  are 
the most effective way  to manage ey e symptoms and maximize ABT -414 dosing.
Use of supportive care measures should be individually  tailored for each su bject based on 
frequent monitoring b y an ophthalmologist to inform the best treatment for the subject.  The 
choice and timing of supportive care measures is not restricted by  the study  protocol, and all 
choices are at the discretion of the study  investigat
or in consultation with the ophthalmologist as 
needed.  Supportive measures can be used throughout the treatment cy cle, including day s on 
which proph ylactic ey e drops are used, and they  may  be initiated prior to the onset of s ymptoms 
at the discretion of the investigator.
Lubricating ey e drops may be used liberally  throughout treatment and are commonly  prescribed 
prior to onset of ey e symptoms.
Feedback from ophthalmologists with experience managing ABT -414 ocular toxicity  suggest 
that use of therapeutic ba ndage contact lenses can have a major impact on improving ey e 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
102symptoms, including photophobia, blurred vision and various forms of ey e discomfort, and thus 
minimize the need for ABT- 414 dose interruptions and dose reductions.  Therefore, use of 
therapeutic bandage contact lenses should be strongl y considered whenever toxicity  suggesting 
the need for ABT -414 dose modification is present, and they  may  also be used for lower grade 
symptoms.
8.1.2.3 Discussions with Subjects
It is important that subjects unders tand this toxicity  and the importance of following the 
recommendations for the prophy lactic ey e drops and supportive care measures, as well as the 
rapid reporting of their sy mptoms.  I t is also important to let them know that at this time, in all of 
the subjects, sy mptoms have improved over time and there is no evidence to suggest that there is 
any permanent damage done to the cornea.  It does take some time, however, for s ymptoms to 
resolve and thus an immediate reversal of s ymptoms should not be promised.   At least 
3 –4 weeks must take place for the regeneration of the cornea; this is an approximate timeline 
for when s ymptoms should improve and corneal healing should take place.  Tumor responses to 
ABT -414 have been sustained in subjects who require treatment holds for 4 or more weeks.
8.1.2.4 ABT -414 Dose Adjustment for Ophthalmologic Toxicity
Guidelines for ABT -414/placebo dose modifications for ophthalmologic toxicities considered by  
the investigator to be related to ABT -414 are shown in Table 10.  Dec isions on dose adjustments 
will be based on CTCAE grades assigned b y the Investigator (not on the ABT -414- TOE grades).  
Re-treatment at a lower dose of ABT -414 has generally  resulted in less severe toxicities.  
However, it is important to fully  utilize sup portive measures as needed in order to minimize the 
need for dose interruptions and dose reductions.
If, after a dose reduction for ocular s ymptoms, changes in supportive care interventions lead to 
significant improvement in ocular s ymptoms for subsequent 
ABT -414/placebo doses, the 
ABT -414/placebo dose may  be re -escalated to the previous higher dose at the discretion of the 
investigator after discussion with the Neuro -Medical Oncology  study  chair or his/her designee.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
103Table 10.  Guidelines for ABT- 414/Placeb o Dose Interruption and Re -Initiation During 
Chemoradiation and Adjuvant Phase for Ophthalmologic Toxicities
Ocular Adverse Event
CTCAE Grade^ABT -414 / Placebo Dosing Modifications
Dose Interruption* Dose Reduction*
1 –Asymptomatic or mild 
symptoms; clinical or diagnostic 
observations only; intervention not 
indicated^Not indicated Not indicated
2 –Symptomatic; medical 
intervention indicated (e.g., topical 
agents); limiting instrumental ADL^Not indicated, but allow ed at 
investigator's discretion
Investigator should fully 
utilize supportive care 
measures** as needed to 
manage ocular findingsNot indicated, but allow ed at 
investigator's discretion
Investigator should fully utilize 
supportive care measures** as 
needed to manage ocular findings
3 –Decline in vision (worse than 
20/40 but better than 20/200); 
limiting self -care ADL^Recommended but not 
required; at investigator’s 
discretion to interrupt study 
drug until AE resolves to at 
least Grade 2
Investigator should fully 
utilize supportive care 
measures** as needed to 
manage ocular findingsRecommended but not required; 
at investigator's discretion unless 
otherwise noted
Investigator should fully utilize 
supportive care measures** as 
needed to manage ocular 
findings
4 –Perforation or blindness (20/200 
or worse) in the affected eye^ Interrupt study drug until AE 
resolves to at least Grade 2 
(required)
 Investigator should fully 
utilize supportive care 
measures** as needed to 
manage ocular findingsRequired if Grade 4 toxicity 
present despite full utilization of 
supportive care measures**
^ Grading criteria shown are for the term "microcystic keratopathy."  For other ocular adverse events considered by the 
investigator to be related to ABT -414, use the applicable CTCAE grading criteria for that ter m.
* If use of supportive measures reduces severity of eye toxicity, the lower CTCAE grade severity (the grade in the presence of 
ongoing supportive measures) may be used to guide potential dose modifications.   
** Supportive care measures include but are not limited to lubricant drops, bandage contact lens, antibiotic drops, ointments, 
punctal plugs and sunglasses.
8.1.3 Severe Allergic Reactions (Grade 3 or Grade 4)
These require the immediate interruption of ABT -414/placebo treatment and discontinuation 
from the study .  Appropriate medical therapy  including epinephrine, s ystemic corticosteroids, 
intravenous antihistamines, bronchodilators, and ox ygen should be available for use in the 
treatment of such reactions.  Subjects should be carefu lly observed until the complete resolution 
of all signs and s ymptoms.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
1048.1.4 Moderate Allergic Reactions (Grade 1 or Grade 2)
These will also require the immediate interruption of ABT -414/placebo infusion.  Once 
symptoms have resolved, retreatment is allowed with an infusion over 60 to 70 minutes.  All 
subsequent infusions will also be administered over 60 to 70 minutes.
8.1.5 Dermatologic Toxicities
Subjects developing dermatologic toxicities while receiving ABT -414/placebo should be 
monitored for the devel opment of inflammatory  or infectious sequelae, and appropriate treatment 
of these s ymptoms initiated.  In subjects with mild and moderate (Grade 1 or Grade 2) skin 
toxicity , treatment should continue without dose delay  or modification.  Treatment with topi cal 
and/or oral antibiotics should be considered.
If a subject experiences severe (Grade 3 or Grade 4) acneiform rash, ABT -414/placebo treatment 
adjustments should be made based on a discussion between the Investigator, the RTOG 
Neuro -Medical Oncology  Stud y Chair and AbbVie Medical Monitor.
Subjects who experience a grade 3 or higher dermatological toxicity  will be treated as following:  
The subject will require a dose interruption and ABT -414/placebo may  be reintroduced at a 
reduced dose (per the guidance previously  stated above) if the toxicity  returns to ≤ grade 1 within 
4 weeks.
8.1.6 Hepatic Laboratory Abnormalities (ABT-414/Placebo)
Guidelines for ABT -414/placebo dose modifications related to hepatic laboratory abnormalities 
are presented in Table 11.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
105Table 11.  ABT -414/Placebo Dose Modification Guidelines for Hepatic Laboratory 
Abnormalities
Hepatic Laboratory Abnormality ABT -414/Placebo
ALT or AST > 5 × ULN* but 
≤ 20 × ULN (and TBL ≤ 2 × ULN)Hold drug regardless of assessed relationship to drug.   See 
Section
 8.4 for guidelines on repeat testing (ALT, AST, ALP, 
TBL) and evaluation. 
Dosing m ay not be resumed until ALT and AST have 
recovered to ≤ 5 ×ULN*
Dosing may be resumed at the sam e dose if ALT or AST w as 
elevated >5 × ULN* for less than 2 weeks.  Additionally, dosing 
may be resumed at the same dose if another likely cause has 
been identified.
Dosing must be resumed at a reduced dose (see Table 9)** if 
ALT or AST w as elevated > 5 × ULN* f or more than 2 weeks 
and no other likely cause has been identified.
Follow ing dose reduction, if ALT and AST remain ≤ 5 × ULN* 
after 2 doses at the reduced dose level, then re-escalation to the 
previous dose is allowed at the investigator's discretion.
If a subsequent dose reduction is required due to hepatic 
laboratory abnormalities, then re -escalation is not allow ed.
ALT or AST > 20 × ULN
or 
ALT or AST > 3 × ULN and 
TBL > 2 × ULNHold drug regardless of assessed relationship to drug.   See 
Section
 8.4 f or guidelines on repeat testing (ALT, AST, ALP, TBL) 
and evaluation.
If another clear cause has been identified, drug may be resumed 
when ALT and AST ≤ 5 × ULN and TBL ≤ 2 × ULN
In general, if no other cause has been identified, drug should be 
permanently discontinued, and rechallenge not attempted.  
Rechallenge can be considered after consultation with the sponsor if
allof the following are met:
the subject has shown important benefit from the drug and other 
options are not available,
ALT and AST have recovered to ≤ 5 × ULN and TBL has 
recovered to ≤ 2 × ULN,
the subject has been informed of the potential risk and has 
consented to the rechallenge,
close follow -up of the subject is feasible.
ALP = alkaline phosphatase, ALT = alanine transferase, AST = aspartate transferase, TBL = total bilirubin
* If elevated at baseline, either 5 × the baseline value or 8 × ULN, whichever is lower.
** Unless the next planned dose is already a lower dose per the protocol (i.e., start of the adjuvant phase).
8.1.7 Other Toxicities
For all other toxicities considered b y the investigator to be potentially related to 
ABT -414/placebo, the general guidelines to be used for dose interruptions and/or dose reductions 
are shown in Table 12.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
106Table 12.  General Guidelines for ABT -414/Placebo Dose Interruptions and Re- Initiation 
During Chemoradiation and Adjuvant Phase (Except Ophthalmologic, Allergic, 
Dermatologic Toxicities and Hepatic Laboratory Abnormalities)
CTCAE GradeABT -414
Dose Interruption Dose Reduction
Grade 1 Not indicated Not indicated
Grade 2 Not indicated Not indicated, but at investigator's 
discretion
Grade 3 Interrupt study drug until AE resolves to 
at least Grade 1 (or baseline if higher than 
Grade 1)Recommended but not required; at 
investigator's discretion
Grade 4 Interrupt study drug until AE resolves to 
at least Grade 1 (or baseline if higher than 
Grade 1)Required
8.2 Ocular Steroid Toxicity Management
Adverse effects related to ocular steroid use should be managed as clinically  indicated in
consultation with the ophthalmologist.  The decision whether to continue prophy lactic ey e drops 
at the same steroid potency  level should weigh both the potential benefits and risks of continuing 
treatment.  As described in Section 5.5, prophy lactic ey e drops must be reduced to Level 1 
(non-steroid drops) if there is evidence of ocular steroid -related toxicity  in the complete absence 
of an y corneal epithelial abnormalities on the ABT -414- TOE.
8.3 Temozolomide Toxicity Management
TMZ should be administered p er the local prescribing regulations.  If local prescribing 
information and the instructions in Section
 8.3.1 or Section 8.3.2 conflict, then either local 
prescribing information or protocol language can be used at the discretion of the investigator.
See Section 8.4 for guidelines on repeat testing and evaluation of hepatic laboratory  
abnormalities regardless of the assessed relationship to study  treatments.
8.3.1 Temozolomide During Concomitant Radiation Therapy
Prophy laxis against Pneumocy stis jirovecii pneumonia (PCP) should be per local regulation 
guidelines for all subjects receiving concomitant TMZ and radiotherap y.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
107No TMZ dose reduction will be made, but delay  or discontinuation of TMZ administration will 
be decided weekl y according to hematologic an d non -hematologic adverse events (AEs), as 
specified below.
If the administration of TMZ has to be interrupted, the radiotherap y will proceed normally.  
Missed doses of TMZ will not be made up at the end of radiotherapy .  The total number of day s 
and total dose of TMZ will be recorded on the eCRFs.
If one or more of the following are observed:
ANC ≥ 0.5 and < 1.5 × 109/L
Platelet count ≥ 10 and < 100 × 109/L
Grade 2 non -hematologic AE considered possibly  related to TMZ (except alopecia, nausea 
and vomiting while on maximal antiemetic therapy , and fatigue)
then treatment with concomitant TMZ will be withheld until all of the following conditions are 
met:
ANC ≥ 1.5 × 109/L
Platelet count ≥ 100 × 109/L
Grade ≤ 1 non -hematologic AE (except alopecia, nausea and vomiting, and fatigue)
In case of hematologic AE as defined above, a complete blood count (CBC) should be performed 
at least twice weekl y.  In case of non -hematologic AE, the subject should be assessed at least 
weekl y with relevant laboratory  test(s).  As soon as all of the above conditions are met, the 
administration of TMZ will resume at the same dose as used initially .
If one or more of the following are observed:
ANC < 0.5 × 109/L (Grade 4)
Platelet count < 10 × 109/L (Grade 4)
Grade 3 or 4 non -hematologic AE considered possibly  related to TMZ (except alopecia, 
nausea and vomiting unless the subject has failed maximal antiemetic therapy , and 
fatigue)
then treatment with concomitant TMZ should be stopped.
If the duration of radiotherap y exceeds 7 weeks, then concomitant treatment with TMZ should be 
stopped after 49 day s of TMZ treatment.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
108Summary of Temozolomide Delay or Discontinuation During Concomitant Radiation 
Therapy
AE Value Action
ANC ≥ 0.5 and < 1.5 × 109/L Delay temozolomide until:
---ANC ≥ 1.5 × 109/L
---Platelet ≥ 100 × 109/L
---Non-hem AE ≤ Grade 1Platelet count ≥ 10 and < 100 × 109/L
Non-hematologic (except alopecia, 
nausea/vomiting unless on maximal 
antiemetic therapy)NA
ANC < 0.5 × 109/L
Stop concomitant temozolomidePlatelet count < 10 × 109/L
Non-hematologic (except alopecia, 
nausea/vomiting)NA
8.3.1.1 Concomitant Temozolomide, if Radiotherapy Is Interrupted
If radiotherap y has to be temporaril y or permanently interrupted for technical or medical reasons 
unrelated to the TMZ administration, then treatment with daily  TMZ should continue.
8.3.2 Post-Radiation (Adjuvant) Temozolomide
Continued dosing administration is based on adverse events (AEs) during the prior treatment 
cycle.  If multiple AEs are seen, the dose administered should be based on the dose reduction 
required for the most severe grade of an y single AE.
Dose LevelTemozolomide Dose, 
mg/m2/day Rem arks
–1 100 Reduction if prior AE
0 150 Starting dose cycle 1 (adjuvant)
+1 200 Escalated dose at cycle 2, for cycles 2 –12 in 
absence of AE
Delay
On Day  1 of each cy cle (within the prior 72 hours), ANC ≥ 1.5 × 109/L, platelet count 
≥ 100 × 109/L and all treatment -related grade 3 or 4 non -hematologic AEs (except alopecia, 
nausea, and vomiting) must have resolved (to grade ≤ 1).
If AEs persist, treatment should be delay ed by 2 weeks for up to 4 consecutive weeks, so that the 
TMZ dosing can coincide with the administration of the ABT -414 or placebo.  If, after 4 weeks 
of delay , all AEs have still not resolved, then any  further adjuvant treatment with TMZ should be 
stopped.  When possible, TMZ treatment when resumed should start on either Day  1 or Day  15 
of a cy cle so that it m ay coincide with ABT -414/placebo treatment.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
109Dose Escalation
If, during the first cy cle, all non -hematologic AEs observed were grade ≤ 2 (except alopecia, 
nausea and vomiting) and with platelets ≥ 100 × 109/L and ANC ≥ 1.5 × 109/L, then the TMZ 
dose should be escalated to dose level 1 and this dose should be used as the starting dose for 
subsequent cy cles.  If treatment after cy cle 1 has to be delay ed because of ongoing non -
hematologic AEs of grade ≥ 2, then no escalation is possible.  I f the dose was not es calated at 
cycle 2, then the dose should not be escalated in further cy cles (C ycles 3 –6).
Dose Reductions
If any non -hematologic AE observed was grade > 2 (except alopecia, nausea and vomiting) 
and/or if platelets < 50 × 109/L and/or ANC < 1 × 109/L, then the dose should be reduced by  
onedose level.  For subjects who would require dose reductions to a dose level 
< 100 mg/m2/day, TMZ will be stopped.  Also, if any  of the same non- hematologic grade 3 AE 
recurs (except alopecia, nausea and vomiting) after r eduction for that AE, then TMZ will be 
stopped.
If any treatment -related non -hematologic AE observed was grade 4 (except alopecia, nausea and 
vomiting) then adjuvant TMZ treatment should be stopped.
Subsequent cy cles (C ycles 3 –12):  Any dose reductions o f TMZ will be determined according 
to (1) non- hematologic AE during the preceding treatment cy cle, as well as (2) the nadir 
(lowest/worst) ANC and platelet counts observed.  No dose escalation should be attempted.  The 
same dose reductions as for the secon d cycle should be applied.
Important:  If the dose was reduced or delay ed for adverse events, there will be no dose 
escalation.
The reason(s) for dose reduction and/or delay  must be documented in the eCRF.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
110Summary of Dose Modification or Discontinuation During Post -Radiation Temozolomide
Worst Non -Hem atologic AE (Except Alopecia, Nausea and Vomiting)
During the Previous Cycles
Grade Dose Modification
0 – 2 No dose modifications for non -hematologic AEs.  Dose escalations (only for cycle 2) or 
reductions based on ANC and platelet counts are applicable.
3 Reduce by one dose level (except alopecia, nausea and vomiting).  Dose modifications 
(escalations or reductions) based on ANC and platelet counts are not applicable.  No further 
escalation is possible.  I f the same non -hematologic grade 3 AE recurs (except alopecia, nausea 
and vomiting) after reduction for that AE, then stop temozolomide.
4 Stop temozolomide (except for alopecia, nausea and vomiting).  Dose modifications (escalations 
or reductions) based on ANC and platelet counts are not applicable.
Nadir Values
ANC Action
≥ 1.5×109/L Escalation to DL1 (cycle2 only)
≥ 1 &< 1.5×109/L Dose unchang ed
<1 × 109/L Reduce by 1 dose le vel
Platelets
≥ 100× 109/L Escalation to DL1 (cycle2 only)
50–99× 109/L Dose unchang ed
< 50× 109/L Reduce by 1 dose level
Note:   A complete blood count must be performed on Day 22 (+/ –3 days) of each adjuvant treatment cycle.
Hematologic AE on Day 1 of Each Cycle (Within 72 Hours Before)
AE Delay
ANC < 1.5 × 109/L and/or 
Platelet count < 100 × 109/LDelay up to 4 w eeks until all resolved.  If unresolved after 4 weeks then stop 
temozolom ide.  If resolved, dose delay/reductions based on non -hematologic 
AEs are applicable.  If treatment has to be delayed for AEs, then no escalation 
is possible.
Non-Hematological AE (Except for Alopecia, Nausea and Vomiting) on Day 1 of Each 
Cycle (Within 72 Hours Before)
Grade Delay 
2 – 3 Delay up to 4 w eeks until all resolved (to grade ≤ 1).  If unresolved after 4 weeks, then stop 
temozolom ide.  If resolved, dose delay/reductions based on ANC and platelets are applicable.  
If treatment has to be delayed for AEs, then no escalation is possi ble. 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
1118.4 Hepatic Laboratory Abnormalities
This section provides information on safet y monitoring, evaluation of potential causes, and 
appropriate documentation for subjects with hepatic laboratory  abnormalities suggesting 
potential drug -induced liver in jury (DILI).  It was adapted with modifications from the FDA 
Guidance for Industry , Drug -Induced Liver Injury:  Premarketing Clinical Evaluation 
(https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM174090.pdf) in consul tation with a hepatologist with expertise in DILI.
Information derived from the scientific literature and public databases on liver injury  attributable 
to prescription and nonprescription medications, herbals and dietary  supplements can be found at 
the L iverTox database (https://livertox.nlm.nih.gov).
If a subject develops one of the following laboratory  abnormalities, hepatic laboratory  
abnormalities should be confirmed b y repeat testing, and the subject should be monitored and 
evaluated as described in this section, regardless of the assessed relationship to the study 
treatments:
ALT or AST > 3 × ULN andTBL > 2 × ULN, or
ALT or AST > 5 × ULN (or > 5 × the baseline value if elevated) or > 8 × ULN, 
whichever is lower
Confirmation of Liver Test Abnormalitie
s
For subjects meeting either of the criteria above, confirmation of hepatic laboratory 
abnormalities should be done as follows: 
Repeat testing of all four of the usual measures (ALT, AST, alkaline 
phosphatase, and TBL) should be performed within 3 days of the initial 
abnormality to confirm the abnormalities and to determine if they are increasing or 
decreasing.
o Serum transaminases may rise and fall quite rapidly , and waiting a week or two 
before obtaining confirmation of elevations may  lead to a false conclusion that 
the initially  observed abnormality  was spurious.
o The need for prompt repeat testing is especially  great if AST or ALT is 
> 3 × ULN andTBL > 2 × ULN.
o If the subject is unable to return to the trial site promptly , the subject should be 
retested locally , with results and normal laboratory  ranges recorded in the CRFs.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
112Inquire about concurrent new or escalating symptoms (e.g., right upper quadrant 
pain or tenderness, fever, rash).  Although non- specific in the setting of GBM 
treatment, fatigue nausea, and vomiting should also be assessed as clinical sy mptoms 
potentially  associated with liver injury .
It is appropriate to initiate close observation (described be low) to determine whether the 
abnormalities are improving or worsening and to consider whether the subject meets 
criteria for stopping study drug if symptoms suggestive of liver injury persist or if repeat 
testing shows:
ALT or AST > 5 × ULN (or > 5 × baseline if elevated or > 8 × ULN, whichever is 
lower) or
ALT/AST > 3 × ULN and total bilirubin > 2 × ULN.
Close Observation
It is critical to initiate close observation immediately  upon detection and confirmation of early  
signals of possible DILI (as described above), and not to wait until the next scheduled visit or 
monitoring interval.  The primary goal of close observation is to determine as quickly  as possible 
whether observed abnormal findings are transient and will resolve spontaneously  or will progress
to marked serum aminotransferase elevation or evidence of functional impairment, as indicated 
by rising bilirubin or INR, which represent substantial liver injury .
Close observation includes:
Repeating liver enzyme and serum bilirubin tests two or three t imes weekly.  If 
total bilirubin is elevated, obtain direct bilirubin.   Frequency  of retesting can 
decrease to once a week or less if abnormalities stabilize or drug has been 
discontinued and the subject is as ymptomatic.
Obtaining additional tests, as appr opriate, to evaluate liver function, 
(e.g., international normalized ratio [INR]); diagnostic measures (e.g., 
ultrasound of the liver), serum ammonia, etc.
Obtaining a more detailed history  of symptoms and prior or concurrent diseases.  
Update the appropri ate eCRFs (if applicable).
Obtaining a history  of concomitant drug use (including nonprescription medications 
and herbal and dietary  supplement preparations), alcohol use, recreational drug use, 
and special diets.  Update the appropriate eCRFs (if applicab le).
Ruling out other immediately  apparent possible causes of aminotransferase (ALT or 
AST) elevation and h yperbilirubinemia, as described below.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
113Obtaining a history  of exposure to environmental chemical agents.
Considering gastroenterology  or hepatology  consultations.
Relevant supplemental information must be collected and entered in the appropriate eCRF(s),
Evaluating Data for Alternative Causes
An important purpose of close observation is to gather additional clinical information to seek 
other possible causes of the observed liver test abnormalities, such as one of the following 
common causes:
Acute viral hepatitis.  The usual onset of hepatocellular DILI is indistinguishable 
from acute viral hepatitis A or B. Hepatitis C is much less often acute in its onset and 
tends to be insidious, but it sometimes can resemble acute DILI.  The presence of 
acute viral hepatitis A, B, and C should be evaluated by  serological markers.  Viral 
hepatitis D (requires concomitant hepatitis B infection) and E are relatively r are in the 
United States.  Hepatitis E is more common in developing countries, including 
Southeast Asia, and should be considered in recent travelers to those countries and in 
patients in trials conducted in those countries.  Also rare are hepatocellular l iver 
injuries caused b y Epstein -Barr virus, cy tomegalovirus, herpes simplex virus, 
toxoplasmosis, varicella, and parvovirus, although these infections are seen more 
typicall y in immuno- suppressed individuals.  Adolescent and young adult patients 
with possi ble DILI should be tested for Epstein -Barr virus.  Hepatitis is common 
among transplant patients with cy tomegalovirus disease.
Alcoholic and autoimmune hepatitis.  Acute alcoholic hepatitis usually  is recurrent, 
with a history  of binging exposure to alcohol preceding episodes, and it has some 
characteristic features, such as associated fever, leukocytosis, right upper quadrant 
pain and tenderness, hepatomegal y, and AST > ALT, that may  help distinguish it 
from other causes of liver injury .  Other features of the phy sical examination may  
include the presence of stigmata of cirrhosis, such as spider nevi, palmar erythema, 
estrogenic changes in males, and Dupu ytren's contractures.  Alcoholic and 
autoimmune hepatitis should be assessed b y history , phy sical examination, and 
laboratory  testing, including serologic testing (e.g., antinuclear or other antibodies).
Hepatobiliary disorders.   Biliary  tract disease, such as migra tion of gallstones or 
intrahepatic lesions, more often causes cholestatic injury  initially  and should be 
investigated with gall bladder and ductal imaging studies, especiall y if alkaline 
phosphatase is increased.  Malignant interruption of the biliary  tract also should be 
considered.
NASH.
  NASH may  be seen in obese, hy perlipoproteinemic, and/or diabetic patients 
and may  be associated with fluctuating aminotransferase levels, and hepatic and 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
114sometimes splenic enlargement.  It is sometimes associated with ci rrhosis and portal 
hypertension.
Cardiovascular causes.   Cardiovascular disease, especiall y right heart failure and 
hypotension or any  cause of impaired oxy genation of the liver, may  cause acute 
centrilobular h ypoxic cell necrosis (ischemic hepatitis) with rapid and sometimes 
spectacular increases of serum transaminases (e.g., AL T or AST > 10,000 U/L ).  
Cardiovascular d ysfunction or impaired liver ox ygenation, including h ypotension or 
right heart failure, should be assessed b y physical examination and histo ry.
Concomitant treatments.
  It is critical to discover concomitant treatments, including 
exposure to nonprescription and dietary  supplement products that might be 
responsible for injury .  The possible exposure to potentially  toxic herbal or dietary  
supple ment mixtures (sometimes of unknown composition), nonprescription 
medications such as acetaminophen, or to occupational chemical agents may  not be 
volunteered unless subjects are specifically  questioned.
Follow -Up to Resolution
All subjects showing hepati c laboratory  abnormalities suggestive of possible DILI should be 
followed until satisfactory  resolution of the laboratory  abnormalities).  DILI may  develop or 
progress even after the causative drug has been stopped.  Local lab results should be recorded on
appropriate eCRFs. 
Dose Modifications for Study Drugs
See the dose modification guidelines for each respective drug.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
1159.0 DRUG INFORMATION
9.1 TMZ
Study  sites must refer to the TMZ package insert for detailed pharmacologic and safet y 
information.
See Section 5.3 for TMZ administration instructions.  Refer to the current package insert/SmPC 
provided with each drug and the site- specific pharmacy  for toxicity  information and instructions 
for drug preparation, handling, and storage.
9.1.1 TMZ Supply
TMZ is commerciall y available.
9.2 ABT -414
9.2.1 Identification of Investigational Product(s)
Information about ABT -414 formulations to be used in this study  is presented in Table 13.
Table 13.  Identification of Investigational Product(s)
Study Drug Form ulation Dosage Form Strength (m g) Manufacturer
ABT -414 Sucrose, histidine, 
polysorbate 80Sterile lyophilisate in 
a vial (to be 
reconstituted and 
further diluted for IV 
infusion)100 mg
20 mgAbbVie
Placebo for 
ABT -414Sucrose, histidine, 
polysorbate 80Sterile lyophilisate in 
a vial (to be 
reconstituted and 
further diluted for IV 
infusion)100 mg
20 mgAbbVie
9.2.2 Packaging and Labeling of Blinded ABT -414/Placebo
Vials containing ABT -414 ly ophilized powder or placebo will be packaged in cartons in a 
blinded fashion.  Vials containing ABT -414 l yophilized powder designated for the hepatic 
impairment sub- study  will be packaged in cartons in an open -labeled fashion.  Each vial and 
carton will be labeled per country  requirements.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
1169.2.3 Storage and Disposition of ABT -414/Placebo
The ABT -414 and placebo ly ophilisate for injection must be stored refrigerated at 2°C to 
8°C/36°F to 46°F, protected from light, and must not be frozen.
The reconstituted ABT -414 or Placebo should be refrigerated at 2°C to 8°C/36°F to 46°F, for no 
more than 20 hours.  After storage at 2°C to 8°C/36°F to 46°F, the solution can be allowed to 
come to room temperature and be administered within 4 hours.  From start to reconstitution until 
the infusion is completed, a total of 24 hours sh ould not be exceeded.  If maintained at room 
temperature, the solution should be used within 4 hours.
Storage temperature logs will be maintained to document proper storage conditions.  The 
refrigerator temperature must be recorded on a daily  basis on the temperature logs to record 
proper function.  Temperature excursions must be reported to AbbVie immediatel y.
The investigational products are for investigational use only  and are to be used only  within the 
context of this study .  The study  drug supplied for this study  must be maintained under adequate 
securit y and stored under the conditions specified on the label until dispensed for subject use or 
returned to AbbVie.
9.2.4 Preparation/Reconstitution of Dosage Form
ABT -414/placebo Study  Medication Preparatio n Guidelines will be provided as a separate 
document outside of this protocol.
9.2.5 Product Complaint
9.2.5.1 Definition
A Product Complaint is any  Complaint related to the biologic or drug component of the product.
For a product this may  include, but is not limited to, damaged/broken product or packaging, 
product appearance whose color/markings do not match the labeling, labeling 
discrepancies/inadequacies in the labeling/instructions (example:  printing illegible), missing 
components/product, or packagin g issues.
Any information available to help in the determination of causality  to the events outlined directly  
above should be captured.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
1179.2.5.2 Reporting
Product Complaints concerning the investigational product must be reported to the Sponsor 
within 24 hours of the study  site's knowledge of the event via the Product Complaint form.  
Product Complaints occurring during the study  will be followed -up to a satisfactory  conclusion.  
All follow -up information is to be reported to the Sponsor (or an authorized re presentative) and 
documented in source as required b y the Sponsor.  Product Complaints associated with adverse 
events will be reported in the study  summary .  All other complaints will be monitored on an 
ongoing basis.
Product Complaints may  require return of the product with the alleged complaint condition. I n 
instances where a return is requested, every  effort should be made by  the Investigator to return 
the product within 30 day s.  If returns cannot be accommodated within 30 day s, the site will need 
to provide justification and an estimated date of return.
The description of the complaint is important for AbbVie in order to enable AbbVie to 
investigate and determine if an y corrective actions are required.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
11810.0 PATHOLOGY/BIOSP ECIMENS
Tumor tissue for EGFR assessment should be prepared and sent to central lab as described in the 
study  specific laboratory  manual and outlined in Section 4.2.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
11911.0 DATA AND RECORD S
11.1 Source Documents
Source documents are defined as original documents, data and records.  These may include 
hospital records, clinical and office charts, laboratory data/information, subject diaries or 
evaluation checklists, pharmacy  dispensing and other records, recorded data from automated 
instruments, microfiches, photographic negatives, microfilm or magnetic media, and/or x -rays.  
Source document data may  be transcribed onto electronic case report forms (eCRFs) as required.  
Data collected during this study  must be recorded on the appropriate source document.
For all adverse events, the onset date and event description will be captured in source documents.  
Other adverse event data points required for eCRF completion can be entered directl y in the 
eCRF and may  serve as the source document and should be printed, signed and dated b y the 
Investigator.
The Investigator/institution will permit study -related monitoring, audits, IEC/I RB review, and 
regulatory  inspection(s), providing direct access to source data documents.
11.2 Case Report Forms
Case report forms (CRF) must be completed for each subject screened/enrolled in this study .  
These forms will be used to transmit information collected during the stud y to AbbVie and 
regulatory  authorities, as applicable.  The CRF data for this study  are b eing collected with an 
electronic data capture (EDC) sy stem called Rave®provided by  the technology  vendor Medidata 
Solutions I ncorporated, NY, USA.  The EDC s ystem and the study -specific electronic case report 
forms (eCRFs) will comply  with Title 21 CFR P art 11.  The documentation related to the 
validation of the EDC system is available through the vendor, Medidata, while the validation of 
the study -specific eCRFs will be conducted b y AbbVie and will be maintained in the Trial 
Master File at AbbVie.
The In vestigator will document subject data in his/her own subject files.  These subject files will 
serve as source data for the study .  All eCRF data required by this protocol will be recorded by  
investigative site personnel in the EDC sy stem with the exception of the ePRO information 
which will be integrated into the eCRFs electronically .  All data entered into the eCRF will be 
supported by  source documentation.
The Investigator or an authorized member of the Investigator's staff will make an y necessary  
correct ions to the eCRF.  All change information, including the date and person performing the 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
120corrections, will be available via the audit trail, which is part of the EDC sy stem.  For any  
correction, a reason for the alteration will be provided.  The eCRFs will be reviewed periodically  
for completeness, legibility , and acceptability  by AbbVie personnel (or their representatives).  
AbbVie (or their representatives) will also be allowed access to all source documents pertinent to 
the study  in order to verify  eCRF e ntries.  The principal Investigator will review the eCRFs for 
completeness and accuracy  and provide his or her electronic signature and date to eCRFs as 
evidence thereof.
Medidata will provide access to the EDC s ystem for the duration of the trial through a 
password -protected method of internet access.  Such access will be removed from Investigator 
sites at the end of the site's participation in the study .  Data from the EDC sy stem will be 
archived on appropriate data media (CD -ROM, etc.) and provided to th e Investigator at that time 
as a durable record of the site's eCRF data.  It will be possible for the Investigator to make paper 
printouts from that media.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
12112.0 QUALITY ASSURANCE REVIEWS FOR DRUG AND RADIATION 
THERAPY
Drug and radiation therapy  reviews wil l be performed by  the Neuro -Medical Oncology  and 
Radiation Therap y stud y chairs or their designees.  The goal of these reviews is to evaluate 
protocol treatment compliance within each of these areas.  These reviews will be ongoing and are 
contingent on tim ely submission of treatment data.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
12314.0 STATISTICAL CON SIDERATIONS
14.1 Study Design
This is a Phase 3 st udy.  The primary  objective of the study  is to assess whether ABT -414 in 
combination with concomitant TMZ/RT followed by  combination of ABT -414 with adjuvant 
TMZ improves overall survival (OS) compared to concomitant TMZ/RT + adjuvant TMZ in 
subjects with EGFR -amplified GBM.  A total of 640 evaluable subjects will be randomized.
14.2 Statistical Methods
This is a comparative randomized, placebo controlled, double -blinded Phase 3 trial.  Al l efficacy  
analyses will be performed in the Full Anal ysis Set (defined below).  OS (primary  efficacy  
endpoint for the overall study ) and PFS (secondary  efficacy  endpoint) will be compared between 
treatment Arms A and B using stratified log- rank test stati stics or a weighted version of this test 
(to be pre -specified in the Statistical Analy sis Plan document (the SAP)), adjusting for the study  
stratification factors.  PFS is defined as time from randomization to progression of disease (per 
RANO criteria) or death, whichever occurs first.
Randomization and Stratification
MGMT methy lation status and RPA (referenced in Appendix VI ) are demonstrated to be 
prognostic of survival for newly  diagnosed GBM subjects.  For this study , subjects will be 
stratified by  MGMT methy lation status (methylated versus unmethy lated), RPA class (III versus 
IV versus V), region of the world (US/Canada versus other) and EGFRvIII mutation status 
(mutated versus other), where EGFRvIII other is defined as wild t ype, indeterminate due to t est 
failure, invalid, or insufficient tissue.  EGFRvIII is a stratification factor because it is potentially  
prognostic and because it is related to the mechanism of action of ABT -414 which binds to both 
activated wild t ype EGFR and EGFRvIII .  After strati fication, subjects will be randomized to 
either Arm A or Arm B in a 1:1 ratio.
Analysis Sets
The following anal ysis sets will used for anal ysis of safety and primary  and secondary  efficacy  
endpoints of the study :
Full Anal ysis Set (FAS) will comprise all r andomized subjects regardless of whether they  
received study  treatment.  Subjects will be classified according to the treatment they  were 
assigned at the time of randomization.  The FAS will be the primary  analysis set for the 
analysis of efficacy  endpoints.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
124Safety  Anal ysis Set (SAS) will comprise all randomized subjects who receive at least 
onedose of stud y treatment (either RT, TMZ or ABT -414).  Subjects will be classified 
according to treatment received.  Thus a subject randomized to Arm A who receives 
RT+TMZ but does not receive ABT -414 will be considered in the control group (Arm B) 
for safety  anal ysis.
Per-protocol Set (PPS) will comprise all randomized subjects excluding those with major 
deviation from study  inclusion and exclusion criteria, complian ce with procedures.  
Subjects will be classified according to treatment assigned.  The PPS will be used for 
supportive anal ysis of efficacy  endpoints.
14.3 Primary Endpoints Study Design
14.3.1 Primary Endpoint
The primary  endpoint for this study  is OS, defined as time from randomization to death from any  
cause.  For subjects who are not reported to have died at the time of an analy sis, OS will be right -
censored at the last date the subject is documented to be al ive.
14.3.2 How Primary Endpoint Will Be Analyzed
Efficacy  anal ysis for the overall study  will be performed in the FAS which includes all 
randomized subjects regardless of whether or not they  received study  treatment.  The PPS will be 
used for supportive a nalysis of efficacy  endpoints.  The primary  endpoint for the overall study  is 
overall survival (OS).  To meet the primary objective, OS will be compared between treatment 
Arms A and B for the FAS and PPS using stratified log-rank test statistics or a weigh ted version 
of the test, adjusting for the study  stratification factors and additional independent prognostic 
factors as deemed appropriate, to be specified in the SAP.  I f a weighted version is considered to 
be more appropriate in view of potentiall y dela yed treatment effect, it will be pre-specified in the 
SAP prior to conducting any unblinded anal ysis of study  data.  The hazard -ratio of OS for 
ABT -414 Arm A compared to placebo Arm B will be estimated by  fitting Cox -proportional 
hazards regression models adjusting for the main -effects of the stratification factors and 
additional independent prognostic factors as deemed appropriate, to be specified in the SAP.
Type I Error Control
To maintain overall ty pe I error control for the overall study , each secondar y endpoint will be 
tested in the order listed if the primary  endpoint (OS) and all preceding secondary  endpoints 
show statistically  significant results at the one -sided 0.025 level of significance.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
125The O'Brien-Fleming method will be implemented to protect the one -sided ty pe I error of 0.025.  
Specificall y, a nominal alpha level of 0.00965 will be used for the interim efficacy  anal ysis for 
OS.  For the final anal ysis, the primary  efficacy  endpoint will be tested at the one -sided nominal 
alpha level of 0.0221 after adjusting for the interim looks at efficacy  data.
14.3.3 Sample Size and Power Calculations
The sample sizes are calculated based on the approach of doing the primary  endpoint anal yses 
(OS) using the FAS.
A total of 640 evaluable subjects are expect ed to be randomized.  With 441 deaths, there will be 
approximately  85% power to detect a 25% reduction in the hazard of death (HR = 0.75) using a 
log-rank test at a one -sided 2.5% level of significance.  Median OS of 16 months is expected in 
the control ar m.
14.4 Study Monitoring of Primary Objectives
Interim Reporting for the DMC
The Independent Data Monitoring Committee (IDMC), as coordinated b y RTOG Foundation, 
will review the stud y at least twice a year with respect to subject accrual, pretreatment 
characteristics of accrued subjects, the frequency  and severit y of toxicities and morbidity .  The 
IDMC is also available to review the stud y on an "as needed" basis.
Safety
AbbVie will assess adverse events, laboratory  data and vital signs throughout the study .  
Analy ses of adverse events will include only  "treatment- emergent" events, i.e., those that start or 
worsen on or after the day  of the first dose of study drug.  Adverse event severity  and laboratory  
evaluation changes will be assessed b y utilizing Natio nal Cancer Institute (NCI) Common 
Terminology  Criteria for Adverse Events (CTCAE) Version 4.0.  Adverse events will be 
summarized by  preferred terms within a Sy stem and Organ Class according to the most current 
Medical Dictionary  for Regulatory  Activities (MedDRA) dictionary .  Changes from baseline will 
be anal yzed for each scheduled post- baseline visit and for the final visit for blood chemistry  and 
hematology  parameters, as well as urinal ysis and vital sign parameters.  Shifts in laboratory  
values from ba seline NCI CTCAE grades to maximum and final post -baseline grades will be 
assessed .
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
126Interim Superiority and Futility Analysis of Efficacy Data
An interim superiority  and futility  anal ysis of efficacy  data will be performed when 75% (332) of 
the 441 required maximum number of deaths are observed.  The anal ysis will be performed using 
the Full Anal ysis Set, with all randomized cases being included in the treatment arm to which 
they were randomized regardless of what treatment the subjects actuall y received.  The primary 
endpoint of OS will be compared between treatment Arms A and B using stratified log -rank test 
statistics (or, a weighted version, a s pre -specified in the SAP) adjusting for the study  
stratification factors and additional independent prognostic factors as deemed appropriate, to be 
specified in the SAP.  The hazard -ratio of OS for ABT- 414 Arm A compared to placebo Arm B 
will be estimate d by fitting Cox -proportional hazards regression models adjusting for the main -
effects of the stratification factors and additional independent prognostic factors as deemed 
appropriate, to be specified in the SAP.  Adjustment of the level of significance ( alpha) for 
multiple testing will be made using the O'Brien -Fleming group sequential spending function for 
early rejection of the null hy pothesis to declare superiority .  Superiority  will therefore be 
assessed at a one -sided significance level of 0.00965, w hich is corresponding to a Z
-score 
superiority  boundary  at –2.34.  The trial may  also be stopped for futility  following this interim 
analysis if the estimated Cox hazard ratio of ABT -414 Arm A to placebo Arm B at interim 
analysis exceeds 0.9.
The unblinded interim results will first be reviewed by the IDMC, and the trial will be 
considered for earl y stopping if the IDMC makes such a recommendation after consideration of 
the OS results and all supportive evidence including all secondary endpoints and safet y.  For the 
final anal ysis, the primary  efficacy  endpoint will be tested at the one -sided nominal alpha level 
of 0.0221 after adjusting for the interim looks at efficacy  data.  Details for the interim efficacy  
analysis will be provided in the I DMC charter.
14.5 Accrual/Study Duration Considerations
Subjects will be accrued for a total of 640 evaluable subjects randomized in the study .  Once the 
target accrual is met, subjects will then be followed for another 18 months following 
randomization of the last subj ect to observe 441 deaths overall  for comparison of OS.  The total 
study  duration and accrual duration is thus projected to be 48 months and 29 months, 
respectivel y.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
12714.6 Secondary or Exploratory Endpoints (Including Correlative Science Aims)
14.6.1 Secon dary Hypotheses and Endpoints
The secondary  efficacy  endpoints include PFS, OS for the MGMT unmethy lated and methy lated 
subgroups , time to deterioration in sy mptom severity  score (MDASI -BT), time to deterioration 
in sy mptom interference score (MDASI -BT), time to deterioration in verbal memory  (HVLT -R) 
total recall score, OS for the EGFRvIII mutated tumor subgroup, and PFS for the EGFRvIII
mutated tumor subgroup.
14.6.2 Definitions of Secondary Endpoints and How These Will Be Analyzed
Each secondary  endpoin t will be tested in the order listed only  after the superiority  of treatment 
Arm A with respect to the primary  efficacy  endpoint (OS) is established. .  To protect overall 
Type I error across primary and all the secondary endpoints, “overall hierarchical” testing 
strategy34will be used for testing the primary  and secondary  endpoints.  Unless otherwise 
specified, the secondary  time -to-event t ype efficacy endpoints (OS, PFS and time to 
deterioration) will be compared between treatment Arms A and B using stra tified log -rank test 
statistics or a weighted version of this test (to be pre -specified in the Statistical Anal ysis Plan 
document), adjusting for the study  stratification factors and additional independent prognostic 
factors as deemed appropriate, to be sp ecified in the SAP.  The hazard ratio for ABT- 414 Arm A 
compared to placebo Arm B will be estimated by fitting Cox proportional hazards regression 
models adjusting for the main -effects of the stratification factors and additional independent 
prognostic fac tors as deemed appropriate, to be specified in the SAP.
Progression Free Survival (PFS)
PFS is defined as time from randomization to progression of disease (per RANO criteria) or 
death, whichever occurs first.  For subjects who are not documented to have e xperienced a PFS 
event at the time of an analy sis, PFS will be right -censored on the date of their last adequate 
radiographic assessment of disease.  PFS will be analy zed in similar way  to OS.  That is, PFS 
will be compared between treatment Arms A and B f or the FAS using stratified log -rank test 
statistics or a weighted version of this test (to be pre -specified in the Statistical Anal ysis Plan 
document, adjusting for the study  stratification factors and additional independent prognostic 
factors as deemed a ppropriate, to be specified in the SAP.  The hazard-ratio of PFS for ABT-414 
Arm A compared to placebo Arm B will be estimated b y fitting Cox -proportional hazards 
regression models adjusting for the main
-effects of the stratification factors and additional
independent prognostic factors as deemed appropriate, to be specified in the SAP.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
128A sensitivity  anal ysis will be conducted to evaluate the robustness of the results, as exploratory  
and supportive of the primary  PFS anal ysis.  Accounting for subjects who died or progressed 
after more than one (> 1) missed visit, the following sensitivity  anal ysis will be performed:  
Considering the date of the earliest missed radiological assessment following the last adequate 
radiological assessment prior to a subject's pr ogression or death, as a date of progression.
No imputation will be used for subjects with no more than one missed visit in the sensitivity  
analysis.  Details for the sensitivity  anal ysis will be provided in the SAP.
Overall Survival for the MGMT Methylated, MGMT Unmethylated and 
EGFRvIII -Mutated Tumor Subgroups
OS analy sis will be performed in the subgroup of patients with MGMT methy lated MGMT 
unmethy lated and EGFRvIII -mutation.   The same methodology  as for the prima ry OS anal ysis 
in the FAS will be applied.
Progression Free Survival for the EGFRvIII -Mutated Tumor Subgroup
PFS analy sis will be performed in the subgroup of patients with EGFRvIII -mutation.  The same 
methodology  as for the PFS anal ysis in the FAS will be applied.
Time to Deterioration in Verbal Memory (HVLT -R)
In the Phase 3 part of the study , time to deterioration in verbal memory , based on the HVLT -R 
Total Recall, will be analyzed as a separate secondary  endpoint.  Other individual components 
and outcom e from HVLT -R and FAS verbal fluency  will be anal yzed on an exploratory  basis.
The HVLT- R Total Recall score will be computed by  summing the total number of words 
recalled across 3 trials.  Standardized scores (mean = 0, SD = 1) for each test are calculate d using 
published normative data from a healthy  population.  At each assessment, change in the HVLT- R 
total recall score relative to baseline will be calculated and verbal memory  performance will be 
categorized as declined or not using the reliable change index (RCI ) criterion based on the raw 
scores.
The deterioration is defined as satisfy ing the deterioration criteria without further improvement 
within 8 weeks or occurrence of death.  TTD endpoints will be derived as follows:
TTD = Date of first occurrenc e of first deterioration event or censoring – date of randomization 
+ 1.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
129Time to deterioration in verbal memory  will be assessed using the standard log -rank test.  The 
hazard- ratio for ABT -414 Arm A compared to placebo Arm B will be estimated by  fitting th e 
Cox PH models with stratification factors included as the covariates.
Time to Deterioration in Symptom Severity and Symptom Interference (MDASI -BT)
In the Phase 3 part of the study , the s ymptom severity  and the s ymptom interference scores of the 
MDASI -BTwill be used as the outcome of interest for this analysis.  Data will be scored 
according to the MDASI user manual.  A change of ≥ 1 point on a 10- point scale at follow -up 
assessment with respect to baseline will be considered as clinically  relevant.  The scores for 
symptom severit y and s ymptom interference are calculated by averaging the scores of the 
symptom severit y-and symptom interference -related questions, respectively .  Changes in 
symptom severit y score and symptom interference score at each time p oint will be classified into 
3 categories:  improved ( ≤ –1), stable (> –1 and < 1), and deteriorated ( ≥ 1).
Time to deterioration in overall s ymptom burden and interference will be analy zed using the 
similar approach for time to deterioration in neurocogni tive failure.
14.7 Exploratory Hypothesis and Endpoints
OS at 1 y ear
OS at 2 y ears
PFS at 1 y
ear
PFS at 2 y ears
OS for non- EGFRvIII subjects (comparison between arms)
PFS for non -EGFRvIII subjects (comparison between arms)
PFS for the MGMT unmethy lated and methy lated sub -groups
OS and PFS for Total EGFR expressions levels
To compare change from baseline in neurocognitive functioning (HVLT -R and 
COWA -FAS)
To evaluate changes from baseline in HRQoL  based on the EORTC QLQ -C30/BN20
To evaluate changes from baseline in performance status based on KPS scores
To compare median time that KPS score was maintained at 70 or higher
Change from baseline in Vision item on the MDASI -BT and EORTC BN20
EGFR amplification and EGFRvIII prognostic value
Changes in EGFR mole cular profile during therapy  among subjects who undergo additional 
surgery  as part of routine care
Change from baseline in sy mptom severit y factor groupings (MDASI -BT neurologic, 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
130cognitive,  treatment and sy mptom interference (activity -related, mood -relate d))
Pharmacokinetics of ABT- 414, total ABT -806, and unconjugated cy s-mcMMAF
To evaluate changes from baseline in average daily  corticosteroid dosing during post -
treatment period.
OS and PFS at 1 y ear and 2 y ears will be summarized and reported b y treatmen t arm.
For the endpoint on the OS and PFS comparison for non -EGFRvIII EGFR amplified subjects, the 
treatment group differences will be evaluated using the similar methodology  as for analy ses in 
the FAS.  Anal ysis details will be provided in the Statistical Analy sis Plan.
Scoring for the EORTC QLQ-C30, QLQ- BN20, MDASI -BT will be based on their 
corresponding user manuals.31-33  Summary  statistics of the EORTC QLQ- C30, QLQ -BN20, 
MDASI -BT, HVLT -R, COWA -FAS, and KPS including their changes from baseline will be 
calculated at each assessment time point for both study  arms.  Anal ysis details will be provided 
in the Statistical Analy sis Plan.
Pharmacokinetic:
Peak and trough concentrations (maximum observed plasma concentration [C max] and C trough) of 
ABT -414 and tot al ABT -806 antibody  will be summarized from the observed concentration data.  
Population pharmacokinetic parameters of ABT -414, total ABT -806 and cy s-mcMMAF such as 
clearance and volume of distribution will be estimated using a nonlinear mixed effect model ing 
analysis.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
13115.0 ETHICS
15.1 Independent Ethics Committee (IEC) or Institutional Review Board (IRB)
Good Clinical Practice (GCP) requires that the clinical protocol, an y protocol amendments, the 
Investigator's Brochure, the informed consent and all other forms of subject information related 
to the study  (e.g., advertisements used to recruit subjects) and an y other necessary documents be 
reviewed b y an IEC/IRB.  The IEC/I RB will review the ethical, scientific and medical 
appropriateness of the study  before it is conducted.  I EC/IRB approval of the protocol, informed 
consent and subject information and/or advertising, as relevant, will be obtained prior to the 
authorization of drug shipment to a study site.
Any amendments to the protocol will require IEC/I RBapproval prior to implementation of an y 
changes made to the study design.  The Investigator will be required to submit, maintain and 
archive stud y essential documents according to ICH GCP.
Serious adverse events that meet the reporting criteria, as dictat ed by local regulations, will be 
reported to both responsible Ethics Committees and Regulatory  Agencies as required b y local 
regulations.  During the conduct of the study , the Investigator should promptly  provide written 
reports (e.g., ICH Expedited Report s or an y additional reports required b y local regulations) to 
the IEC/I RB of an y changes that affect the conduct of the study and/or increase the risk to 
subjects.  Written documentation of the submission to the I EC/IRB should also be provided to 
AbbVie.
15.2 Ethical Conduct of the Study
The study  will be conducted in accordance with the protocol, International Conference on 
Harmonization (I CH) GCP guidelines, applicable regulations and guidelines governing clinical 
study  conduct and ethical principles that have their origin in the Declaration of Helsinki.  
Responsibilities of the clinical Investigator are specified in
 Appendix V.
15.3 Subject Information and Consent
Prior to the initiation of any  screening or study -specific procedures, the Investigator or h is/her 
representative will explain the nature of the study  to the subject and answer all questions 
regarding this study .  Subjects who provide optional samples for anal ysis will also sign an 
informed consent regarding the collection of these samples (i.e., pharmacogenetic [PG] blood 
sample and tissue samples).  Each informed consent will be reviewed, signed and dated b y the 
subject, the person who administered the informed consent, and an y other signatories according 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
132to local requirements.  A copy  of each i nformed consent will be given to the subject and each 
original will be placed in the subject's medical record.  An entry  must also be made in the 
subject's dated source documents to confirm that informed consent was obtained prior to an y 
study -related proc edures and that the subject received a signed cop y.
Post-treatment tissue collection and analy sis will only  be performed if the subject has voluntaril y 
signed and dated a separate post- treatment tissue informed consent (or indicated consent within 
the main study  informed consent form), approved by  an IRB/IEC, after the nature of the testing 
has been explained and the subject has had an opportunity to ask questions.  The post -treatment 
tissue informed consent must be signed before the tissue collection and a nalysis is performed.  If 
a subject does not consent to the post- treatment tissue collection and anal ysis, it will not impact 
the subject's participation in the study .
A sample for pharmacogenetic analy sis will only  be collected if the subject has voluntar ily 
signed and dated a separate pharmacogenetic informed consent (or indicated consent within the 
main study  informed consent form), approved by  an IRB/IEC, after the nature of the testing has 
been explained and the subject has had an opportunity  to ask questions.  The pharmacogenetic 
informed consent must be signed before the pharmacogenetic testing is performed.  If the subject 
does not consent to the pharmacogenetic testing, it will not impact the subject's participation in 
the study .
In the event a subj ect withdraws from the stud y stored biomarker samples will also be destroyed 
upon request (samples will not be stored for more than 20 y ears from the time the Clinical Study  
Report is completed).  In the event that destruction is not possible, they  will no longer be linked 
to the subject.  If the subject changes his/her consent, and the samples have alread y been tested, 
those results will still remain part of the overall research data.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
13316.0 DATA QUALITY AS SURANCE
Prior to enrolling an y subject in the study, an initiation meeting will be held with AbbVie 
personnel, the Investigator(s), and the stud y coordinators/project manager(s).  This meeting will 
include a detailed discussion and review of the protocol and essential documents, performance of 
study  procedures, case report form completion and specimen collection methods.
The AbbVie monitor will monitor the study  site throughout the stud y.  Source document review 
will be made against entries on the case report forms and a quality  assurance check will be 
perfo rmed to ensure that the I nvestigator is comply ing with the protocol and regulations.  In 
addition, after the case report forms are retrieved, a review of the data will be conducted b y a 
physician or representative at AbbVie.
All data hand entered in the da tabase will be verified at AbbVie.  An y discrepancies will be 
reviewed against the hard -copy case report form and corrected on -line.  After completion of the 
entry  process, computer logic and manual checks will be created to identify  such items as 
inconsis tent study  dates.  Any  necessary  corrections will be made to the database via the 
appropriate change form/electronic CRF.
Routine hematology , serum chemistry  and serology , and urinal ysis tests will be conducted using 
a certified clinical laboratory .  Labor atory  reference ranges will be obtained prior to the initiation 
of the study .  A review of all laboratory  results will be conducted by  the AbbVie monitor, the 
Investigator and other appropriate personnel from AbbVie.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
13417.0 USE OF INFORMAT ION
All information concerning ABT -414 and AbbVie operations, such as AbbVie patent 
applications, formulas, manufacturing processes, basic scientific data, or formulation 
information, supplied by  AbbVie and not previously  published is considered confidential 
information.
Theinformation developed during the conduct of this clinical study  is also considered 
confidential and will be used by  AbbVie in connection with the development of ABT- 414.  This 
information may be disclosed as deemed necessary  by AbbVie to other clinical In vestigators, 
other pharmaceutical companies, and to governmental agencies.  To allow for the use of the 
information derived from this clinical study  and to ensure complete and thorough anal ysis, the 
Investigator is obligated to provide AbbVie with complete test results and all data developed in 
this study  and to provide direct access to source data/documents for study -related monitoring, 
audits, I EC/IRB review, and regulatory  inspection.
This confidential information shall remain the sole propert y of AbbVie , shall not be disclosed to 
others without the written consent of AbbVie, and shall not be used except in the performance of 
this study .
The Investigator will maintain a confidential subject identification code list of all subjects 
enrolled in the study , including each subject's name, subject number, address, phone number and 
emergency  contact information.  This list will be maintained at the study  site with other study  
records under adequate securit y and restricted access, and will not be retrieved by AbbVie.
Any pharmacogenetic and exploratory  biomarker research that may  be done using DNA samples 
from this study  will be experimental in nat ure and the results will not be suitable for clinical 
decision making or subject management.  Hence, neither the Investigator, the subject, nor the
subject's ph ysician (if different from the Investigator) will be informed of individual subject 
results should analy ses be performed, nor will anyone not directl y involved in this research.  
Correspondingl y, researchers will have no access to subject identifiers.  Individual results will 
not be reported to an yone not directly involved in this research other than for regulatory  
purposes.  Aggregate pharmacogenetic and exploratory  biomarker information from this study  
may be used in scientific publications or presented at medical conventions.  Pharmacogenetic 
and exploratory  biomarker information will be published or presented onl y in a way  that does not 
identify  any individual subject.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
13518.0 COMPLETION OF STUDY
The Investigator will conduct the study in compliance with the protocol and complete the study  
within the timeframe specified in the contract between the Inv estigator and AbbVie.  
Continuation of this study  beyond this date must be mutually  agreed upon in writing b y both the 
Investigator and AbbVie.  The Investigator will provide a final report to the I EC/IRB following 
conclusion of the study, and will forward a cop y of this report to AbbVie or their representative.
The Investigator must retain an y records related to the study according to local requirements.  If 
the Investigator is not able to retain the records, he/she must notify  AbbVie to arrange alternativ e 
archiving options.
AbbVie will select the signatory  coordinating Investigator from the Investigators who participate 
in each multi -center study .  Selection criteria for this signatory  Investigator will be based on 
level of participation, and significant knowledge of the clinical research, investigational drug, 
and study  protocol.  The signatory  Investigator for the study  will review and sign the final study  
report in accordance with the European Medicines Agency  (EMA) Guidance on Investigator's 
Signature for Study  Reports.
The end of stud y is defined as the date of the last subject's last visit.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
13619.0 INVESTIGATOR'S AGREEMENT
1. I have received and reviewed the Investigator's Brochure for ABT -414.
2. I have read this protocol and agree that the stud y is ethical .
3. I agree to conduct the study  as outlined and in accordance with all applicable regulations 
and guidelines.
4. I agree to maintain the confidentiality  of all information received or developed in 
connection with this protocol.
5. I agree that all electronic sign atures will be considered the equivalent of a handwritten 
signature and will be legally  binding.
Protocol Title: A Randomized, Placebo Controlled Phase 3 Study  of ABT -414 with 
Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects 
with Newl y Diagnosed Glioblastoma (GBM) with Epidermal Growth 
Factor Receptor ( EGFR ) Amplification (Intellance1)
Protocol Date: 26May 2019
Signature of Principal Investigator Date
Name of Principal Investigator (printed or t yped)
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
13720.0 REFERENCES
1. Preusser M, de Ribaupierre S, Wohrer A, et al.  Current concepts and management of 
glioblastoma.  Ann Neurol.  2011;70(1):9-21.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherap y plus concomitant and adjuvant 
temozolomide for glioblastoma. N Engl J Med.  2005;352(10):987 -96.
3. Mason WP, Del Maestro R, Eisenstat D, et al.  Canadian recommendations for the 
treatment of glioblastoma multiforme.  Curr Oncol.  2007;14(3):110 -7.
4. Thompson JA, Forero A, Heath EI, et al.  SGN -75 in the treatment of patients with 
CD70- positive malignancies including metastatic renal cell carcinoma [abstract].  J Clin 
Oncol.  2013;31 (Suppl 6):S368.
5. Schag CC, Heinrich RL , Ganz PA.  Karnofsk y performance status revisited:  reliability , 
validity , and guidelines.  J Clin Oncol.  1984;2:187 -93.
6. Ellingson BM, Bendszus M, Boxerman, et al.  Consensus recommendations for a 
standardized brain tumor imaging protocol (BTIP) in clinical trials.  Neuro Oncol . 2015, 
In Press .
7. Wen PY, M acdonald DR, Reardon DA.  Updated response assessment criteria for 
high-grade gliomas:  response assessment in Neuro -Oncology  Working Group.  J Clin 
Oncol.  2010;28:1963-72.
8. Wefel JS, Saleeba AK, Buzdar AU, et al.  Acute and late onset cognitive dy sfunctio n 
associated with chemotherap
y in women with breast cancer.  Cancer.  
2010;116:3348-3356.
9. Meyers CA, Smith JA, Bezjak A, et al.  Neurocognitive function and progression in 
patients with brain metastases treated with whole- brain radiation and motexafin 
gado linium:  results of a randomized phase III trial.  J Clin Oncol.  2004;22:157 -165.
10. Barry  D, Bates ME, Labouvie E.  FAS and CFL forms of verbal fluency  differ in 
difficulty :  a meta -analytic study .  Appl Neurops ychol.  2008;15(2):97-106.
11. Gilbert MR, Dignam 
JJ, Armstrong TS, et al.  A randomized trial of bevacizumab for 
newly  diagnosed glioblastoma.  N Engl J Med.  2014;370(8):699 -708.
12. Meyers CA, Smith JA, Bezjak A, et al.  Neurocognitive function and progression in 
patients with brain metastases treated with whole- brain radiation and motexafin 
gadolinium:  results of a randomized phase III trial.  J Clin Oncol.  2004;22:157 -165.
13. Meyers CA, Hess KR.  Multifaceted end points in brain tumor clinical trials:  cognitive 
deterioration precedes MRI  progression.  Neu ro Oncol.  2003;5:89-95.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
13814. Meyers CA, Hess KR, Yung WK, et al.  Cognitive function as a predictor of survival in 
patients with recurrent malignant glioma.  J Clin Oncol.  2000;18:646 -65.
15. Klein M, Postma TJ, Taphoorn MJ, et al.  The prognostic value of cognit ive functioning in 
the survival of patients with high- grade glioma.  Neurology .  2003;61:1796 -8.
16. Johnson DR, Sawy er AM, Mey ers CA, et al.  Early  measures of cognitive function predict 
survival in patients with newly  diagnosed glioblastoma.  Neuro Oncol.  
2012;14(6):808 -16.
17. Armstrong TS, Wefel JS, Wang M, et al.  Net clinical benefit anal ysis of Radiation 
Therap y Oncology  Group 0525:  a phase III trial comparing conventional adjuvant 
temozolomide with dose -intensive temozolomide in patients with newly  diagnosed 
glioblastoma.  J Clin Oncol.  2013;31(32):4076-84.
18. Benedict RH, Schretten D, Groninger L, et al.  Hopkins verbal learning test- revised:  
normative data and anal ysis of inter -form and test -retest reliability .  Clin Neuropsy chol.  
1998;12:43-55.
19. Tombaug h TN, Kozak J, Rees L .  Normative data stratified by  age and education for 
twomeasures of verbal fluency :  FAS and Animal Naming.  Arch Clin Neuropsy chol.  
1999;14(2):167 -77.
20. Aaronson NK, Ahmedzai S, Bergman B, et al.  The European Organization for Resear ch 
and Treatment of Cancer QLQ- C30:  a quality -of-life instrument for use in international 
clinical trials in oncology.  J Natl Cancer Inst.  1993;85(5):365 -76.
21. Osoba D, Aaronson NK, Muller M, et al.  The development and psy chometric validation 
of a brain cancer qualit y-of- life questionnaire for use in combination with general 
cancer -specific questionnaires.  Qual Life Res.  1996;5(1):139 -50.
22. Taphoorn MJ, Claassens L, Aaronson NK et al.  An international validation study  of the 
EORTC brain cancer module (EO RTC QLQ -BN20) for assessing health -related quality  of 
life and s ymptoms in brain cancer patients.  Eur J Cancer.  2010;46(6):1033-40.
23. Armstrong TS, Mendoza T, Gning I, et al.  Validation of the M.D. Anderson Sy mptom 
Inventory  Brain Tumor Module (MDASI -BT).  J Neurooncol.  2006;80(1):27 - 35.
24. EQ-5D- 5L and EQ -5D-VAS:  http://www.euroqol.org.
25. Stupp  R, Mason WP, van den Bent MJ, et al.  Radiotherap y plus concomitant and 
adjuvant temozolomide for glioblastoma.  N Engl J Med.  2005;352(10):987 -96.
26. Schuster J, Lai, RK, Recht L D, et al.  A phase II, multicenter trial of rindopepimut 
(CDX -110) in newl y diagnosed glioblastoma:  the ACT III stud y.  Neuro Oncol.  
2015;0:1 -8.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
13927. Common Terminology  Criteria for Adverse Events, Version 4.0, DCTD, NCI , NIH, 
DHHS. 28 May  2009 [c ited 13 April 2011].  Available from:  
http://evsnci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 06 
14_QuickReference_8.5x11.pdf.
28. Dresemann G, Weller M, Rosenthal MA, et al.  Imatinib in combination with hy droxyurea 
versus h ydrox yurea alone as oral therap y in patie nts with progressive pretreated 
glioblastoma resistant to standard dose temozolomide.  J Neurooncol.  
2010;96(3):393 -402.
29. Pintilie M.  Dealing with competing risks: testing covariates and calculating sample size, 
Statistics in medicine, 2002;21(22):3317 -3324.
30. Fayers P, Aaronson, N, Bjordal K et al.  The EORTC QL Q
-C30 scoring manual.  2nded.  
Brussels:  the European Organisation for Research and Treatment of Cancer, 1999.
31. Cleeland CS, Mendoza TR, Wang XS, et al.  Assessing s ymptom distress in cancer 
patient s:  the MD Anderson Sy mptom Inventory .  Cancer.  2010:89(7):1634 -46.
32. Mangione CM.  (2000) NEI -VFQ Scoring Algorithm.  Version 2000.
33. AbbVie.   ABT -414 Investigator’s Brochure Edition 5.  01 July  2016.
34. Glimm E, Maurer W, Bretz F.  Hierarchical testing of mul tiple endpoints in group -
sequential trials.  Stat Med.  2010;29(2), 219 -28.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
140APPENDIX I SUMMARY O F RANO RESPONSE CRIT ERIA
Tumor assessments will be assessed using the RANO criteria as outlined below according to 
Wen, et al, "Updated Response Assessment Criteria for High- Grade Gliomas:  Response 
Assessment in Neuro- Oncology  Working Group."
Table 1. Criteria for Determining First Progression Depending on Time from Initial 
Chemoradiotherapy
First Progression Definition
Progressive disease 
<12weeks after completion 
of chemoradiotherapyProgression can only be defined using diagnostic imaging if there is new 
enhancement outside of the radiation field (beyond the high -dose region or 
80% isodose line) or if there is unequivocal evidence of viable tumor on 
histopathologic sampling (e.g., solid tumor areas [i.e., > 70% tumor cell nuclei 
in areas], high or progressive increase in MIB -1 proliferation index compared 
with prior biopsy, or evidence for histologic progression or increased anaplasia 
in tumor).
Note:  G iven the difficulty of differentiating true progression from 
pseudoprogression, clinical decline alone, in the absence of radiographic or 
histologic confirmation of progression, will not be sufficient for definition of 
progressive disease in the first 12 w eeks after completion of concurrent 
chemoradiotherapy.
Progressive disease 
≥12weeks after 
chemoradiotherapy 
completion1.New  contrast -enhancing lesion outside of radiation field on decreasing, 
stable, or increasing doses of corticosteroids.
2.Increase by ≥ 25% in the sum of the products of perpendicular diameters 
betw een the first post -radiotherapy scan, or a subsequent scan with smaller 
tumor size, and the scan at 12 weeks or later on stable or increasing doses 
of corticosteroids.
3.Clinical deterior ation not attributable to concurrent medication or 
comorbid conditions is sufficient to declare progression on current 
treatment but not for entry onto a clinical trial for recurrence.
4.For patients receiving anti -angiogenic therapy, significant increase in 
T2/FLAIR non -enhancing lesion may also be considered progressive 
disease.  The increased T2/FLAIR must have occurred w ith the patient on 
stable or increasing doses of corticosteroids compared w ith baseline scan 
or best response after initiation of ther apy and not be a result of comorbid 
events (e.g., effects of radiation therapy, demyelination, ischemic injury, 
infection, seizures, post -operative changes, or other treatment effects).
FLAIR = fluid -attenuated inversion recovery
Pseudoprogression and Ra diation Effects
The proposed new response criteria suggest that within the first 12 weeks of completion of 
radiotherap y, when pseudoprogression is most prevalent, progression can only be determined if 
the majority  of the new enhancement is outside of the r adiation field (for example, bey ond the 
high-dose region or 80% isodose line) or if there is pathologic confirmation of progressive 
disease.  It is recognized that the proposed histologic criteria have important limitations, but they  
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
141provide guidance on th e type of findings that are suggestive of progressive disease.  For patients 
in whom pseudoprogression cannot be differentiated from true tumor progression, enrollment 
onto trials for recurrent gliomas should not be permitted.  Patients who remain clinical ly stable 
and/or are suspected to have pseudoprogression based on metabolic or vascular imaging should 
continue with their current therap y.
Enhancement as a Result of Surgery and Other Therapies
Increased enhancement often develops in the wall of the surgi cal cavity  48 to 72 hours after 
surgery .  To avoid interpretation of post-operative changes as residual enhancing disease, a 
baseline MRI scan should ideally  be obtained within 24 to 48 hours after surgery  and no later 
than 72 hours after surgery .  The inc lusion of diffusion weighted imaging in the immediate 
post-operative MRI scan can be helpful in determining whether new enhancement developing in 
the subsequent weeks or months is caused by  sequelae of ischemia or by  tumor recurrence.  In 
addition, a transient increase in enhancement that can be difficult to distinguish from recurrent 
disease can also occur after locally administered therapies.  These include chemotherap y wafers, 
immunotoxins delivered by  convection enhanced delivery , regionally  administere d gene and 
viral therapies, immunotherapies, and focal irradiation with brach ytherap y and stereotactic 
radiosurgery .  Imaging modalities such as perfusion imaging, magnetic resonance spectroscopy , 
and positron emission tomograph y scans may  sometimes be hel pful in differentiating treatment 
effects from recurrent tumor.  However, no imaging modalit y currentl y has sufficient specificity 
to conclusively  differentiate recurrent tumor from treatment effects, and surgical sampling may  
occasionall y be needed to obt ain a definitive diagnosis.
Definition of Clinical Deterioration
The definition of clinical deterioration is left to the discretion of the treating phy sician, but it is 
recommended that a decline in the KPS from 100 or 90 to 70 or less, a decline in KPS of at least 
20 from 80 or less, or a decline in KPS from an y baseline to 50 or less, for at least 7 days, be 
considered neurologic deterioration unless attributable to comorbid events or changes in 
corticosteroid dose.  Similarly , a decline in the Eastern Cooperative Oncology  Group and WHO 
performance scores from 0 or 1 to 2 or 2 to 3 would be considered neurologic deterioration.
For those subjects who have measurable disease post resection, RANO criteria for assessment of 
CR, PR, SD and PD can be applied.  See the below tables for the definitions to be used.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
142Definition of Radiographic Response
Radiographic response should be determined in comparison to the tumor measurement obtained 
at pretreatment baseline for determination of response, and the smallest tum or measurement at 
either pretreatment baseline should be used for determination of progression.  The criteria for 
radiographic changes after therap y are listed in Table 1.  In the event that the radiographic 
changes are equivocal and it is unclear whether the patient is stable or has developed progressive 
disease, it is permissible to continue treatment and observe the patient closely , for example at 
4-week intervals.  If subsequent imaging studies demonstrate that progression has occurred, the 
date of prog ression should be the date of the scan at which this issue was first raised.  The 
determination of radiographic response after treatment with agents that affect vascular 
permeability  is particularly  difficult.  In these patients, consideration should be gi ven to 
performing a second scan at 4
weeks to confirm the presence of response or stable disease.  All 
measurable and nonmeasurable lesions should be assessed using the same techniques as at 
baseline.  Ideally , patients should be imaged on the same MRI sca nner, or at least with the same 
magnet strength, for the duration of the study to reduce difficulties in interpreting changes.
Patients with nonmeasurable enhancing disease whose lesions have significantly  increased in 
size and become measurable (minimal bidirectional diameter of ≥ 10 mm and visible on at least 
two axial slices that are preferabl y, at most, 5 mm apart with 0 mm skip) will also be considered 
to have experienced progression.  The transition from a nonmeasurable lesion to a measurable 
lesion r esulting in progression can theoretically  occur with relativel y small increases in tumor 
size (e.g., a 9 × 9 mm lesion [nonmeasurable] increasing to a 10 × 11 mm lesion [measurable]).  
Ideally, the change should be significant (> 5 mm increase in maximal d iameter or ≥ 25% 
increase in sum of the products of perpendicular diameters of enhancing lesions).  I n general, if 
there is doubt about whether the lesion has progressed, continued treatment and close follow -
up 
evaluation will help clarify  whether there is true progression.  If there is uncertaint y regarding 
whether there is progression, the patient may  continue on treatment and remain under close 
observation (e.g., evaluated at 4 -week intervals).  If subsequent evaluations suggest that the 
patient is in fa ct experiencing progression, then the date of progression should be the time point 
at which this issue was first raised.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
143Table 2. Summary of the Proposed RANO Response Criteria
Criterion CR PR SD PD
T1 gadolinium enhancing disease None ≥ 50% ↓ < 50% ↓ but < 25% ↑ ≥ 25% ↑*
T2/FLAIR Stable or ↓ Stable or ↓ Stable or ↓ ↑*
New  Lesion None None None Present*
Corticosteroids None Stable or ↓ Stable or ↓ NA**
Clinical status Stable or ↑ Stable or ↑ Stable or ↑ ↓*
Requirement for response All All All Any*
RANO = Response Assessment in Neuro -Oncology; CR = complete response; PR = partial response; SD = stable disease; 
PD=progressive disease; FLAIR = fluid -attenuated inversion recovery; NA = not applicable
* Progression occurs when this criterion is present .
** Increase in corticosteroids alone will not be taken into account in determining progression in the absence of persistent 
clinical deterioration.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
144APPENDIX II RTOG 3508/ABBVIE STUDY M13 -813 PROTOCOL SYNOPSIS
AbbVie Inc. Protocol Num ber:  M13 -813
Nam e of Study Drug:   ABT -414 Phase of Developm ent:  3
Nam e of Active Ingredient:   ABT -414 Date of Protocol Synopsis:   26May 2019
Protocol Title:   A Randomized, Placebo Controlled Phase 3 Study of ABT -414 w ith Concurrent Chemoradiation 
and Adjuvant Temozolomi de in Subjects w ith Newly Diagnosed Glioblastoma (GBM) w ith Epidermal Growth 
Factor Receptor ( EGFR ) Amplification (Intellance1)
Prim ary Objective:
To determine whether the addition of ABT -414 to concomitant radiotherapy and TMZ plus adjuvant TMZ 
prolongs Overall Survival (OS) among subjects with newly diagnosed GBM harboring EGFR amplification.
Secondary Objectives:   To determine whether the addition of ABT -414 to concomitant radiotherapy and TMZ 
plus adjuvant TMZ improves outcomes among subjects with newly diagnosed GBM harboring EGFR
amplification for the following endpoints:
PFS
OS for the MGMT unmethylated tumor subgroup
OS for the MGMT methylated tumor subgroup
Time to deterioration in symptom severity score  (MDASI -BT)
Time to deterioration in symptom interference score (MDASI -BT)
Time to deterioration in neurocognitive functioning on the Hopkins Verbal Learning Test Revised 
(HVLT -R) total recal l score
OS for the EGFRvIII -mutated tumor subgroup
PFS for EGFRvIII -mutated tumor subgroup
Safety:
Assessment of comparative safety
Tools:
Symptom Inventory:   MD Anderson Symptom Index for Brain Tumors (MDASI -BT).
Neurocognitive Functioning:   The Hopkins Verbal Learning Test -Revised (HVLT -R) for memory; and COWA -
FAS verbal fluency test for executive function.
Quality of Life:   (Exploratory Objective) European Organization for Research and Treatment of Cancer Quality 
of Life Questionnaire (EOR TC QLQ -C30 with EORTC -QLQ -BN20 (brain tumor module) and EQ -5D-5L
Investigators:
Multicenter, multi -national
Study Site s:
Approximately 200
Study Population:
Newly diagnosed GBM subjects with EGFR amplification.
Number of Subjects to be Enrolled:
Approximately 640
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
145Mechanism  of Action:
ABT -414 is a new er generation ADC consisting of:  (1) a veneered "humanized" recombinant IgG1κ antibody 
that has binding properties specific to a unique epitope of human EGFR with (2) non -cleavable maleimido -
caproyl linkers each attached to (3) a potent antimicrotubule agent, monomethylauristatin F (MMAF).  The 
antibody binds to the activated EGFR epitope (even in the absence of the EGFRvIII mutation), is internalized, 
and then intracellular enzymes release the toxin leading to inhibition of microtubule function, the disruption of 
critical cellular processes, and cell death.  Importantly, ABT -414 binds to an epitope that is available 
predominantly on tumor cells with either the EGFR de2-7 (EGFRvII I) deletion mutant or o n tumor cells with 
activated wild -type EGFR (i.e., w ith EGFR amplification).  The epitope is largely inaccessible when EGFR is 
expressed at normal physiological levels; thus, ABT -414 has limited binding to non -activated, w ild-type EGFR
expressed on normal tissues.  These properties, therefore, favor limited effects of the toxin on normal tissues 
while maintaining a high degree of activity on EGFR -amplified tumor cells.
Methodology:
This is a Phase 3 randomized double -blind, placebo -controlled trial comparing the efficacy and safety of 
ABT -414 versus placebo, each as concurrent treatment with standard -of-care therapy of radiation/TMZ plus 
adjuvant TMZ and followed by ABT -414/placebo monotherapy, in subjects w ith newly diagnosed GBM.
The study comprise s a Screening Period of up to 7 weeks from surgery; a 6 -week concomitant Chemoradiation 
Phase; an Adjuvant Phase beginning approximately 4 weeks after completion of chemoradiation, and a 
Follow -Up Phase.  The Adjuvant Phase is comprised of 28 -day cycles, w ith subjects receiving concomitant TMZ 
and study drug (ABT -414/placebo) for the first 6 cycles, and study drug (ABT -414/placebo) monotherapy for the 
following 6 cycles.  Subsequent cycles will start approximately 28 days from the start of the previous cycl e, and 
the cycle schedule will not be affected by delays or interruptions in TMZ or ABT -414/placebo dosing.  Adjuvant 
treatment will be discontinued once disease progression has been determined.  A Final Study Drug Visit will be 
performed upon discontinuat ion of study drug (ABT -414/placebo) for any reasons, followed by a 35 -Day and 
49-Day Follow -up Visits (± 3 days).  Subjects who are unable to attend the 49 Day Follow -up will be phoned to 
obtain adverse event and concomitant medication information.  In the Follow -Up Phase, subjects who complete 
adjuvant treatment or discontinue study drug prior to disease progression will continue to undergo MR imaging 
and assessment of neurocognitive functioning and patient reported outcomes (PRO) approximates every 8 week s 
up to and including at the time of disease progression, starting 8 w eeks after the last scheduled PRO assessments 
in the Adjuvant Phase.  After disease progression, overall survival will continue to be assessed quarterly.
A sample of pre -treatment tumor tissues will be collected and sent to central laboratories to confirm diagnosis of 
GBM (required to enroll in the trial) and test for EGFR amplification (required to enroll in the trial), 
MGMT
prom oter methylation (a stratification factor), EGFRvIII mutati on (a stratification factor) and other biomarkers 
prior to starting chemoradiation.  If a subject has a repeat surgery before initiating treatment, then the tissue from 
either biopsy/resection may be used for histologic and EGFR amplification, EGFRvIII mutation and MGMT
prom oter methylation testing.  If molecular results are discordant betw een multiple specimens from the same 
patient, then the results that permit eligibility will be used.  Remaining sample tissue will be retained for other 
exploratory molec ular analysis where allowed by local regulations.  If local regulations do not allow  tissue 
shipment or storage, the tissue w ill be immediately returned or destroyed after eligibility testing.
Screening procedures must be completed prior to Day 1 of the Ch emoradiation Phase.  Screening procedures will 
include signing of a study consent form, medical history, Karnofsky Performance Scale (KPS) assessment and 
recursive partitioning analysis (RPA) classification, baseline ECG, physical, ophthalmologic and neuro logical 
examinations, Patient Reported Outcomes (PRO) and neurocognitive assessments, laboratory tests ( ≤ 21 days 
from treatment start), and pregnancy test ( ≤ 7 days from treatment start) if applicable.  If a subject starts 
chemoradiation more than 28 days after surgery, the subjects will have a brain MRI 21 (but preferably fewer) 
days prior to Day 1 Week 1 of the Chemoradiation Phase to be used as the baseline for efficacy analyses; the 
timing of the MRI should allow sufficient time to revise the radiation therapy plan if needed due to a significant 
change in tumor since surgery.  Safety -related evaluations will be conducted w ithin 14 or few er days prior to Day 
1 of the Chemoradiation Phase.  Subjects who screen positive for EGFR amplification in the tumor tissue may 
enter the study if all inclusion/exclusion criteria are met.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
146Methodology (Continued):
Upon study entry, subjects will be stratified according to the following 4 factors:  region of the world (US/Canada 
or other), RPA classes (III, IV or V), MGM Tmethylation (methylated or unmethylated), and EGFRvIII status 
(mutated or other).  Subjects will be randomized within each stratum on a 1:1 ratio to receive either ABT -414 
Arm A or Placebo Arm B during the Chemoradiation and Adjuvant therapy phases.
During the Chemoradiation Phase, all subjects will undergo focal RT, w ith one treatment of approximately 2 gray 
(Gy) given daily 5 days per week for a total of approximately 60 Gy over approximately 6 weeks (and no more 
than 7 weeks).  TMZ w ill be administ ered continuously from Day 1 of radiotherapy to the last day of radiation 
(including weekends and holidays) at a daily oral dose of 75 mg/m2for a maximum of 49 days.  Subjects in 
ArmA will receive blinded ABT -414 at 2.0 mg/kg IV infusion over 30 –40 min utes once every 2 weeks (Day 1 
of Weeks 1, 3, and 5 of the 6 -week regimen).  Subjects in Arm B w ill receive blinded placebo IV infusion over 
30 –40minutes once every 2 weeks (Day 1 of Weeks 1, 3, and 5 of the 6 -week regimen).  Treatment in the 
Chemoradiation Phase must begin ≤ 7 weeks after biopsy/surgery.
The start of the first cycle during the Adjuvant Therapy Phase w ill be scheduled approximately 28 days after the 
last day of radiotherapy.  During the Adjuvant Therapy Phase, all subjects w ill receive o ral TMZ 150 – 200 
mg/m2once daily on Days 1 –5 of each 28 -day cycle for 6 cycles unless there is disease progression, 
unacceptable toxicity, or other reasons to discontinue.  Subjects in Arm A will receive blinded ABT -414 at 1.25 
mg/kg by intravenous inf usion on Day 1 and Day 15 of each 28 -day cycle for 12 cycles.  Subjects in Arm B will 
receive blinded placebo IV infusion on Day 1 and Day 15 of each 28 -day cycle for 12 cycles.
If, after completing 12 cycles of adjuvant treatment, the subject is toleratin g study drug (ABT -414 or placebo) 
and the Investigator believes the subject is continuing to benefit from ongoing study drug treatment, the 
Investigator may extend the Adjuvant Phase after consultation with the Neuro -Medical Oncology Chair or 
AbbVie Medical Monitor, as long as disease progression has not been determined.
Occurrence of disease progression to calculate PFS will be determined by the Investigator, based on local 
evaluation of images and other clinical information using the Response Assessment i n Neuro oncology (RANO) 
criteria.  Post -baseline scans will be obtained ≤ 14 days before Day 1 of each odd -numbered cycle (Cycles 1, 3, 5, 
etc.) of the Adjuvant Phase and ≤ 14 days before each visit (approximately every 8 weeks) of the Follow -Up 
Phase.  MR images will also be reviewed centrally by an independent blinded reviewer for radiographic evidence 
of disease progression.  When study drug is discontinued for any reason, a Final Study Drug Visit will be 
conducted.  All subjects will have a 35 -Day and 4 9-Day Follow -Up Visits (± 3 days) after the last dose of 
ABT -414/placebo.  Overall survival will be assessed quarterly after study discontinuation.
All subjects will receive prophylactic eye drops w ith each dose of ABT -414/placebo for 7 consecutive days, 
starting from 2 days prior to infusion and continuing until 4 days after infusion.  The eye drop formulations 
recommended for the study are ranked by steroid potency from Level 1 (non -steroid artificial tears) to Level 4 
(high -potency steroid where availabl e.  Subjects will be monitored w ith regular ophthalmologic examinations 
(with additional symptom -driven examinations as needed).  The potency of the eye drop formulation given with 
subsequent ABT -414/placebo doses w ill be adjusted upw ard or dow nward based on corneal findings.  To 
minimize unnecessary risks associated w ith prolonged administration of ocular steroids there is a step -down in 
the level of eye drop potency for subjects w ho have received at least 2 doses of ABT -414/Placebo and w ith Grade 
1 or no eye toxicity who have no evidence of corneal microcysts on 2 consecutive ophthalmic examinations.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
147Methodology (Continued):
During chemoradiation, subjects should receive antiemetic prophylaxis and antibiotics should be per local 
regulation guidelines to prevent Pneumocystis ( jirovecii ) pneumonia (PCP) w hile receiving TMZ.  Supportive 
care including systemic corticosteroid use is allowed.  Anti -cancer agents, other investigational anti -neoplastic 
drugs and some uses of growth factors are prohibited during the study.  Any other type of chemotherapy, 
immunotherapy, biologic therapy, medication (including over the counter) or vaccine used for antineoplastic 
intent are also prohibited.
An open -label, single -group sub -study of ABT -414 use in new ly diagnosed GBM subjects w ith mild to moderate 
hepatic impairment is included in Appendix IX.
Diagnosis and Main Criteria for Inclusion/Exclusion:
Main Inclusion:
1. Histologically confirmed de novo Grade IV glioma (GBM, gliosarcoma or other subvariants) confirmed 
by central pathology tissue screening.
2. EGFR amplification in tumor tissue confirmed by central assessment.
3. Inclusion Criteria removed in Amendment 5.
4. The subject must have recovered from the effects of surgery, pos t-operative infection, and other 
complications before enrollment including suture/staple removal from brain surgery and sufficient wound 
healing before randomization.
5. ≥ 18 years of age.
6. Karnofsky performance status ≥ 70 at assessment ≤ 14 days prior to randomization.
7. Results for required stratification factors ( EGFRvIII status, MGMT methylation status, Recursive 
Partitioning Analysis (RPA) class, and region of world) available prior to randomization.
8. Subject has adequate bone marrow , renal, and hepatic function ≤ 21 days prior to randomization as 
follows:
Absolute neutrophil count (ANC) ≥ 1,500/mm3.
Platelets ≥ 100,000/mm3.
Hem oglobin (Hgb) ≥ 9.0 g/dL (Note:  The use of transfusion or other intervention to achieve Hgb 
≥9.0g/dL is acceptable.).
Renal function:  calculated creatinine clearance ≥ 30 m L/min by the Cockcroft -Gault formula.
Hepatic function:  Total bilirubin ≤ 1.5 times upper limit of normal (ULN), Aspartate 
Aminotransferase (AST), and Alanine Aminotransferase (ALT) ≤ 3 times upper li mit of normal 
(ULN).  Subjects with Gilbert's syndrome documented in medical history may be enrolled if total 
bilirubin is < 3 times ULN.
9. Electrocardiogram (ECG) without evidence of acute cardiac ischemia ≤ 21 days prior to randomization.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
148Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):
Main Inclusion (Continued):
10. Fem ale subjects of childbearing potential (i.e., those who are not postmenopausal for at least 1 year or 
surgically sterile by bilateral salpingectomy, bilateral oophorect omy or hysterectomy) should practice at 
least one accepted method of birth control listed below  during study entry, for the entire duration of the 
study and for at least 6 months after treatment with ABT -414 and TMZ treatment has ended.  Male 
subjects shou ld practice at least one of the accepted methods of birth control during study and for at least 
6 months after ABT -414 and TMZ.  If using a condom, practice at least one other methods of birth 
control listed below  during the study and for at least 6 months after ABT -414 and TMZ:
Com bined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, 
transdermal) associated with the inhibition of ovulation, initiated at least 1 month prior to Study 
Day 1;
Progestogen -only hormonal contraception (oral, injectable, implantable) associated with inhibition of 
ovulation, initiated at least 1 month prior to Study Day 1;
Bilateral tubal occlusion/ligation;
True abstinence:  Refraining from heterosexual intercourse when this is in line with the preferred and 
usual lifestyle of the subject [periodic abstinence (e.g., calendar, ovulation, symptothermal, post -
ovulation methods) and withdraw al are not acceptable];
A vasectomized male subject or a vasectomized partner of a female subject;
Intraut erine device, IUD (females);
Intrauterine hormone -releasing system, IUS (females);
Double -barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal 
jellies or cream) unless not deemed acceptable as highly effective contracep tion by local regulations.
11. Wom en of child -bearing potential must have a negative pregnancy test (urine or serum) within 7 days 
prior to randomization.
12. Must voluntarily sign and date informed consent form, for tumor tissue biomarker testing and for study 
participation, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), 
prior to the initiation of any screening or study -specific procedures.
Main Exclusion:
1. Subject has multifocal GBM, defined as discrete sites of disease without contiguous T2/FLAIR 
abnormality that require distinct radiotherapy ports.
Note that satellite lesions that are associated w ith a contiguous area of T2/FLAIR abnormality as the 
main lesion(s) and that are encompassed within the same radiotherapy  port as the main lesion(s) are 
permitted.  For any questions, please contact the Sponsor.
2. Exclusion criteria removed in Amendment 5.
3. Subject has recurrent GBM.
4. Exclusion criteria removed in Amendment 5.
5. Subject has metastatic GBM.
6. Prior chemotherapy or radiosensitizers for cancers of the head and neck region; note that prior 
chemotherapy for a different cancer is allowable, except prior TMZ.
7. Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation 
fields.
8. Any prior therapy for glioblastoma except surgery (intra -operative techniques to guide resection are 
allow ed as are experimental imaging techniques).
9. Prior invasive malignancy (except for non -melanomatous skin cancer; carcinoma in situ of the breast, oral 
cavity, or cervix) unless disease free for ≥ 2 years.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
149Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):
Main Exclusion (Continued):
10. Prior, concomitant, or planned concomitant treatment with anti -neoplastic intent including but not limited 
to Novo Tumor Treatment Fields (Novo TTF, EGFR -targeted therapy (including EGFRvIII -directed 
therapy), bevacizumab, Gliadel w afers or other intratumo ral or intracavitary anti -neoplastic therapy, or 
other experimental therapeutics intended to treat the tumor.  Diagnostic or imaging studies, quality of life, 
biomarker or epidemiological studies; surgery and operative guides to improve extent of resection are 
allow ed.
11. Subject has had major immunologic reaction to an IgG -containing agent.
12. Subject has had LASIK (laser -assisted in situ keratomileusis) procedure w ithin the last 1 year or cataract 
surgery within the last 3 months.
13. Subject has a hist ory of hypersensitivity to TMZ or excipients, ABT -414 components or excipients, and 
dacarbazine (contraindication for TMZ).
14. Subject is unsuitable for receiving ocular steroids:
Subject has any active viral disease of the cornea or conjunctiva, including epithelial herpes simplex 
keratitis (dendritic keratitis), vaccinia, and varicella; mycobacterial infection of the eye; fungal 
diseases of ocular structures; or any other contraindication for ocular steroid use.
Subject has a known or suspected h ypersensitivity to any ocular steroid.
Subject has primary open angle glaucoma or a history of steroid -induced intraocular pressure 
elevation.
15. Subject is a lactating or pregnant female.
16. Severe, active co -morbidity, defined as follows:
Severe hepatic impairment (Child -Pugh category C or higher [score of 10 or higher (Appendix VII)]):  
Subjects with mild or moderate hepatic impairment (Child -Pugh score of 5 –9) may be eligible for 
treatment, as described in Appendix IX.
Unstable angina and/or c ongestive heart failure within the last 6 months.
Transmural myocardial infarction within the last 6 months.
Evidence of recent myocardial infarction or ischemia by the findings of S -T elevations of ≥2 mm 
using the analysis of an EKG performed within 21 d ays prior to enrollment.
New  York Heart Association grade II or greater congestive heart failure requiring hospitalization 
within 12 months prior to enrollment (Appendix IV).
History of stroke, cerebral vascular accident (CVA) or transient ischemic attack within 6 months.
Serious and inadequately controlled cardiac arrhythmia.
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of enrollment.
Chronic obstructive pulmonary disease exacerbation or other respiratory illness requir ing 
hospitalization or precluding study therapy at the time of enrollment.
Subjects with clinically defined Acquired Immune -Deficiency Syndrome (AIDS) -defining illness.  
This is necessary to ensure subjects are likely to be able to receive the full TMZ reg imen.
Active connective tissue disorders, such as lupus or scleroderma that in the opinion of the 
Investigator may put the subject at high risk for radiation toxicity.
Any other major medical illnesses or psychiatric impairments that in the Investigator's 
opinion will 
prevent administration or completion of protocol therapy.
17. Subjects treated on any other therapeutic clinical protocols within 30 days prior to study entry or during 
participation in the study except intra -operative therapy to guide resecti on or experimental imaging 
without therapeutic intent.
18. Inability to undergo contrast -enhanced MRI scans.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
150Background Therapy:
All subjects will receive standard -of-care treatment for newly diagnosed glioblastoma, per local prescribing 
information and local institutional guidelines, as background therapy.
Chemoradiation Phase:   All subjects will undergo focal radiotherapy, 60 Gy in 30 fractions (or 59.4 Gy in 
33fractions) over approximately 6 w eeks (and no more than 7 w eeks).  TMZ w ill be administered continuously 
from Day 1 of radiotherapy to the last day of radiation (including weekends and holidays) at a daily oral dose of 
75 mg/m2for a maximum of 49 days.
Adjuvant Phase:   During the Adjuvant Therapy Phase, all subjects w ill receive oral TMZ 150 – 200 mg/m2once 
daily on Days 1 –5 of each 28 -day cycle for 6 cycles unless there is disease progression, unacceptable toxicity, or 
other reasons to discontinue.  The start of th e first cycle during the Adjuvant Therapy Phase w ill be scheduled 
approximately 28 days after the last day of radiotherapy.
Investigational Product: ABT -414
Dose s: 20 mg and 100 mg vials
sterile lyophilisate to be reconstituted and further diluted for IV infusion
Mode of Adm inistration: Intravenous (IV) infusion administered over 30 to 40 minutes.
Reference Therapy: Placebo solution
Dose s: To match 20 mg and 100 mg vials
sterile lyophilisate to be reconstituted and further diluted for IV infusion
Mode of Adm inistration: Intravenous (IV) infusion administered over 30 to 40 minutes
Reference Therapy: Temozolom ide (TMZ)
Dose s: Daily Day 1 to maximum 49 days in chemoradiation phase
Daily Days 1 –5 every 28 days in adjuvant phase
Mode of Adm inistration: Oral
Duration of Treatm ent:
In the absence of treatment delays due to adverse event(s), treatment may continue as specified in the Treatment 
Plan Overvie w, Section 5.1, or until one of the fol lowing criteria applies:
The subject experiences disease progression
The subject experiences intercurrent illness that prevents further administration of treatment
The subject experiences excessive toxicity precluding further therapy with either ABT -414 or TMZ, 
according to the Investigator
Subject decides to withdraw consent for participation in the study
General or specific changes in the subject's condition render the subject unacceptable for further treatment 
in the judgment of the Investigator
Subject becomes pregnant while on study
Subjects unable to continue either TMZ or ABT -414/placebo due to excessive drug -specific toxicity will be 
allow ed to continue therapy with the other, tolerated therapy components until one of the other criteria above is 
met.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
151Criteria for Evaluation:
Efficacy:
The primary efficacy endpoint w ill be OS.
Secondary endpoints are as follow s:
PFS
OS for the MGMT unmethylated tumor subgroup
OS for the MGMT methylated tumor subgroup
Time to deterioration in symptom severity score (MDASI -BT)
Time to deterioration in symptom interference score (MDASI -BT)
Time to deterioration neurocognitive functioning on the Hopkins Verbal Learning Test -Revised 
(HVLT -R) total recall score
OSfor EGFRvIII -mutated tumor subgroup
PFS for EGFRvIII -mutat ed tumor subgroup
Safety:
Assessment of comparative safety
Tools:
Symptom Inventory:   MD Anderson Symptom Index for Brain Tumors (MDASI -BT).
Neurocognitive Functioning:   HVLT -R for verbal memory, and COWA -FAS for executive function.
Quality of Life:   European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 
(EORTC QLQ -C30) with the EORTC -QLQ -BN20 (brain tumor) module, EQ -5D-5L and EQ -5D-VAS for health 
status; National Eye Institute Visual Function Questionnaire (NEI- VFQ -25) for visual function and impact on 
daily activities.
Pharm acokinetic:
Blood samples for assay of ABT -414, total ABT -806, anti -drug antibodies (ADA), neutralizing anti -drug 
antibodies (nADA) and unconjugated cys -mcMMAF will be collected at designated t ime points throughout the 
study.
Pharm acodynamic:
Plasma and serum will be collected at designated time points throughout the study.  Tumor tissues obtained 
during biopsy or surgery will also be used for pharmacodynamic studies.
Safety:
Adverse events, l aboratory profiles, physical exams, ECGs, and vital signs will be assessed throughout the study.  
Eye examinations will be assessed at baseline and throughout the study.
Statistical Methods
Analysis Sets:
The follow ing analysis sets will used for analysis of safety and primary and secondary efficacy endpoints of the 
study:
Full Analysis Set will comprise all randomized subjects regardless of whether they received study 
treatment.  Subjects will be classified according to the treatment they were assigned at the time of 
randomization.  The Full Analysis Set will be the primary analysis set for the analysis of efficacy 
endpoints.
Safety Analysis Set (SAS) will comprise all randomized subjects w ho receive at least 1 dose of study 
treatment (either RT, TMZ, or A BT-414).  Subjects w ill be classified according to treatment received.  
Thus, a subject randomized to Arm A who receives RT + TMZ but does not receive ABT -414 w ill be 
considered in the control group (Arm B) for safety analysis.
Per-protocol Set (PPS) w ill comprise all randomized subjects excluding those with major deviation from 
study inclusion and exclusion criteria and compliance with procedures.  Subjects w ill be classified 
according to treatment assigned.  The PPS w ill be used for supportive analysis of efficacy endpoints.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
152Statistical Methods (Continued):
Efficacy Analysis:
Analysis of OS and PFS:
The primary efficacy endpoint for the study is OS and PFS is considered as one of the secondary efficacy 
endpoints.  Overall survival is defined as time from randomization to death.  For subjects who are not reported to 
have died at the time of an analysis , OS will be right -censored at the last date the subject is documented to be 
alive.  PFS is defined as time from randomization to progression of disease (per RANO criteria) or death, 
whichever occurs first.  For subjects who are not documented to have expe rienced a PFS event at the time of an 
analysis, PFS will be right -censored on the date of their last adequate radiographic assessment of disease.  To 
meet the primary and secondary objectives, OS and PFS will be compared betw een treatment arms A and B usin g 
stratified log -rank test statistics or a w eighted version of this test (to be pre- specified in the Statistical Analysis 
Plan document (the SAP), adjusting for the study stratification factors and additional independent prognostic 
factors as deemed approp riate, to be specified in the SAP.  The hazard -ratio of OS and PFS for ABT -414 Arm A 
compared to placebo Arm B will be estimated by fitting Cox -proportional hazards regression models adjusting 
for the main -effects of the stratification factors and additional independent prognostic factors as deemed 
appropriate, to be specified in the SAP.
Interim Analysis
An interim superiority and futility analysis of efficacy data will be performed when 75% (332) of the 
441required maximum number of deaths are observed.  The analysis will be performed using the Full Analysis 
Set, with all randomized cases being included in the treatment arm to which they were randomized regardless of 
what treatment the subjects actually received.  The primary endpoint of OS will be compared betw een treatment 
Arms A and B using stratified log -rank test statistics or a w eighted version, as pre-specified in the SAP, adjusting 
for the study stratification factors and additional independent prognostic factors as deemed appropriate, to be 
specified in the SAP.  The hazard -ratio of OS for ABT -414 Arm A compared to placebo Arm B w ill be estimated 
by fitting Cox -proportional hazards regression models adjusting for the main -effects of the stratification factors 
and additional independent prognostic factors as deemed appropriate, to be specified in the SAP.  Adjustment of 
the level of significance (al pha) for multiple testing will be made using the O'Brien -Fleming group sequential 
spending function for early rejection of the null hypothesis to declare superiority.  In addition, futility analysis 
will be carried at same time.  If the estimated Cox HR ex ceeds 0.90 then trial may be stopped for futility.
The unblinded interim results will first be reviewed by the IDMC, and the trial will be considered for early 
stopping if the IDMC makes such a recommendation after consideration of the OS results and all s upportive 
evidence including all secondary endpoints and safety.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
153Statistical Methods (Continued):
Sample- Size Justification:
The sample sizes are calculated based on the approach of doing the primary endpoint analyses (OS) using the 
FAS.
A total of 640 evaluable subjects are expected to be randomized.  With 441 deaths there will be 85% pow er to 
detect a 25% reduction in the hazard of death (HR = 0.75) using a log rank test at a one -sided 2.5% level of 
significance.  Median OS of 16 months is expected in the placebo arm.
Type I Error Control:
To maintain overall type I error control for the overall study, each secondary endpoint will be tested in the order 
listed if the primary endpoint (OS) and all preceding secondary endpoints show statistically signific ant results at 
the 1 -sided 0.025 level of significance.  The O'Brien -Fleming method will be implemented to protect the 
one-sided type I error of 0.025.  A nominal alpha level of 0.00969 w ill be used for the interim efficacy analysis 
for OS.  For the final analysis, the primary efficacy endpoint w ill be tested at the one -sided nominal alpha level of 
0.0221 after adjusting for the interim look at efficacy data.
Pharm acokinetic:
Peak and trough concentrations (C maxand C trough) of ABT -414 and total ABT -806 ant ibody w ill be summarized 
from the observed concentration data.  Population pharmacokinetic parameters of ABT -414, total ABT -806 and 
cys-mcMMAF such as clearance and volume of distribution will be estimated using a nonlinear mixed effect 
modeling analysis.
Safety Analysis:
AbbVie will assess adverse events, laboratory data, and vital signs throughout the study.  Analyses of adverse 
events will include only "treatment -emergent" events, i.e., those that start or w orsen on or after the day of the 
firstdose of study drug.  Adverse events severity and laboratory evaluation changes will be assessed by utilizing 
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.  
Adverse events will be summarized by preferred terms within a System and Organ Class according to the most 
current Medical Dictionary for Regulatory Activities (MedDRA) dictionary.  Changes from baseline will be 
analyzed for each scheduled post -baseline visit and for the final visit for blood chemistry and h ematology 
parameters, as well as urinalysis and vital sign parameters.  Shifts in laboratory values from baseline NCI 
CTCAE grades to maximum and final post -baseline grades will be assessed.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
154APPENDIX III ADVERSE EVENTS EXPEC TED DUE TO GBM OR PR OGRESSION 
OF GBM
Tinnitus
Diplopia
Dysphagia
Hypoaesthesia oral
Paraesthesia oral
Facial pain
Disease progression
Pyrexia
Subdural haematoma
Subdural haemorrhage
Abnorm al loss of weight
Decreased appetite
Dehydration
Anaplastic astrocytoma
Glioblastoma
Glioblastoma multiforme
Malignant glioma
Malignant neoplasm progression
Neoplasm progression
VIIth nerve paralysis
Oculofacial paralysis
Facial nerve disorder
Facial paresis
Facial neuralgia
Hypoaesthesia
Burning sensation
Paralysis
Dem entia
Dysarthria
Agnosia
Prosopagnosia
Apraxia
Hem iapraxia
Gait apraxia
Dyspraxia
Agraphia
Alexia
Cerebral haemorrhage
Cerebral haematoma
Hyperaesthesia
Ataxia
Cerebellar ataxia
Cerebral ataxia
Myoclonus
Post-anoxic myoclonus
Amnesia
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
155Ataxia
Atonic seizures
Balance disorder
Brain compression
Brain oedema
Cerebrospinal fluid retention
Cerebrospinal thrombotic tamponade
Cervicogenic headache
Clonic convulsion
Clumsiness
Cluster headache
Convulsion
Convulsions local
Coordination abnormal
Cranial nerve disorder
Cranial nerve palsies multiple
Cranial nerve paralysis
Epilepsy
Epileptic aura
Exertional headache
Fumbling
Headache
Hem ianopia
Hem iparesis
Hem iplegia
IIIrd nerve paralysis
IIIrd nerve paresis
Incoherent
Intracranial pressure increased
IVth nerve paresis
Language disorder
Lethargy
Loss of consciousness
Mem ory impairm ent
Movement disorder
Myoclonic epilepsy
Paraesthesia
Paresis cranial nerve
Partial seizures
Partial seizures with secondary generalisation
Postictal headache
Postictal state
Preictal state
Quadranopia
Sedation
Seizure like phenomena
Slow  speech
Somnolence
Speech disorder
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
156Status epilepticus
Stupor
Tension headache
Tonic clonic movements
Tonic convulsion
Tonic posturing
Tunnel vision
Typical aura without headache
Vascular headache
Vertigo CNS origin
VIIIth nerve lesion
Visual field defect
Affect lability
Agitation
Anxiety
Anxiety disorder
Anxiety disorder due to a general medical condition
Depressed mood
Distractibility
Elevated mood
Executive dysfunction
Hyposomnia
Impaired reasoning
Inappropriate affect
Initial insomnia
Insomnia
Mood altered
Mood sw ings
Incontinence
Urinary incontinence
Intracerebral haematoma evacuation
Subdural haematoma evacuation
Drain of cerebral subdural space
Deep vein thrombosis
Thrombosis
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
157APPENDIX IV NEW YORK HEART ASSOCIATION F UNCTIONAL 
CLASSIFICATION
The NYHA classifies heart failure into classes based on functional limitations and severit y
Class Patient Symptoms
Class I
(Normal)Few observable s ymptoms, no limitation in ordinary  physical activity .
Class II
(Mild)Mild observable s ymptoms and slight limitation during ordinary  activity .  
Comfortable at rest.
Class III
(Moderate)Marked limitation in physical activity  due to sy mptoms even during 
less-than- ordinary  activity .  Comfortable onl y at rest.
Class I V
(Severe)End- stage heart failure.  Severe limitations.  Experience s ymptoms even 
while at rest.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
158APPENDIX V RESPONSIB ILITIES OF THE CLINI CAL INVESTIGATOR
Clinical research studies sponsored by  AbbVie are subject to the Good Clinical Practices (GCP) 
and local regulations and guidelines governing the study  at the site location. In signing the 
Investigator Agreement in Section 19.0 of this protocol, the Investigator is agreeing to the 
following:
1. Conducting the stud y in accordance with the relevant, current protocol, making changes in 
a protocol only  after notify ing AbbVie, except when necessary  to protect the safet y, rights 
or welfare of subjects.
2. Personally  conducting or supervising the described investigation(s).
3. Informing all subjects, or persons used as controls, that the drugs are being used for 
investigational purpo ses and comply ing with the requirements relating to informed 
consent and ethics committees [e.g., independent ethics committee (IEC) or institutional 
review board (IRB)] review and approval of the protocol and amendments.
4. Reporting adverse experiences t hat occur in the course of the investigation(s) to AbbVie 
and the site director.
5. Reading the information in the I nvestigator's Brochure/safet y material provided, including 
the instructions for use and the potential risks and side effects of the investig ational 
product(s).
6. Informing all associates, colleagues, and employ ees assisting in the conduct of the study  
about their obligations in meeting the above commitments.
7. Maintaining adequate and accurate records of the conduct of the study , making thos e 
records available for inspection by  representatives of AbbVie and/or the appropriate 
regulatory  agency , and retaining all study -related documents until notification from 
AbbVie.
8. Maintaining records demonstrating that an ethics committee reviewed and approved the 
initial clinical investigation and all amendments.
9. Reporting promptl y, all changes in the research activity and all unanticipated problems 
involving risks to human subjects or others, to the appropriate individuals 
(e.g., Coordinating Invest igator, Institution Director) and/or directl y to the ethics 
committees and AbbVie.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
15910. Following the protocol and not make any changes in the research without ethics 
committee approval, except where necessary  to eliminate apparent immediate hazards to 
huma n subjects.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
160APPENDIX VI RPA CLAS SIFICATION CRITERIA
RPA Class Criteria
Class III Age < 50 and KPS 90 – 100
Class I V Age < 50 and KPS < 90:  OR age ≥ 50 and KPS 70 – 100 and 
partially  or total resected with no worse than minor neurofunction 
impairment
Class V Age ≥ 50 and KPS 70 – 100 and underwent prior partial or total 
tumor resection with worse than minor neurofunction impairment:  
OR age ≥ 50 and KPS 70 – 100 and underwent prior tumor biopsy  
only
If a subject has a repeat surgery  prior to randomiz ation, the extent of surgical resection after the 
repeat surgery  (biops y-only vs. partial/total resection) will be used for determining RPA class.
 
   
   
 
 
    
      
       
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
161APPENDIX VII CHILD -PUGH SCORE
Param eterPoints Assigned for Observed Findings
1 2 3
Total bilirubin, µmol/L (mg/dL) < 34.2
(< 2)34.2 –51.3
(2 –3)> 51.3
(> 3)
Serum albumin, g/L (g/dL) > 35
(> 3.5)28 –35
(2.8 –3.5)< 28
(< 2.8)
INR < 1.7 1.7 –2.3 > 2.3
Ascites None Slight Moderate to severe
Hepatic encephalopathy* None Grade 1 or 2
(or suppressed w ith 
medication)Grade 3 or 4
(or refractory)
* Grade 0:  normal consciousness, personality, neurological examination, electroencephalogram.
Grade 1:  restless, sleep disturbed, irritable/agitated, tremor, impaired handwriting, 5 cps waves.
Grade 2:  lethargic, time -disoriented, inappropriate behavior, asterixis, ataxia, slow triphasic waves.
Grade 3:  somnolent, stuporous, place-disoriented, hyperactive reflexes, rigidity, slower waves.
Grade 4:  unarousable coma, no personality/behavior, d ecerebrate, slow 2 to 3 cps delta activity.
The Child -Pugh classification is defined in terms of the sum of the scores for the five parameters, as shown in Appendix VII.
 A score of 5 or 6 indicates Child -Pugh Category A (mild hepatic impairment).
 A score of 7, 8, or 9 indicates Child -Pugh Category B (moderate hepatic impairment).
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
162APPENDIX VIII LIST OF ABBREVIATIONS AND DEFINITION OF TERMS
Abbreviations
ADC Antibody Drug Conjugate
AE Adverse Event
ALT Alanine Aminotransferase
ANC Absolute Neutrophil Co unt
aPTT Activated Partial Thromboplastin Time
AST Aspartate Aminotransferase
BSA Body  Surface Area
BUN Blood Urea Nitrogen
CBC Com plete Blood Count
CTB Clinical Trial Battery
CNS Central Nervous System
COWA Controlled Oral Word Association
CR Com plete Response
CT Com puterized tomography
CUSA Cavetron Ultrasonic Aspirator
D Day
Depatux -M Depatuxizumab Mafodotin (ABT -414)
DICOM Digital Imaging and Communications in Medicine
DLT Dose Limiting Toxicities
DNA Deoxyribonucleic acid
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
EDC Electronic Data Capture
eCRFs Electronic Case Report Forms
EGFR Epidermal Growth Factor Receptor
EORTC European Organization for Research and Treatment of Cancer
EORTC QLQ European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire
EQ-5D EuroQol 5 Dimensions
EQ-5D-VAS EuroQol 5 Dimensions Value Sets
EU European Union
FAS Full Analysis Set
FFPE Form alin-fixed Paraffin Embedded
FLAIR Fluid Attenuated Inversion Recovery
GBM Glioblastoma
GCP Good Clinical Practice
GGT Gamma -glutamyl transferase
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
163GTT Eye drop(s)
Gy Gray
Hgb Hem oglobin
HRQoL Health Related Quality of Life
HVLT -R Hopkins Verbal Learning Test -Revised
ICH International Conference on Harm onization
IDMC Independent Data Monitoring Committee
IEC Independent Ethics Committee
IGRT Image-guided Radiation Therapy
IMRT Intensity -modulated Radiation Therapy
IMP Investigational Medicinal Product
INR International Normalized Ratio 
IRB Institutional Review Board
IRT Interactive Response Technology
IV Intravenous
K2EDTA Potassium Edetic acid (ethylenediaminetetraacetic acid)
KPS Karnofsky Performance Status
LDH Lactate Dehydrogenase
mAbs monoclonal antibodies
MCV Mean Corpuscular Volume
MDASI -BT M.D. Anderson Symptom Inventory Brain Tumor Module
MedDRA Medical Dictionary for Regulatory Activities
MGMT O6-methylguaninemethlytransferese
MMAF monomethylauristatin F
MRI Magnetic Resonance Imaging
MTD Maximum Tolerated Dose
MV Megavoltage
NCIC National Cancer Institute of Canada
NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events
NEI-VFQ -25 National Eye Institute Visual Functioning Questionnaire –25
NOVOTTF NovoTumor Treatment Fields
OU Each Eye
OS Overall Survival
PCP Pneumocystis jirovecii pneumonia
PD Progressive Disease
PE Physical Exam
PFS Progression -Free Survival
PG Pharm acogenetic
PK Pharm acokinetics
PPS Per-protocol Set
PRO Patient -Reported Outcomes
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
164PR Partial Response
PT Prothrombin Time
RANO Response Assessment in Neuro Oncology
RT Radiation Therapy
RBC Red Blood Cell Count
RPA Recursive Partitioning Analysis
RTOG Radiation Therapy Oncology Group 
SAD Source Axis Distance
SAE Serious Adverse Event
SAP Statistical Analysis Plan
SAS Safety Analysis Set
SD Stable Disease
SGPT Serum glutamic -pyruvic transaminase
SGOT Serum glutamic -oxaloacetic transaminase 
SmPC Summary of Product Characteristics
SOC Standard of Care
SUSAR Suspected Unexpected Serious Adverse Reactions
SSD Source Skin Distance
TOE Targeted Ophthalmologic Examination
TPS Treatment Planning System
TMZ Temozolom ide
TRIAD Transmission of Imaging and Data
ULN Upper Limits of Normal
VMAT Volumetric Arc Therapy
WBC White Blood Cell Count
5-HT3 5-hydroxytryptamine3
Pharmacokinetic and Statistical Abbreviations
Cmax Maximum observed plasma concentration
Cmin Minimum observed plasma concentration
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
165APPENDIX IX. SUBJECT S WITH MILD TO MODER ATE HEPATIC IMPAIRME NT
This appendix outlines the ABT -414 sub- study  in subjects with hepatic impairment.  The revised 
schedule of assessments for the hepatic impairment sub- study  is provided in Table 3H below.
Sub-Study Objective
To assess the pharmacokinetics, safet y and tolerability  of ABT -414 in subjects with newly  
diagnosed EGFR- amplified GBM who have mild or moderate hepatic impairment.
Overview
This is a Phase 1, open- label, multicenter sub -study .  Approximately  6 subjects with mild hepatic 
impairment and 6 subjects with moderate hepatic impairment w ill be enrolled if they  meet all 
inclusion criteria and do not meet an y of the exclusion criteria.
All subjects with hepatic impairment will be assigned to active treatment with ABT -414 during 
the Chemoradiation and Adjuvant Phases of treatment.  Radiation therap y and TMZ therap y will 
be administered to hepatically  impaired subjects the same way  as those with normal hepatic 
function.  The pharmacokinetics of TMZ in patients with mild -to-moderate hepatic impairment 
have been shown to be similar to those obse rved in normal hepatic function.  Caution should 
only be exercised when TMZ is administered to patients with severe hepatic impairment.  The 
visit schedule and study procedures will be the same as for other study  subjects unless described 
otherwise in this appendix.
After meeting the selection criteria for subjects with hepatic impairment, as shown below, 
approximately  6 subjects will be assigned to each of the two cohorts according to their hepatic 
function as shown in Table 1H.  Within each cohort, the fi rst 3 subjects will be assigned to dose 
level 1.  If the dose level 1 was tolerated, the subsequent subjects may  be assigned to dose 
level 2.
Table 1H. Cohorts of Subjects with Hepatic Impairment and Treatment
CohortsHepatic 
Function Dose LevelChemoradia tion 
PhaseAdjuvant Phase
(Cycles 1 –2)Maintenance Phase
(Cycle 3 and After)
A Child- Pugh A 1a 1.0 mg/kg 1.0 mg/kg 1.0 mg/kg
2 2.0 mg/kg 1.25 mg/kg 1.25 mg/kg
B Child- Pugh B 1b 1.0 mg/kg 0.5 mg/kg 1.0 mg/kg
2 2.0 mg/kg 1.25 mg/kg 1.25 mg/kg
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
166Forsubjects with hepatic impairment, pharmacokinetic assay s will be performed as samples are 
received on an ongoing basis to inform dose selection for subsequent subjects throughout the 
study .  Prior to proceeding with dose level 2 in each cohort, safet y dat a and pharmacokinetic data 
for the subjects at dose level 1 within that cohort will be assessed b y the sponsor and the 
Neuro -Medical Oncology  Chair.  The doses to be given for dose level 2 in each cohort may  be 
reduced if indicated b y safety and/or pharmac okinetic data from prior subjects.
Selection Criteria
Because reducing variability  for efficacy  evaluations is not necessary  for the pharmacokinetic 
and safet y objectives for these cohorts, eligibility  criteria are onl y restricted to those ensuring the 
subject has EGFR- amplified GBM and those to ensure safety  for subjects taking ABT- 414 and 
ocular steroids.
Inclusion Criteria
A subject cannot be considered eligible for this study unless ALL of the following 
conditions are met.
Subjects may  only be randomized if the additional criteria below are met:
1. Histologicall y confirmed de novo Grade IV glioma (GBM, gliosarcoma or other 
subvariants) confirmed by  central pathology  tissue screening.
2. EGFR amplification in tumor tissue confirmed b y central assessmen t.
3. Not applicable to this substudy.
4. The subject must have recovered from the effects of surgery , post -operative infection, 
and other complications before enrollment including, suture/staple removal from brain 
surgery  and sufficient wound healing before reg istration.
5. ≥ 18 y ears of age.
6. Not applicable to this substudy.
7. Not applicable to this substudy.
8. Subject has adequate bone marrow and renal function ≤ 21 day s prior to randomization 
and has mild- to-moderate hepatic impairment as follows:
a. Absolute neutrophil count (ANC) ≥ 1,500/mm3;
b. Platelets ≥ 100,000/mm3;
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
167c. Hemoglobin (Hgb) ≥ 9.0 g/dL (Note:  The use of transfusion or other intervention to 
achieve Hgb ≥ 9.0 g/dL is acceptable.);
d. Renal function:  calculated creatinine clearance ≥ 30 mL /min by  the Cockcroft -Gault 
formula;
e. Hepatic function (for subjects participating in the hepatic impairment 
sub-study only): The subject has chronic liver disease and/or cirrhosis documented 
by the presence of at least 1 of the following:
Liver biopsy  with histologic findings cons istent with cirrhosis
Computerized tomographic or ultrasonographic evidence of liver disease
Physical examination, clinical or laboratory  evidence of chronic liver disease
Colloid shift on a liver -spleen scan
And the subject has mild -to-moderate hepatic im pairment, including Category A 
(score of 5 or 6) and Category B (score of 7, 8, or 9) impairment according to the 
Child -Pugh classification (see Table 2H for scoring), with no clinical history of 
liver decompensation based on clinical laboratory values and clinical findings 
assessed within 14 days prior to the start of Chemoradiation.
Patients with biliary  obstruction for which a shunt has been placed are eligible, 
provided the shunt has been in place for at least 10 day s prior to the first dose of 
the stud y drug and the liver function has stabilized.  Two measurements at least 2 
days apart that put the patient in the same hepatic dy sfunction stratum will be 
accepted as evidence of stable hepatic function.  There should be no evidence of 
biliary  sepsis.  Ele ctrocardiogram (ECG) without evidence of acute cardiac 
ischemia ≤ 21 day s prior to randomization. 
9. Female subjects of childbearing potential (i.e., those who are not postmenopausal for at 
least 1 y ear or surgicall y sterile by  bilateral salpingectomy , bilat eral oophorectom y or 
hysterectom y) and their male partners should practice at least one accepted method of 
birth control listed below during stud y entr y, for the entire duration of the study  and for at 
least 6 months after treatment with ABT- 414 and TMZ tr eatment has ended.  Male 
subjects and their female partners of childbearing potential should practice at least one of 
the accepted methods of birth control during study and for at least 6 months after 
ABT -414 and TMZ.  In addition to the use of a condom, m ale subjects and their female 
partners of childbearing potential should practice at least one of the methods of birth 
control listed below during the stud y and for at least 6 months after ABT -414 and TMZ:
Total abstinence from sexual intercourse beginning at least one complete menstrual 
cycle prior to study  drug administration (of note:  sexual abstinence as a method of 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
168contraception should be limited to those cases where it is alread y established as the 
pre-existing lifest yle choice of the subject);
A vase ctomized male subject or a vasectomized partner of a female subject;
Hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months prior 
to study  drug administration;
Intrauterine device (females);
Double-barrier method (condoms, contrace ptive sponge, diaphragm or vaginal ring 
with spermicidal jellies or cream) unless not deemed acceptable as highl y effective 
contraception by  local regulations.
10. Women of child- bearing potential must have a negative pregnancy  test (urine or serum) 
within 7 days prior to randomization.
11. Must voluntarily  sign and date informed consent form, for tumor tissue biomarker testing 
and for stud y participation, approved b y an Independent Ethics Committee (IEC)/ 
Institutional Review Board (IRB), prior to the initiation of an y screening or 
study -specific procedures.
Exclusion Criteria
Subjects with one or more of the following conditions are NOT eligible for this study.
Randomization Criteria
1. Not applicable to this substudy.
2. Not applicable to this substudy.
3. Subject has recurrent GBM.
4. Not applicable to this substudy.
5. Subject has metastatic GBM.
6. Prior chemotherap y or radiosensitizers for cancers of the head and neck region; note that 
prior chemotherap y for a different cancer is allowable, except prior temozolomide.
7. Prior r adiotherap y to the head or neck (except for T1 glottic cancer), resulting in overlap 
of radiation fields.
8. Any prior therapy  for glioblastoma (intra -operative techniques to guide resection are 
allowed as are experimental imaging techniques).
9. Prior invasive malignancy  (except for non -melanomatous skin cancer; carcinoma in situ 
of the breast, oral cavity , or cervix) unless disease free for ≥ 2 y ears.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
16910. Prior, concomitant, or planned concomitant treatment with NovoTumor Treatment Fields 
(Novo TTF), EGFR- targeted therap y (including EGFRvIII -directed therapy), 
bevacizumab, Gliadel wafers or other intratumoral or intracavitary  anti-neoplastic 
therap y, or other experimental therapeutics intended to treat the tumor; the exceptions are 
diagnostic or imaging studies, qua lity of life, biomarker or epidemiological studies; and 
operative guides to improve extent of resection.
11. Subject has had major immunologic reaction to an IgG -containing agent.
12. Subject has had LASIK (laser -assisted in situ keratomileusis) procedure within t he last 
1year or cataract surgery within the last 3 months.
13. Subject has a history  of hy persensitivity  to TMZ or excipients, ABT -414 components or 
excipients, and dacarbazine (contraindication for TMZ).
14. Subject is unsuitable for receiving ocular steroids:
Subject has an y active viral disease of the cornea or conjunctiva, including epithelial 
herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella; my cobacterial 
infection of the ey e; fungal diseases of ocular structures; or any  other contrain dication 
for ocular steroid use.
Subject has a known or suspected h ypersensitivity to any ocular steroid.
Subject has primary  open angle glaucoma or a history of steroid -induced intraocular 
pressure elevation.
15. Subject is a lactating or pregnant female.
16. Severe, active co -morbidity , defined as follows:
Subject has severe hepatic impairment (Child -Pugh score of 10 or higher; see 
Table 2H)
Unstable angina and/or congestive heart failure within the last 6 months;
Transmural m yocardial infarction within t he last 6 months;
Evidence of recent my ocardial infarction or ischemia by  the findings of 
S-Televations of ≥ 2 mm using the anal ysis of an EKG performed within 14 days 
prior to enrollment;
New York Heart Association grade II or greater congestive heart fa ilure requiring 
hospitalization within 12 months prior to enrollment (Appendix I V);
History  of stroke, cerebral vascular accident (CVA) or transient ischemic attack 
within 6 months;
Serious and inadequately controlled cardiac arrh ythmia;
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
170Acute bacterial or fungal infection requiring intravenous antibiotics at the time of 
enrollment;
Chronic obstructive pulmonary  disease exacerbation or other respiratory  illness 
requiring hospitalization or precluding stud y therapy  at the time of enrollment;
Subjects with cl inically  defined Acquired Immune- Deficiency  Syndrome 
(AIDS) -defining illness.  This is necessary  to ensure subjects are likel y to be able to 
receive the full TMZ regimen;
Active connective tissue disorders, such as lupus or scleroderma, that in the opinion
of the Investigator may  put the subject at high risk for radiation toxicity ;
Any other major medical illnesses or psychiatric impairments that in the I nvestigator's 
opinion will prevent administration or completion of protocol therap y;
17. Subjects treate d on an y other therapeutic clinical protocols within 30 days prior to study 
entry  or during participation in the study except intra -operative therapy  to guide resection 
or experimental imaging without therapeutic intent.
18. Inability  to undergo contrast -enhanced MRI scans.
Criteria for Cohort Assessment
The Child- Pugh classification presented in Table 2H will be used to categorize the degree of 
hepatic impairment for assignment into the mild and moderate hepatic impairment groups.
Table 2H. Child -Pugh Scale for the Assessment of Hepatic Impairment
Param eterPoints Assigned for Observed Findings
1 2 3
Total bilirubin, µmol/L (mg/dL) < 34.2
(< 2)34.2 –51.3
(2 –3)> 51.3
(> 3)
Serum albumin, g/L (g/dL) > 35
(> 3.5)28 –35
(2.8 –3.5)< 28
(< 2.8)
INR < 1.7 1.7 –2.3 > 2.3
Ascites None Slight Moderate to severe
Hepatic encephalopathy* None Grade 1 or 2
(or suppressed w ith 
medication)Grade 3 or 4
(or refractory)
* Grade 0:  normal consciousness, personality, neurological examination, electroencephal ogram
Grade 1:  restless, sleep disturbed, irritable/agitated, tremor, impaired handwriting, 5 cps waves
Grade 2:  lethargic, time -disoriented, inappropriate behavior, asterixis, ataxia, slow triphasic waves
Grade 3:  somnolent, stuporous, place -disoriented, hyperactive reflexes, rigidity, slower waves
Grade 4:  unarousable coma, no personality/behavior, decerebrate, slow 2 to 3 cps delta activity
The Child -Pugh classification is defined in terms of the sum of the scores for the five paramet ers, as shown in Table 2H.
 A score of 5 or 6 indicates Child -Pugh Category A (mild hepatic impairment).
 A score of 7, 8, or 9 indicates Child-Pugh Category B (moderate hepatic impairment).
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
171Table 3H. Tables of Activities for Hepatic Sub Study
Tabl e 1.  Study Activities –
Chemoradiation Phase ScreeningaChemoradiation Phaseb
Activity Screening 1 Screening 2Day 1 Wk 1 
(Fraction 1 
of RT)Day 1 of 
Wk 2Day 1 of 
Wk 3Day 1 of 
Wk 4Day 1 of 
Wk 5Day 1 of 
Wk 6Day 1 of 
Wk 7
Informed Consent X
Medical and Oncologic History X
Physical Exam (Including Weight and 
Karnofsky Performance Status)cX X X X
Vital Signs X X X X
Ophthalmology Exam X XdXd
ECGeX
Serum Pregnancy Test X Xf
Chemistry X X X X X X X X
Hematology X X X X X X X X
Urinalysis X
Coagulation X
MRI With and Without Contrast Xk
Submit Tissue Sample for Confirmation of 
GBM, testing of EGFR amplification, 
EGFRvIII and MGMTX
Adverse Event Assessment/Concomitant 
Medications/Supportive CareX X X
Radiation TherapygX
Temozolomide Administration Xh
ABT-414 or Placebo Administration X X X
Prophylactic Eye Drop Administration XiXiXi
Enrollment X
Wk= Week; F/U = Follow -up; RT= Radiation Therapy; KPS = Karnofsky Performance Status
a. Screening procedures may be conducted before or after results of EGFR amplification are received.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
172b. Chemoradiation Phase will be approximately 6 weeks (up to 7 weeks) o f treatment with RT, TMZ, and ABT-414.
c. Height will be assessed at Screening only.  Weight will be collected at all visits.  Complete physical examination will be pe rformed at Screening only.  Symptom directed physical 
examination will be performed at al l other designated visits as clinically indicated.
d. Ophthalmology exams are to be performed 7 to 14 days after the 2ndand 3rdinfusions of ABT -414/placebo and must be completed prior to the next infusion of ABT -414/placebo.
e. ECG will be performed at s creening, final visit and when clinically indicated.
f. For female subjects of childbearing potential, a serum pregnancy test will be performed within 21 days before Day 1 of chemor adiation.  A urine or serum pregnancy test will be 
done on Day 1 Week 1 if a serum pregnancy test was performed more than 7 days before Day 1.
g. During Chemoradiation Phase, radiation therapy will begin on Day 1, Week 1 (Fraction 1).  60 Gy will be administered in ~30 fractions over 6 weeks (up to 49 days) per the local 
prescribing information or local institutional guidelines.
h. During Chemoradiation Phase, temozolomide (75 mg/m2) will be given once per day, continuously (including weekend s), from Day 1, Week 1 until completion of radiotherapy 
(up to 49 days).
i. Prophylactic eye drops will be administered for 7 days, from 2 days before until 4 days after, each dose of study drug (ABT -414 or placebo), as described in Section 5.5.
j. Baseline measure can be done at any time during Screening, up to and including Day 1 of Chemoradiation Phase, but preferably after EGFR amplification has been confirmed.  
The assessments will be translated into the local languages.
k. A brain MRI scan with and without contrast, performed at any time after diagnostic biopsy/resection but prior to randomization, is required to serv e as a baseline scan for RANO 
tumor response assessments.  If a subject starts chemoradiation more than 28 days after surgery, the baseline MRI is to be performed no more than 21 (but preferably fewer) days 
prior to Day 1 Week 1 of Chemoradiation Phase and should allow sufficient time to revise the radiation therapy plan if needed due to a significant change in tumor since surgery.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
173Table 2.  Study Activities –Adjuvant 
Phase Adjuvant Phase –28-Day Cyclesa
ActivityDay 1 of 
Every 
Cycle 
(1, 2, 3 
etc.)Day 1 of 
Odd -
Numbered 
Cycles 
(1, 3, 5, 
etc.)Day 1 
of 
Cycle 2Day 15 
of 
Every 
CyclebDay 22 
of 
Every 
CyclecFinal 
Study 
Drug 
Visitd35 
Day 
F/Ue49 Day 
F/UFollow -Up 
Phase (Every 
8Weeks 
Until Disease 
Progression)fAt 
Progression Survival
Physical Exam (Including Weight and 
Karnofsky Performance Status)gX X XdX X
Vital Signs X X X X
Ophthalmology ExamhX X Xi
ECG X
Chemistry X X X
Hematology X X X X
MRI and Clinical Disease Progression 
AssessmentXjXd,kXj
Adverse Event Assessment/Concomitant 
Medications/Supportive CareX X X X Xp
Temozolomide Administration Xl
ABT-414 or Placebo Administration XmXm
Prophylactic Eye Drop Administration XnXn
Survival AssessmentoX
Wk = Week; F/U = Follow -up; RT = Radiation Therapy; KPS = Karnofsky Performance Status; EORTC -QLQ -C30/BN20 = EORTC Quality of Life Questionnaire, Cancer and Brain 
modules; MDASI -BT = MD Anderson Symptom Index for Brain Tumors; NEI VFQ -25 = National Eye Institute Visual Functioning Questionnaire – 25; 
HVLT -R = Hopkins Verbal Learning Test -Revised; COWA = Controlled Oral Word Association (FAS form); EQ -5D-5L = EuroQoL 5 Dimensions; VAS = Visual Analog Scale
a. Assessments in the Adjuvant Phase will be based on 28 -day treatment cycles, with the first cycle starting approxima tely 4 weeks after completion of radiation therapy.  Subjects 
will receive concomitant TMZ and study drug (placebo or ABT-414) for the first 6 cycles,and study drug monotherapy for an additional 6 cycles or until disease progression or 
study drug discontin uation.  Subjects demonstrating continued benefit and no unacceptable toxicity from adjuvant TMZ can continue adjuvant TMZ to a maximum of 12 cycles at 
the discretion of the Investigator if this is considered an acceptable standard of care per local regula tions.  For subjects demonstrating continued benefit and no unacceptable 
toxicity with ABT -414/placebo after 12 cycles, the Adjuvant Phase may be extended at the discretion of the Investigator in discussion with the Neuro -Medical Oncology Chair or 
AbbVie M edical Monitor, with continued ABT -414/placebo treatment until disease progression is confirmed.
b. Day 15 visit will not be performed after discontinuation of study drug (ABT -414/placebo) treatment.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
174c. As per TMZ prescribing information, during the 28-day cycle of TMZ, a blood count for ANC and platelets should be performed 21 days (± 2 days) after the start of each TMZ 
cycle.  If the ANC falls below 1,500/µL or if the platelet count falls below 100,000/mm3, then blood counts should be performed weekly unt il recovery to these levels before 
TMZ dosing. A certified local lab may be used instead of central lab; if so, ANC and platelet results should be reported in t he eCRF.  Day 22 testing may be omitted for cycles in 
which TMZ is not administered or if local prescribing information allows for a different testing schedule for ANC and platelets.
d. Final Study Drug Visit to be performed approximately 14 days after last dose of ABT -414/placebo.  The physical examination and MR imaging from the first visit of the 
Follow -Up Phase will be used for the Final Study Drug Visit if these visits coincide (e.g., if the subject completes 12 cycles of Ad juvant Phase).
e. To be performed 35 days (± 3 days) after the last dose of study drug (placebo or ABT -414).  If the Final S tudy Drug Visit is more than 35/49 days after the last dose of study 
drug, then 35 -day safety follow -up procedures will not be performed.
f. Visits in Follow -Up Phase to occur every 8 weeks, beginning 8 weeks after Day 1 of the last odd -numbered cycle in t he Adjuvant Phase.
g. Height will be assessed at Screening only.  Weight will be collected at all visits.  Complete physical examination will be pe rformed at Screening only.  Symptom directed physical 
examination will be performed at all other designated visits as clinically indicated.
h. Ophthalmology exam to be performed prior to ABT -414/placebo dosing on Day 1 (or up to 7 days prior to Day 1) of Cycle 1, Cycle 2, and every odd -numbered cycle thereafter 
(Cycles 3, 5, 7, etc.).  Ophthalmology exam for Cycl e 1 Day 1 may be omitted if the subject had no corneal microcysts or ocular adverse events during or after the 
Chemoradiation Phase.  Ophthalmology exams may be discontinued if the subject has been on Level 1 eye drops with no ocular to xicity for 2 consecu tive eye exams.
i. Ophthalmology exam at Day 35 Follow -Up Visit to be done only if subject had corneal microcysts or other ocular findings related to ABT -414 or ocular steroids on previous 
exam and repeated at least every 8 weeks until satisfactory resolution of eye toxicities.
j. MRI to be performed ≤ 14 days before the start of each odd -numbered cycle or follow -up visit, starting at Cycle 1.  If the subject discontinues study drug prior to disease 
progression, MRIs should continue to be obtained ap proximately every 8 weeks until disease progression is confirmed.
k. MRI to be performed, if not performed within last 3 weeks, if subject withdraws from study prior to disease progression.
l. TMZ will be administered once daily on Days 1 through 5 of each 28-day cycle for 6 cycles per the local prescribing information.
m. ABT
-414 or placebo infusion will be administered on Day 1 and Day 15 of each 28 -day cycle for 12 cycles.  For subjects demonstrating continued benefit and no unacceptable 
toxicity with AB T-414/placebo after 12 cycles, the Adjuvant Phase may be extended at the discretion of the Investigator in discussion with the Neuro -Medical Oncology Chair or 
AbbVie Medical Monitor, with continued ABT -414/placebo treatment until disease progression is con firmed.
n. Prophylactic eye drops will be administered daily for 7 days with each dose of ABT -414/placebo, from 2 days before until 4 days after each dose of study drug (ABT -414 or 
placebo), as described in Section 5.5.
o. Survival will be assessed quarterly after treatment discontinuation until death.
p. If the subject is unable to return to the site for the Day 49 Follow -Up Visit, a phone call may be conducted to obtain AE and concomitant medication information.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
175Pharmacokinetic Evaluation
For all subjects in this sub -study , blood samples for PK and immunogenicity  evaluation will be 
collected according to the schedule described in Table 4H.  PK samples should be processed 
according to the guidelines in Section 4.2 and the laboratory  manua l.
Values for the pharmacokinetic parameters of ABT- 414, Total ABT -806 and cy s -mcMMAF, 
including the maximum observed plasma concentration (C max), the time to C max(peak time, 
Tmax), the terminal phase elimination rate constant and the area under the plasm a concentration 
time curve (AUC) from time 0 to the time of the last measurable concentration (AUC t) and from 
time 0 to infinite time (AUC ∞), will be determined using noncompartmental methods.  
Confirmed positive ADA results will be reported in Titer units .  Additional parameters may  be 
calculated if useful in the interpretation of the data.
Plasma or serum concentrations and pharmacokinetic parameter values of each anal yte will be 
tabulated for each subject and each dose level, and summary  statistics will be computed for each 
sampling time and each parameter b y hepatic impairment category.
An anal ysis of covariance (ANCOVA) will be performed for dose- normalized AUC tand C max.  
The factor of primary  interest is hepatic function category .  Body  weight, sex, a ge and other 
variables will be considered as possible covariates.  Covariates such as age, gender, and perhaps 
others that might explain some of the variabilit y in the population will be included in the model 
initially .  However, a covariate may  be dropped from the model if the regression coefficient is 
not significant at level 0.10.  The natural logarithmic transformation will be employed for AUC 
and C maxunless the data clearl y indicate that other transformation or the untransformed variable 
provides more nearl y symmetric probability distributions and/or more nearly homogenous 
variances across dose levels.  Additional analy ses will be performed if useful and appropriate.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
176Table 4H. Schedule of Pharmacokinetic Sampling for Subjects with Hepatic 
Impairment
Chemoradiation Phase
ActivityDay 1 Wk 1 
(Fraction 1 of 
RT)Day 2 of
Wk 1Day 3 of
Wk 1Day 5 of
Wk 1Day 1 of
Wk 2Day 1 of 
Wk 3Day 1 of 
Wk 5
PK –
ABT-414 
and Total 
ABT-806 
Assays0 hour (pre -dose),  
0.5 hour 
(immediately after 
infusion), and 4 
hour after start of 
infusionSample at 
24-hour 
post-
dose
(within 
± 4hour)Sample at 
48-hour 
post-dose
(within 
± 4hour)Sample at 
96-hour 
post-
dose
(within 
± 4hour)Sample at 
168-hour 
post-dose
(within 
± 4hour)0 hour 
(pre-dose) 
and within 
30min 
post-dose0 hour 
(pre-dose) and 
within 30 min 
post-dose
PK –Cys-
mcMMAF 
assay0 hour (pre -dose), 
0.5 hour 
(immediately after 
infusion), and 4 
hour after start of 
infusionSample at 
24-hour 
post-
dose
(within ±
4hour)Sample at 
48-hour post -
dose
(within ±
4hour)Sample at 
96-hour post -
dose
(within ±
4hour)Sample at 
168- hour 
post-dose
(within ±
4hour)0 hour 
(pre-dose) 
and within 
30min 
post-dose0 hour 
(pre-dose) and 
within 30 min 
post-dose
PK –
Antidrug 
Antibody0 hour (pre -dose) 0 hour 
(pre-dose)0 hour 
(pre-dose)
Adjuvant Phase 
–28-day Cycles
Activity Day 1 of Cycle 1Day 1 of Cycles 2 –12 
(Every Cycle)
PK –
ABT-414 and 
Total 
ABT-806 
Assays0 hour (pre -dose) and within 
30min post -dose on Day 1 of 
Cycle 10 hour (pre -dose)
PK –Antidrug 
Antibody0 hour (pre -dose) 0 hour (pre -dose)
Radiation Therapy and Temozolomide Administration
Radiation therap y and temozolomide therapy will be administered as described in the main 
protocol.
ABT -414 Administration
At the Screening Visit, all subjects will be assigned a unique subject number that will indicate 
the subject is enrolling into the open label hepatic impairment sub -study .  The subjects in this 
sub-study  will be stratified by  their Child -Pugh scores (mild or moderate impairment) as 
described in Table 2H.
Subjects will receive ABT- 414 by  IV infusion over 30 – 40 minutes once every  2 weeks during 
the Chemoradiation Phase (on Day  1 of Weeks 1, 3, and 5 of the 6- week regimen) and during the 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
177Adjuvant Phase (on Day  1 and Day  15 of each 28- day cycle for 12 cy cles).  If, after completing 
12 cy cles of ABT -414 in the Adjuvant Phase, the subject is tolerating the drug and the 
Investigator be lieves the subject is continuing to benefit from ongoing ABT- 414 treatment, the 
Adjuvant Phase may  be extended following consultation with the Neuro- Medical Oncology  
Chair.  ABT -414 will continue according to the same dosing schedule at the discretion of t he 
Investigator as long as disease progression has not been determined.
The mg/kg dose for each dose will be as described in Table 1H.  The mg/kg dose will be 
determined from the weight on Day  1 of the Chemoradiation Phase and need not change during 
subsequent treatment unless there is a weight change b y more than 10% from baseline.  
Recalculation of dose for < 10% weight changes is allowed at the discretion of the Investigator.  
There will be no cap on the weight of the subject or on the number of milligra ms administered 
for overweight subjects.
If TMZ treatment is discontinued due to intolerance during either the Chemoradiation Phase or 
Adjuvant Phase, subjects will continue receiving ABT -414 infusions according to the same study  
schedule.
ABT -414 Toxicity Management and Individual Subject Dose Modifications
Subjects will be closely  monitored for treatment -related adverse events during all infusions.  For 
the initial ABT -414 infusion, pre infusion vital signs should be taken and direct observation is 
requir ed for the first 15 minutes of the infusion.  Also for the initial ABT -414 infusion, subjects 
must remain at the site for monitoring for 60 minutes post-infusion.  For subsequent infusions, 
post-infusion monitoring is not required; however, pre- infusion vital signs should still be taken.  
Longer observation periods and more frequent vital sign checks may  be required in subjects who 
experience infusion reactions.
Recommendations for dose reductions (either as required by  protocol or at the discretion of the 
investigator) are as follows:  For a current dose of 1.5 – 2.0 mg/kg, it is recommended that the 
dose be reduced b y 0.5 mg (or more, at the investigators discretion).  For a current dose of 
0.75 – 1.25 mg/kg, it is recommended that the dose be reduced b y 0.25 mg (or more, at the 
investigators discretion).
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26 May2019
178APPENDIX X SUBJECTS CONTINUING PARTICIPATION AFTER MAIN STUDY
This appendix outlines the modifications to the study  procedures and ABT -414 dosing in 
subjects who are currently receiving ABT -414 and who choose to continue ABT- 414 treatment 
after the results from the pre -planned interim efficacy  analy sis.Subjects who received placebo 
will be discontinued from the study .
At the time of the interim efficacy  anal ysis, there were approximately  48 subjects who remained 
on active ABT- 414 treatment.  The RTOG Steering Committee and AbbVie determined it was 
appropriate to allow subjects who are receiving ABT- 414 to continue doing so based on 
investigator and subject decision.
Requirements for continuing treatment w ith ABT -414 after interim efficacy analysis
If the subject was receiving blinded treatment, they must be confirmed to be receiving 
ABT -414.
Must voluntarily  sign and date the updated informed consent form, approved by  an 
Independent Ethics Committee (IEC)/ Institutional Review Board (I RB)
Study Activities
Only  study  activities necessary  for study  drug dosing, safet y monitoring and adverse event
reporting will be continued.  The revised schedule of study  assessments for these subjects is 
provided in Table 2bbelow. 
 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
179Table 2b.  Study Activities 28-Day Cyclesa
Final Study 
Drug 
Visitd/At 
Progression 35-Day F/Ue49-Day F/U ActivityDay 1 of 
Every Cycle 
(1, 2, 3 etc.)Day 1 of Odd -
Numbered Cycles 
(1, 3, 5, etc.)Day 15 
of Every 
CyclebDay 22 of 
Every 
Cyclec
Symptom -directed Physical Exam XfXf
Ophthalmology Exam XgXgXg
Chemistry X X X
Hem atology X X X X
Adverse Event Assessment/Concomitant 
MedicationsX X X X Xk
Temozolom ide Administration Xh
ABT -414 Administration XiXi
Prophylactic Eye Drop Administration XjXj
F/U = Follow -up
a. Assessments will be based on 28-day treatment cycles, with the first cycle starting approximately 4 weeks after completion of radiation therapy.  Subjects wi ll receive 
concomitant TMZ and study drug (ABT-414) for the first 6 cycles, and study drug monother apy for an additional 6 cycles or until disease progression or study drug 
discontinuation.  
b. Day 15 visit will not be performed after discontinuation of study drug (ABT -414) treatment.
c. As per TMZ prescribing information, during the 28-day cycle of TM Z, a blood count for ANC and platelets should be performed 21 days (± 2 days) after the start of each TMZ 
cycle.  If the ANC falls below 1,500/µL or if the platelet count falls below 100,000/mm3, then blood counts should be performed weekly until recovery to these levels before 
TMZ dosing.  A certified local lab may be used instead of central lab; if so, ANC and platelet results should be reported in the eCRF.  Day 22 testing may be omitted for cycles in 
which TMZ is not administered or if local prescribing information allows for a different testing schedule for ANC and platelets.
d. Final Study Drug Visit to be performed approximately 14 days after last dose of ABT -414.
e. To be performed 35 days (± 3 days) after the last dose of study drug (ABT -414).  If t he Final Study Drug Visit is more than 35 days after the last dose of study drug, then 35 -day 
safety follow -up procedures will not be performed.
f. Physical exams will be performed only as needed for safety management and adverse event reporting.
g. Ophtha lmology exams will be performed only as needed for safety management and AE/SAE reporting. The last ophthalmology exam following discontinuation of ABT-414 
may be done at the 35 -Day F/U or 49 -Day F/U Visit. Targeted ophthalmology exam data will not be co llected by the Sponsor.
h. TMZ will be administered once daily on Days 1 through 5 of each 28 -day cycle for 6 cycles per the local prescribing information.
i. ABT-414 infusion will be administered on Day 1 and Day 15 of each 28 -day cycle for 12 cycles.  
j. Prophylactic eye drops will be administered daily for 7 days with each dose of ABT -414, from 2 days before until 4 days after each dose of study drug (ABT -414), as described in 
Section 5.5 of the main study.  Patients will receive management of ocular si de effects as per investigator discretion. In this case, ABT- 414 dose interruption and/or reduction may 
be used, and any available prophylactic or supportive care measures may be employed without restriction, at the discretion of the investigator.
k. If the subject is unable to return to the site for the Day 49 Follow Up Visit, a phone call may be conducted to obtain AE/SAE and concomitant medication information.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
180ABT -414 Administration and Individual Subject Discontinuation
ABT -414 will be administered as described in the main protocol.
Subjects may  continue receiving ABT -414 while drug suppl y is available as long as disease 
progression has not been determined.
ABT -414 Toxicity Management and Individual Subject Dose Modifications
Section 8.0 of the main protocol provides guidance for toxicity  management and dose 
modifications.
Adverse Events
and Concomitant Medications
Adverse event and concomitant medication data will be collected to support regulatory  safet y 
reporting requirements.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
181APPEN DIX XI PROTOCOL AMEN DMENT:  LIST OF CHANGES
Title Page
"Investigator:"
"Neurosurgery " previously read:
Has been changed to read:
Title Page
"Investigato r:"
"Statistician" previously read:
Has been changed to read:

Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
182Section 1.0  INTRODUCTION AND BACKGROUND
Subsection Additional Safety Information
Delete:  last paragraph
Taken together, the efficacy  and safet y data available to date demonstrate an acceptable
benefit/risk profile of ABT- 414 in patients with EGFR -amplified GBM (see Section 1.2) and 
support continued investigation of this investigational agent in the current trial.
Section 1.0  INTRODUCTION AND BACKGROUND
Subsection Summary of Results from Pre -planned Interim Efficacy Analysis
Add:  new subsection title and text
Summary of Results from Pre -planned Interim Efficacy Analysis
An interim efficacy  analy sis based on a data cut of 30 April 2019 was performed by  the RTOG 
Independent Data Monitoring Commi ttee (IDMC), at which time 346 OS events had been 
observed out of 639 subjects included in the main part of the study .  The primary  anal ysis of OS 
based on the Intent -to-Treat (ITT) population showed no difference in OS between groups, with 
a median OS of 18.9 vs. 18.7 months for ABT- 414 and placebo, respectively .  The weighted (ρ = 
0, γ = 0.2) stratified log- rank test p -value (1 -sided) was 0.628, and the observed hazard ratio 
(HR) (95% CI) for OS was 1.01 (0.82, 1.25).  The median PFS was 8.0 vs. 6.3 month s for ABT -
414 and placebo, respectively , with a stratified log- rank test p -value (1-sided) of 0.029.  The 
observed hazard ratio (HR) (95% CI) for PFS was 0.84 (0.70, 1.02).  Preliminary  anal ysis of 
demographic and clinical characteristics did not reveal an y factors predictive of OS benefit for 
the addition of ABT -414 to standard RT/TMZ therapy .
Overall, 99.4% and 97.8% of subjects experienced at least 1 adverse event, and 87.3% and 
62.3% experienced a Grade 3 or higher AE in the ABT -414 and placebo arms, re spectivel y.  
Overall, 94.7% and 36.1% of subjects experienced at least 1 ocular adverse event related to 
corneal epitheliopathy , 61.0% and 0.6% experienced a Grade 3 or higher AE related to corneal 
epitheliopathy , and 11.8% and 0% discontinued study  drug ( ABT -414 or placebo) in the ABT -
414 and placebo arms due to corneal epitheliopathy , respectivel y.  The most common (> 10%) 
events related to corneal epitheliopathy  included keratopath y, vision blurred, photophobia, dry 
eye, ey e pain, keratitis, and punctate keratitis.  Excluding events related to corneal 
epitheliopathy , events for which the incidence in the ABT -414 group was ≥ 5% greater than in 
the placebo group included thrombocy topenia, gamma -glutam yltransferase increased, aspartate 
aminotransferase incre ased, alanine aminotransferase increased, constipation, blood alkaline 

Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26 May2019
183phosphatase increased, fatigue, and platelet count decreased.  Excluding events related to corneal 
epitheliopathy , Grade 3 or higher events for which the incidence in the ABT -414 group was at 
least 5% and was ≥ 2% greater than in the placebo group included thrombocy topenia, gamma -
glutam yltransferase increased, and alanine aminotransferase increased.
The interim efficacy  analy sis results overall indicate no survival benefit for adding ABT -414 to 
standard RT/TMZ therapy in newl y diagnosed GBM patients.  However, given that no new 
important safet y risks were identified, the RTOG Steering Committee and AbbVie believe it is 
appropriate to allow subjects who are currentl y receiving ABT -414 to continue ABT -414 
treatment if the investigator and subject believe it is in the subject's best interest.  For those 
subjects who choose to continue ABT -414, study  procedures have been modified as described in 
Appendix X.  The appendix provides guidance for study  drug administration and collection of 
safet y data related to AEs and SAEs.   No additional efficacy  data will be collected.
APPENDIX X  SUBJECTS CONTINUING PARTICIPATION AFTER MAIN STUDY
Add:  new appendix title and text
APPENDIX X SUBJECTS CONTINUING PARTICIPATION AFTER MAIN 
STUDY
This appendix outlines the modifications to the study  procedures and ABT -414 dosing in 
subjects who are currently receiving ABT -414 and who choose to continue ABT- 414 treatment 
after the results from the pre -planned interim efficacy  analy sis.Subjects who received placebo 
will be discontinued from the study .
At the time of the interim efficacy  anal ysis, there were approximately  48 subjects who remained 
on active ABT- 414 treatment.  The RTOG Steering Committee and AbbVie dete rmined it was 
appropriate to allow subjects who are receiving ABT- 414 to continue doing so based on 
investigator and subject decision.
Requirements for continuing treatment with ABT -414 after interim efficacy analysis
If the subject was receiving blinded t reatment, they  must be confirmed to be receiving 
ABT -414.
Must voluntarily  sign and date the updated informed consent form, approved by  an 
Independent Ethics Committee (IEC)/Institutional Review Board (I RB) 
 
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
184Study Activities
Only  study  activities necessary for study  drug dosing, safet y monitoring and adverse event
reporting will be continued.  The revised schedule of study  assessments for these subjects is 
provided in Table 2b below.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
185Table 2b.  Study Activities 28-Day Cyclesa
Final Study 
Drug 
Visitd/At 
Progression 35-Day F/Ue49-Day F/U ActivityDay 1 of 
Every Cycle 
(1, 2, 3 etc.)Day 1 of Odd -
Numbered Cycles 
(1, 3, 5, etc.)Day 15 
of Every 
CyclebDay 22 of 
Every 
Cyclec
Symptom -directed Physical Exam XfXf
Ophthalmology Exam XgXgXg
Chemistry X X X
Hem atology X X X X
Adverse Event Assessment/Concomitant 
MedicationsX X X X Xk
Temozolom ide Administration Xh
ABT -414 Administration XiXi
Prophylactic Eye Drop Administration XjXj
F/U = Follow -up
a. Assessments will be based on 28-day treatment cycles, with the first cycle starting approximately 4 weeks after completion of radiation therapy.  Subjects wi ll receive 
concomitant TMZ and study drug (ABT-414) for the first 6 cycles, and study drug monother apy for an additional 6 cycles or until disease progression or study drug 
discontinuation.  
b. Day 15 visit will not be performed after discontinuation of study drug (ABT -414) treatment.
c. As per TMZ prescribing information, during the 28-day cycle of TMZ, a blood count for ANC and platelets should be performed 21 days (± 2 days) after the start of each TMZ 
cycle.  If the ANC falls below 1,500/µL or if the platelet count falls below 100,000/mm3, then blood counts should be performed weekly until recover y to these levels before 
TMZ dosing.  A certified local lab may be used instead of central lab; if so, ANC and platelet results should be reported in the eCRF.  Day 22 testing may be omitted for cycles in 
which TMZ is not administered or if local prescribi ng information allows for a different testing schedule for ANC and platelets.
d. Final Study Drug Visit to be performed approximately 14 days after last dose of ABT -414.
e. To be performed 35 days (± 3 days) after the last dose of study drug (ABT -414).  If the Final Study Drug Visit is more than 35 days after the last dose of study drug, then 35 -day 
safety follow -up procedures will not be performed.
f. Physical exams will be performed only as needed for safety management and adverse event reporting.
g. Opht halmology exams will be performed only as needed for safety management and AE/SAE reporting. The last ophthalmology exam following discontinuation of ABT-414 
may be done at the 35 -Day F/U or 49 -Day F/U Visit. Targeted ophthalmology exam data will not be collected by the Sponsor.
h. TMZ will be administered once daily on Days 1 through 5 of each 28 -day cycle for 6 cycles per the local prescribing information.
i. ABT-414 infusion will be administered on Day 1 and Day 15 of each 28 -day cycle for 12 cycles.
j. Prophylactic eye drops will be administered daily for 7 days with each dose of ABT -414, from 2 days before until 4 days after each dose of study drug (ABT -414), as described in 
Section 5.5 of the main study.  Patients will receive management of ocular si de effects as per investigator discretion. In this case, ABT- 414 dose interruption and/or reduction 
many be used, and any available prophylactic or supportive care measures may be employed without restriction, at the discreti on of the investigator.
k. If the subject is unable to return to the site for the Day 49 Follow Up Visit, a phone call may be conducted to obtain AE/SAE and concomitant medication information.
Protocol Number RTOG 3508/ AbbVie M13 -813 Version Date:  26May 2019
186ABT -414 Administration and Individual Subject Discontinuation
ABT -414 will be administered as described in the main protocol.
Subjects may  continue receiving ABT -414 while drug suppl y is available as long as disease 
progression has not been determined.
ABT -414 Toxicity Management and Individual Subject Dose Modifications
Section 8.0 of the main protocol provides guidance for toxicity  management and dose 
modifications.
Adverse Events and Concomitant Medications
Adverse event and concomitant medication data will be collected to support regulatory  safet y 
reporting requirements.